saccharomyc
boulardii
sb
nonpathogen
yeast
use
prevent
treatment
gastrointestin
disord
human
be
hors
aim
studi
evalu
effect
sb
healthi
dog
dog
chronic
enteropathi
ce
sb
formul
cfu
capsul
concentr
viabil
within
capsul
control
yeast
cultur
subsequ
step
expir
date
four
healthi
dog
hd
dog
ce
inflammatori
bowel
diseas
ibd
protein
lose
enteropathi
ple
includ
hd
sb
administ
day
cfukg
bid
daili
clinic
evalu
perform
assess
possibl
advers
effect
quantit
stool
cultur
yeast
perform
administr
dog
ce
random
doubl
blind
placebocontrol
studi
perform
administ
sb
cfukg
bid
placebo
pl
sb
pl
administr
ad
standard
therapeut
protocol
diet
antibiot
immunosuppress
drug
evalu
efficaci
treatment
ibd
ple
complet
blood
work
abdomin
ultrasonographi
gastroduoden
colon
endoscopi
histopatholog
evalu
intestin
sampl
perform
diagnosi
day
treatment
valid
score
system
clinic
sign
ceccai
ultrasonographi
endoscopi
histopatholog
appli
signific
set
p
result
hd
show
absenc
sb
faec
treatment
presenc
one
day
steadi
state
cfug
day
complet
elimin
day
withdraw
treatment
advers
effect
report
ce
dog
clinic
score
improv
significantli
dog
receiv
sb
compar
dog
receiv
pl
p
ple
dog
albumin
concentr
increas
significantli
p
group
receiv
sb
respect
pl
daili
frequenc
defec
sb
group
significantli
lower
respect
pl
p
p
day
treatment
statist
differ
found
dog
receiv
sb
pl
treatment
base
endoscop
evalu
duodenum
colon
statist
differ
found
two
group
duoden
ultrasonograph
histolog
evalu
treatment
conclus
sb
safe
use
dog
ce
addit
standard
treatment
achiev
better
control
clinic
sign
signific
increas
albumin
concentr
compar
standard
therapi
alon
conflict
interest
report
canin
inflammatori
bowel
diseas
ibd
immunemedi
enteropathi
like
trigger
environment
immunoregulatori
factor
genet
suscept
dog
previou
studi
suggest
pivot
role
gut
bacteria
diseas
pathogenesi
sinc
lumin
microbi
composit
markedli
alter
ie
dysbiosi
diagnosi
probiot
bacteria
appear
therapeut
effect
form
human
ibd
control
studi
evalu
efficaci
probiot
therapi
canin
ibd
previous
report
aim
present
studi
character
mucosaassoci
microbiota
determin
clinic
microbiolog
mucos
homeostat
effect
oral
administ
vsl
probiot
dog
ibd
twenti
dog
diagnos
moderatetosever
ibd
cibdai
score
random
receiv
standard
therapi
ie
elimin
diet
glucocorticoid
without
probiot
vsl
mucos
microbiota
endoscop
intestin
biopsi
ibd
dog
control
evalu
fluoresc
situ
hybrid
fish
target
rrna
gene
total
bacteria
groupspecif
organ
individu
bacteri
speci
shown
relev
human
ibd
epitheli
tight
junction
protein
tjp
express
studi
use
immunohistochemistri
clinic
sign
chang
mucos
microbiota
tjp
express
assess
probiot
vsl
therapi
ibd
dog
show
reduct
gi
sign
follow
week
probiot
therapi
compar
baselin
cibdai
score
p
adher
sporad
invas
bacteria
eub
observ
small
intestin
colon
healthi
dog
diseas
canin
duodenum
nearli
bacteriafre
ibd
dog
given
probiot
vsl
alter
spatial
redistribut
bacteri
group
mucu
adher
compart
colon
subset
analysi
show
lactobacilli
significantli
p
increas
lumen
mucu
postvsl
number
mucu
laden
bifidobacteria
approach
signific
p
express
tjp
show
occludin
significantli
lower
control
intestin
compar
duoden
colon
mucosa
obtain
ibd
dog
receiv
probiot
p
p
respect
contrast
express
colon
significantli
higher
p
control
dog
versu
vsl
treat
ibd
dog
data
demonstr
probiot
vsl
alter
mucosaassoci
microbiota
dog
ibd
probiot
chang
bacteri
composit
associ
upregul
tjp
express
indic
enhanc
epitheli
barrier
integr
similar
vsl
diseas
protect
seen
human
ibd
probiot
use
trial
suppli
free
charg
manufactur
canin
inflammatori
bowel
diseas
ibd
thought
partial
caus
aberr
immun
respons
toward
intestin
microbiom
human
mice
administr
probiot
allevi
ibd
sever
andor
prevent
relaps
induct
toler
microenviron
aim
studi
investig
effect
probiot
enterococcu
faecium
ncimb
ef
intestin
microbiom
composit
dog
recruit
receiv
ef
cfu
doubleblind
placebocontrol
manner
addit
exclus
diet
hydrolys
protein
seven
dog
includ
probiot
group
dog
placebo
group
dog
improv
clinic
treatment
howev
obviou
effect
clinic
sever
receiv
probiot
fresh
natur
void
faecal
sampl
collect
dog
treatment
snapfrozen
liquid
nitrogen
store
analysi
genom
dna
extract
faecal
sampl
use
mobio
power
soil
dna
isol
kit
mobio
laboratori
recommend
manufactur
next
gener
sequenc
perform
iontorr
trademark
life
technolog
platform
base
upon
region
e
coli
posit
rrna
gene
follow
primer
forward
gagtttgatcntggctcag
revers
gtnttacn
gcggckgctg
raw
sequenc
data
screen
trim
filter
chimera
deplet
default
set
use
qiim
pipelin
version
uchim
softwar
microbiom
composit
treatment
group
treatment
compar
microbiota
composit
significantli
differ
probiot
placebo
treatment
group
chang
significantli
treatment
howev
larg
individu
variabl
microbiom
composit
speci
rich
faecal
sampl
increas
treatment
group
statist
signific
probiot
treatment
group
conclus
probiot
treatment
dog
ibd
lead
significantli
increas
rich
faecal
bacteri
microbiom
possibl
addit
effect
chang
diet
exclud
studi
investig
microbiom
chang
healthi
dog
fed
diet
assess
similar
chang
fecal
microbiom
occur
due
dietari
chang
alon
studi
base
phd
support
probiot
ltd
somerset
uk
manufactur
probiot
product
enterococcu
faecium
mention
studi
aim
studi
assess
preval
risk
factor
faecal
carriag
extendedspectrum
betalactamas
esbl
plasmid
ampc
betalactamas
pampc
e
coliproduc
healthi
dog
crosssect
studi
conduct
privat
hospit
lisbon
portug
rectal
swab
obtain
healthi
dog
dog
includ
studi
healthi
histori
antimicrobi
consumpt
previou
month
esbl
pampc
gene
detect
pcr
sequenc
potenti
risk
factor
esbland
pampcproduc
e
coli
faecal
carriag
obtain
questionnair
owner
regard
reason
veterinari
visit
hospitalis
antimicrobi
treatment
within
last
year
habitat
shelter
dog
breeder
privat
owner
cohabit
anim
street
access
kennelhotel
access
age
gender
data
analys
sa
softwar
version
sa
institut
inc
cari
nc
logist
regress
model
use
rectal
swab
obtain
healthi
dog
yield
posit
sampl
e
coli
isol
carri
esbl
gene
bla
n
bla
n
bla
n
bla
n
carri
pampc
gene
bla
n
bla
n
bla
n
thirteen
dog
carri
e
coli
isol
esbl
pampc
gene
dog
previous
treat
antimicrobi
within
last
year
higher
risk
carri
least
one
p
ci
p
ci
nontreat
dog
dog
sheltersbreed
tend
show
higher
incid
esblproduc
e
coli
p
ci
least
one
produc
e
coli
p
ci
dog
privat
owner
male
tend
less
like
carri
least
one
esbl
pampc
p
ci
pampc
enzym
p
ci
femal
studi
suggest
dog
may
act
reservoir
resist
bacteria
name
cephalosporinresist
e
coli
three
potenti
risk
factor
associ
carriag
esblandor
pampcproduc
e
coli
dog
identifi
import
implement
effect
control
measur
judici
antimicrobi
therapi
conflict
interest
dr
pomba
current
receiv
research
fund
govern
nation
programm
fundac
para
e
tecnologia
past
occasion
receiv
research
support
honoraria
lectur
pharmaceut
compani
includ
zoeti
atral
cipan
vicechair
antimicrobi
work
parti
report
literatur
report
longterm
relaps
rate
owner
complianc
clinic
sever
dog
chronic
enteropathi
goal
studi
compar
clinic
activ
index
ccecai
number
relaps
complianc
rate
year
diagnosi
foodrespons
diseas
frd
defin
dog
respond
elimin
diet
alon
within
week
initi
therapi
wherea
antibioticrespons
diseas
ard
dog
unsuccess
dietari
trial
respond
metronidazol
within
week
initi
therapi
steroidrespons
diseas
srd
dog
unsuccess
dietari
antimicrobi
trial
requir
immunosuppress
therapi
control
clinic
sign
ccecai
extract
medic
record
databas
year
diagnosi
relaps
rate
obtain
request
medic
record
refer
veterinarian
defin
number
return
visit
refer
practic
diagnosi
complianc
data
obtain
telephon
questionnair
owner
frd
group
consist
dog
wherea
ard
srd
group
consist
dog
respect
signific
differ
ccecai
followup
frd
ard
frd
srd
median
ccecai
rang
frd
rang
ard
rang
srd
p
frd
dog
owner
state
deviat
prescript
diet
daili
basi
week
month
median
ccecai
time
deviat
diet
rang
relaps
rate
highest
ard
group
compar
frd
srd
ard
frd
srd
p
frd
group
dog
kept
prescrib
diet
dog
chang
supermarket
brand
ard
dog
given
immunosuppress
treatment
addit
antibiot
time
followup
srd
dog
still
immunosuppress
treatment
one
dog
remiss
dietari
treatment
alon
conclus
pilot
studi
indic
complianc
rate
frd
dog
lowest
owner
will
toler
highest
sever
clinic
sign
relat
deviat
prescript
diet
ard
dog
highest
relaps
rate
cohort
indic
poor
respons
treatment
longterm
conflict
interest
dr
allenspach
receiv
research
fund
bbsrc
american
kennel
club
compar
gastroenterolog
societi
probiot
ltd
uk
laboklin
gmbh
germani
bioiberica
sp
also
undertaken
paid
consult
work
bioiberica
spain
hoffmannlaroch
switzerland
despit
high
preval
canin
pancreat
postmortem
studi
introduct
new
diagnost
test
believ
diseas
particularli
chronic
form
remain
recognis
due
nonspecif
natur
present
sign
histolog
consid
gold
standard
diagnosi
canin
pancreat
howev
clinician
reluct
take
pancreat
biopsi
due
signific
risk
patient
numer
serum
marker
report
elev
canin
pancreat
although
lack
sensit
specif
consequ
confirm
diagnosi
requir
result
rang
test
includ
imag
serum
biochemistri
physic
examin
other
previous
shown
diseas
perform
individu
low
specif
marker
dramat
improv
combin
data
multipl
marker
clinic
inform
use
analyt
algorithm
therefor
appli
approach
detect
pancreat
dog
activ
two
nonspecif
biomark
amylas
lipas
determin
serum
sampl
dog
suspect
pancreat
veterinarian
sampl
posit
virtu
pancreat
lipas
cpli
result
cpli
ugl
amylas
lipas
data
use
develop
seri
algorithm
use
mathemat
data
mine
classif
techniqu
addit
algorithm
develop
use
extra
paramet
includ
age
sex
vomit
diarrhoea
abdomin
pain
addit
two
enzym
level
perform
algorithm
assess
use
separ
blind
serum
sampl
taken
dog
score
clinic
acut
pancreat
accord
system
describ
mccord
et
al
j
vet
intern
med
case
present
evalu
vomit
diarrhoea
inappet
abdomin
pain
includ
clinic
histori
result
routin
haematolog
biochemistri
cpli
assay
abdomin
ultrasound
avail
result
multifactori
analysi
cpli
assay
result
compar
clinic
score
use
amylas
lipas
data
alon
algorithm
gave
sensit
specif
compar
cpli
result
sampl
respect
method
refer
clinic
score
presenc
addit
clinic
data
also
includ
algorithm
sensit
increas
specif
data
suggest
test
perform
canin
pancreat
dramat
improv
multipl
diagnost
paramet
combin
use
diseas
specif
algorithm
author
receiv
salari
editor
bsava
journal
companion
undertaken
unrel
paid
consult
bayer
merial
author
also
receiv
salari
avacta
anim
health
duti
involv
work
directli
project
canin
chronic
enteropathi
cce
caus
signific
longterm
morbid
case
due
intestin
inflamm
result
idiopath
inflammatori
bowel
diseas
ibd
current
diagnosi
idiopath
ibd
assess
diseas
sever
reli
result
subject
clinic
indic
laboratori
data
diagnost
imag
intestin
histopatholog
whilst
rule
known
caus
inflamm
human
ibd
number
faecal
biomark
includ
lactoferrin
aid
diagnosi
determin
diseas
activ
may
therefor
valuabl
develop
similar
noninvas
object
method
aid
diagnosi
clinic
assess
diseas
sever
dog
intestin
inflamm
due
idiopath
ibd
pilot
studi
aim
measur
faecal
lactoferrin
concentr
flc
dog
cce
histolog
confirm
intestin
inflamm
hcii
compar
control
dog
addit
flc
dog
hcii
would
compar
canin
inflammatori
bowel
diseas
activ
index
cibdai
wsava
standard
histopatholog
criteria
intestin
inflamm
determin
whether
correl
method
assess
diseas
sever
faecal
sampl
obtain
dog
hcii
n
undergon
investig
cce
serum
biochemistri
complet
blood
count
full
faecal
urinalysi
serum
cobalamin
quantit
cpli
abdomin
ultrasound
intestin
biopsi
control
popul
dog
present
reason
unrel
cce
n
analysi
carri
use
faecal
lactoferrin
elisa
previous
valid
dog
techlab
usa
flc
dog
hcii
median
lgg
rang
significantli
higher
control
dog
median
lgg
rang
p
cutoff
flc
lgg
correctli
identifi
dog
hcii
use
cutoff
overlap
noncc
dog
flc
hcii
group
give
sensit
specif
neither
presenc
neutrophil
extent
inflamm
histopatholog
show
signific
correl
flc
cibdai
show
moder
correl
flc
dog
hcii
r
p
result
pilot
studi
suggest
flc
abl
discrimin
dog
cce
due
hcii
dog
without
cce
possibl
incorpor
flc
panel
faecal
biomark
enabl
noninvas
assess
hcii
could
serv
adjunct
current
measur
diseas
sever
dog
idiopath
ibd
ryan
bettencourt
jame
boon
employe
techlab
usa
provid
elisa
kit
free
charg
work
incent
provid
result
openli
discuss
parti
censorship
place
result
techlab
support
work
submiss
abstract
conflict
disclos
fecal
fecal
calprotectin
concentr
describ
biomark
dog
chronic
enteropathi
howev
date
direct
comparison
two
marker
dog
chronic
diarrhea
aim
studi
evalu
perform
two
marker
situat
thirti
one
dog
present
histori
chronic
diarrhea
prospect
enrol
initi
diagnost
workup
patient
includ
serum
biochemistri
profil
fecal
parasitolog
abdomin
ultrasound
examin
gastrointestin
endoscopi
collect
endoscop
biopsi
sever
clinic
sign
evalu
use
ccecai
score
index
patient
group
ccecai
fecal
calprotectin
quantifi
previous
describ
correl
evalu
spearman
rank
correl
test
marker
receiv
oper
characterist
roc
curv
use
select
cutoff
valu
allow
best
discrimin
dog
ccecai
dog
ccecai
sensit
specif
calcul
correl
analys
reveal
signific
posit
correl
calprotectin
r
p
optim
cutoff
valu
fecal
calprotectin
concentr
lgg
associ
sensit
specif
p
optim
cutoff
valu
fecal
concentr
ngg
associ
sensit
specif
p
sensit
fecal
higher
fecal
calprotectin
p
signific
differ
observ
specif
two
marker
p
dog
concord
result
calprotectin
test
among
dog
present
ccecai
dog
marker
cutoff
valu
among
dog
dog
marker
cutoff
valu
dog
present
histolog
sign
inflamm
sensit
fecal
calprotectin
concentr
histopatholog
intestin
inflamm
respect
specif
respect
least
group
patient
fecal
concentr
sensit
less
specif
detect
dog
ccecai
histopatholog
intestin
inflamm
fecal
calprotectin
concentr
weight
loss
malabsorpt
fat
protein
cobalamin
tocopherol
face
normal
exocrin
pancreat
function
report
cat
older
year
age
fed
varieti
nutrit
balanc
dri
wet
food
patil
ap
cupp
cj
proc
nestlepurina
compan
anim
nutr
summit
focu
gastroenterolog
object
studi
determin
serum
cobalamin
concentr
increas
oral
administr
cobalamin
supplement
affect
cat
durat
posit
respons
follow
cessat
supplement
studi
evalu
cat
older
year
age
fat
malabsorpt
demonstr
either
increas
fecal
fat
subnorm
fat
digest
without
exocrin
pancreat
insuffici
epi
assess
assay
serum
trypsinlik
immunoreact
ftli
commerci
avail
solut
cobalamin
contain
mg
mix
ml
liquid
flavor
enhanc
ad
food
cat
singl
dose
day
month
supplement
ceas
serum
cobalamin
assay
competit
bind
assay
perform
gi
laboratori
texa
univers
evalu
use
refer
rang
deriv
laboratori
determin
immedi
prior
initi
supplement
weekli
week
monthli
month
start
studi
serum
cobalamin
subnorm
ngl
cat
rang
ngl
within
refer
rang
ngl
remain
cat
ngl
serum
cobalamin
refer
rang
everi
cat
ngl
one
week
supplement
remain
refer
rang
everi
sampl
collect
supplement
period
except
two
cat
valu
within
refer
rang
supplement
stop
serum
cobalamin
month
cessat
supplement
rang
ngl
respect
end
studi
serum
cobalamin
subnorm
cat
conclud
oral
cobalamin
supplement
effect
increas
serum
cobalamin
concentr
geriatr
cat
idiopath
chronic
enteropathi
follow
cessat
supplement
concentr
decreas
rapidli
becom
subnorm
within
week
primari
author
collabor
nestlepurinaon
work
report
abstract
coauthori
employe
nestlepurina
primari
author
previous
receiv
fund
iam
mar
hill
nestlepurina
author
also
act
paid
consult
gilab
texa
univers
left
atrial
measur
crucial
assess
sever
cardiac
diseas
dog
myxomat
mitral
valv
diseas
mmvd
howev
linear
area
dimens
might
provid
comprehens
assess
patient
statu
differenti
sever
subclin
clinic
diseas
chf
estim
left
atrial
function
could
provid
addit
inform
help
categor
patient
examin
dog
mmvd
normal
c
present
cardiac
evalu
echocardiographi
left
atrial
linear
area
dimens
right
parastern
short
long
axi
view
obtain
time
point
earli
diastol
la
max
prior
mitral
valv
open
onset
atrial
systol
la
p
prior
mitral
valv
closur
la
min
calcul
indic
la
function
total
la
empti
fraction
la
tef
activ
la
empti
fraction
la
act
passiv
la
empti
fraction
la
pa
la
reservoir
function
la
re
set
measur
examin
differ
select
la
function
indic
differ
diseas
stage
kruskal
walli
test
posthoc
multipl
comparison
also
examin
diagnost
accuraci
select
indic
la
function
differenti
dog
stage
stage
c
chf
use
roc
analysi
three
function
indic
consist
differ
across
variou
stage
mmvd
la
tef
la
act
la
re
differ
appar
rpla
view
linear
measur
rpsa
view
area
measur
dog
chf
wors
function
group
differ
variabl
depend
function
index
examin
laarea
act
show
best
abil
discrimin
chf
dog
specif
sensit
auc
better
use
la
ao
measur
data
suggest
la
function
differ
dog
differ
sever
mmvd
provid
clear
distinct
dog
subclin
diseas
chf
conflict
interest
report
materi
method
use
evalu
consecut
nonsed
dog
weigh
kg
studi
popul
morpholog
studi
includ
normal
dog
dog
acvim
stage
mmvd
imag
data
digit
record
analyz
offlin
use
commerci
avail
softwar
result
imag
acquisit
feasibl
consecut
dog
patient
anxieti
arrhythmia
pant
explain
failur
obtain
dataset
fortyon
dataset
analyz
qualiti
bodi
weight
heart
rate
significantli
lower
dog
possibl
perform
dog
analyz
dataset
significantli
older
weigh
less
dog
could
analyz
mitral
valv
normal
dog
saddl
shape
annulu
height
commissur
width
ratio
ahcwr
ae
mean
ae
sd
ellipt
annulu
spheric
index
si
ae
follow
measur
significantli
relat
bodi
surfac
area
bsa
anteroposterior
diamet
apd
r
p
anterolateralposteromedi
diamet
alpmd
r
p
annulu
area
aa
r
p
anterior
leaflet
length
r
p
anterior
leaflet
area
ala
r
p
variabl
index
bsa
subsequ
statist
analys
dog
mmvd
significantli
greater
si
nonplanar
angl
apdi
alpmdi
alai
alli
significantli
lower
posterior
leaflet
area
pla
posterior
leaflet
length
pll
annulu
height
ah
tent
height
th
tent
volum
tv
tent
area
ta
ahcwr
compar
normal
dog
ah
tv
ta
significantli
greater
normal
dog
compar
dog
mmvd
si
apdi
alpmdi
aai
alai
alli
significantli
greater
dog
stage
mmvd
compar
normal
dog
stage
pll
pla
significantli
lower
dog
compar
normal
dog
th
significantli
differ
three
group
greatest
normal
dog
lowest
dog
stage
suggest
flatten
mv
occur
diseas
progress
conclus
assess
canin
mv
feasibl
morpholog
chang
associ
mmvd
progress
present
effect
regurgit
orific
area
eroa
calcul
measur
width
vena
contracta
vc
narrowest
portion
proxim
regurgit
jet
might
use
estim
sever
mitral
regurgit
mr
howev
simplifi
assumpt
hold
eroa
circular
might
true
dog
myxomat
mitral
valv
diseas
mmvd
aim
studi
compar
measur
eroa
use
color
doppler
realtim
dimension
echocardiographi
calcul
eroa
estim
dimension
echocardiographi
chamber
chamber
view
left
ventricl
lv
dog
mmvd
ninetythre
privat
own
dog
breed
diagnos
natur
acquir
mmvd
examin
use
accord
acvim
classif
congest
heart
failur
chf
dog
classifi
chf
class
class
dog
without
chf
dog
class
dog
class
age
rang
year
median
year
bodi
weight
rang
kg
median
kg
fiftynin
male
femal
includ
heart
rate
rang
beatsminut
median
bmin
eroa
calcul
measur
vc
diamet
view
assum
circular
regurgit
orific
measur
vc
diamet
view
assum
elipt
regurgit
orific
lv
blandaltman
plot
use
compar
eroa
measur
calcul
eroa
obtain
lv
view
none
estim
eroa
show
good
agreement
measur
eroa
correct
bsa
differ
method
increas
increas
eroa
differ
method
normal
mean
eroa
valu
increas
increas
eroa
show
systemat
underestim
eroa
respect
compar
beattobeat
variat
eroa
assess
n
coeffici
variat
rang
median
conclus
substitut
assess
eroa
measur
vc
dimens
might
underestim
mr
sever
dog
mmvd
dog
beattobeat
variat
eroa
larg
therebi
necessit
need
sever
consecut
measur
conflict
interest
report
microrna
mirna
short
nucleotid
singlestrand
noncod
rna
specif
anneal
complementari
sequenc
multipl
mrna
target
silenc
mrna
suppress
downstream
protein
translat
mirna
act
finetun
gene
express
onoff
switch
featur
highlight
potenti
mirna
therapeut
target
role
mirna
myocardi
fibrosi
hypertroph
cardiomyopathi
wide
studi
human
patient
howev
data
avail
canin
human
myxomat
mitral
valv
diseas
mmvd
aim
studi
investig
mirna
transcriptom
canin
mmvd
use
global
transcript
profil
mirna
target
predict
softwar
diana
tool
targetscan
network
analysi
softwar
biolayout
express
four
myxomat
mitral
valv
ckc
control
valv
profil
use
affymetrix
canin
gene
st
array
total
mirna
found
statist
significantli
differenti
express
downregul
base
fals
discoveri
rate
pvalu
foldchang
express
three
mirna
also
valid
quantit
polymeras
chain
reaction
qpcr
taqman
result
agreement
microarray
find
network
analysi
visual
markov
cluster
algorithm
conduct
biolayout
express
major
cluster
mirna
export
upload
dianamirpath
kegg
pathway
webserv
pathway
identifi
main
cluster
attribut
biolog
function
focal
adhes
cytoskeleton
actin
regul
tgfb
signal
glycosaminoglycan
biosynthesi
osteoclast
differenti
notch
signal
vegf
signal
significantli
downregul
mirna
mmvd
endotheli
specif
mirna
shown
regul
endotheli
migrat
vessel
pattern
top
predict
target
glucuron
acid
epimeras
glce
main
enzym
control
heparan
sulphat
biosynthesi
interest
find
downregul
member
famili
target
multipl
extracellular
matrix
transcript
collagen
elastin
integrin
laminin
mmp
matrix
metalloproteinas
adamt
disintegrin
metalloproteinas
thrombospondin
motif
wherea
target
hyaluron
acid
synthas
sinc
major
patholog
mmvd
aberr
turnov
extracellular
matrix
protein
may
link
mirna
regul
dysregul
valv
mirna
might
potenti
therapeut
target
treatment
canin
mmvd
conflict
interest
report
mitral
regurgit
mr
progress
slowli
dog
live
long
enough
often
develop
congest
heart
failur
chf
howev
tool
predict
onset
chf
spars
echocardiograph
examin
dog
perform
longitudin
multicent
studi
surveil
time
year
clientown
dogswer
enrol
univers
hospit
finland
sweden
denmark
subset
svep
studi
left
ventricular
end
diastol
lvidd
systol
lvid
diamet
fraction
shorten
fs
left
atrial
la
aortic
root
ao
diamet
estim
valu
normal
bodi
size
nlvidd
nlvid
nla
respect
comparison
ratio
aortic
root
calcul
lviddao
lvidsao
laao
respect
cox
proport
hazard
analysi
count
process
approach
use
spline
smooth
graphic
model
construct
evalu
linear
hazard
curv
use
find
cutoff
valu
interv
hazard
ratio
hr
hr
nlvidd
nlvid
nla
per
unit
confid
interv
p
p
p
respect
hr
lviddao
lvidsao
laao
unit
increas
p
p
p
respect
hr
fs
p
rel
hazard
plot
present
steep
increas
fs
valu
hr
interv
p
p
p
respect
hr
nlvidd
increas
linearli
hr
interv
p
p
p
p
respect
contrast
hazard
nlvid
remain
stabl
whereaft
increas
hr
nlvid
p
p
p
p
respect
hr
valu
normal
ao
diamet
behav
parallel
way
conclud
fs
left
ventricular
atrial
size
may
use
predict
chf
howev
valu
hr
depend
unit
use
essenti
account
nonlinear
chang
hazard
interpret
hazard
challeng
contrast
interv
hazard
depend
refer
interv
use
therefor
easier
implement
everi
day
clinic
work
conflict
interest
report
system
arteri
hypertens
frequent
recogn
dog
mitral
valv
degener
mvd
although
borderlin
hypertens
difficult
assess
mainli
differ
measur
techniqu
interoper
variabl
importantli
examinationrel
stress
object
studi
evalu
systol
arteri
blood
pressur
sbp
initi
present
regular
interv
dog
variou
clinic
stage
mvd
fifti
six
dog
mvd
receiv
heart
medic
prior
admiss
includ
studi
base
isachc
stage
system
assign
class
group
class
ii
group
b
class
iii
smallbre
dog
miniatur
poodl
particular
overrepres
comorbid
could
affect
sbp
rule
prior
enrol
sbp
measur
use
commerci
avail
veterinari
oscillometr
devic
appli
proper
cuff
cephal
arteri
dog
left
acclim
minut
measur
alway
taken
investig
examin
perform
dog
sit
owner
lap
total
read
taken
outlier
valu
discard
mean
remain
measur
document
initi
consult
treatment
custom
accord
clinic
stage
sbp
measur
everi
month
month
initi
admiss
present
class
dog
sbp
mm
hg
spb
mm
hg
wherea
class
ii
dog
sbp
mm
hg
class
iii
dog
sbp
mm
hg
sbp
mm
hg
linear
mix
effect
model
use
assess
tempor
variabl
measur
paramet
group
group
match
gender
age
bodi
weight
blood
pressur
measur
durat
studi
higher
group
dog
compar
group
b
c
p
time
group
c
significantli
higher
sbp
valu
group
b
dog
p
asymptomat
mvd
dog
seem
higher
sbp
measur
compar
clinic
evid
heart
failur
whether
differ
stressrel
maladapt
mechan
sympathet
raa
activ
mvd
idiopath
remain
elucid
conflict
interest
report
sarcoplasm
reticulum
sr
ca
atpas
regulatori
protein
pivot
determin
myocardi
activ
relax
via
calcium
uptak
srcytoplasm
gradient
lower
densiti
sr
ca
atpas
well
demonstr
mani
speci
chronic
hemodynam
overload
gene
link
sr
calcium
uptak
report
express
peripher
blood
serv
potenti
cardiac
biomark
dog
chronic
mitral
regurgit
sr
ca
adenosin
triphosphatas
isoform
phospholamban
pln
associ
protein
aim
studi
determin
whether
target
gene
express
blood
translat
myocardi
set
cardiac
biomark
mrna
express
level
target
gene
pln
biopsi
left
ventricl
lv
peripher
white
blood
cell
pwbc
surgic
mitral
valv
repair
case
estim
quantit
realtim
pcr
use
compar
ct
method
gapdh
gene
express
level
lv
pwbc
compar
clinic
relationship
evalu
diagnost
power
genet
express
pwbc
analyz
compar
normal
dog
level
target
gene
express
lv
pwbc
highli
correl
linear
regress
analysi
p
r
r
pln
r
r
r
r
although
lv
pwbc
show
differ
express
level
pair
comparison
p
accord
sever
heart
failur
isachc
express
level
gene
gradual
significantli
reduc
lv
pwbc
p
especi
pln
express
pwbc
could
clearli
discrimin
isachc
group
control
p
multivari
regress
adjust
age
bodi
weight
reveal
pln
lv
neg
associ
lv
intern
systol
dimens
p
adjust
r
p
adjust
r
respect
pln
also
neg
relat
lv
intern
diastol
dimens
p
adjust
r
addit
receiveroper
characterist
analysi
use
pwbc
show
high
area
curv
auc
valu
target
gene
overal
isachc
group
p
pln
conclus
transcript
chang
calcium
uptak
relat
gene
pwbc
may
abl
reflect
myocardi
hemodynam
stress
well
util
promis
cardiac
biomark
conflict
interest
report
aim
studi
estim
heartrat
normal
pulmonari
transit
time
nptt
cardiomyopath
cat
without
congest
heart
failur
chf
assess
potenti
associ
echocardiograph
variabl
nptt
evalu
nptt
test
presenc
chf
privat
own
cat
includ
nptt
measur
use
echocardiographi
ultrasound
contrast
media
sonovu
group
cat
healthi
cat
group
cat
cardiomyopathi
cm
without
chf
group
cat
cm
chf
group
receiv
oper
characterist
curv
roc
creat
nptt
left
atrial
diamet
lad
left
atrial
aortic
root
ratio
la
ao
assess
compar
use
test
presenc
chf
interrel
pulmonari
blood
volum
pbv
nptt
stroke
volum
sv
echocardiograph
variabl
investig
mean
uniand
multivari
analysi
nptt
valu
group
group
group
interquartil
rang
iqr
iqr
iqr
respect
valu
significantli
differ
group
pulmonari
blood
volum
group
group
group
ml
iqr
ml
ml
iqr
ml
ml
iqr
ml
sv
pbv
shorten
fraction
signific
predictor
nptt
nptt
la
ao
ratio
sv
main
predictor
pbv
analyz
roc
nptt
clinic
test
chf
yield
auc
similar
la
ao
ratio
nptt
may
use
test
presenc
chf
cat
cm
measur
cardiac
perform
nptt
la
ao
ratio
predict
chf
equal
accuraci
increas
pbv
significantli
associ
higher
nptt
la
ao
ratio
decreas
sv
increas
pbv
explain
increas
nptt
cardiomyopath
cat
author
receiv
travel
scholarship
zoeti
attend
congress
acut
arteri
thromboembol
aat
occur
commonli
cat
less
frequent
dog
mostli
result
limb
paresi
paralysi
diagnosi
base
typic
physic
examin
advanc
imag
diminish
affectedlimb
peripher
blood
flow
induc
chang
sever
analyt
concentr
affect
limb
venou
sampl
compar
peripher
venou
concentr
hypothes
aat
local
affectedlimb
venou
glucos
concentr
decreas
refer
interv
system
glucos
concentr
remain
unaffect
studi
includ
group
speci
paralyt
aat
case
nonambulatori
control
limb
paralysi
orthoped
neurolog
disord
ambulatori
control
diagnos
variou
diseas
system
peripher
affectedlimb
blood
glucos
concentr
measur
group
absolut
dglu
rel
dglu
differ
compar
procedureassoci
complic
pain
note
peripher
blood
glucos
concentr
decreas
p
cat
dog
aat
dglu
dglu
higher
aat
group
cat
dog
compar
respect
control
group
p
p
respect
differ
control
group
receiv
oper
characterist
analysi
dglu
dglu
predictor
aat
cat
area
curv
respect
dog
respect
dglu
cutoff
mgdl
mgdl
cat
dog
respect
correspond
sensit
specif
cat
respect
dog
dglu
dglu
extrem
accur
readilyavail
simpl
diagnost
marker
aat
cat
dog
conflict
interest
report
glycaemia
determin
usual
includ
routin
biochemisti
panel
work
devot
evalu
pheripher
glycaemia
anim
suffer
arteri
thrombosi
aim
studi
document
pheripher
glycaemia
variat
hypoperfus
limb
patient
affect
mriconfirm
arteri
thrombosi
eleven
dog
refer
monoparesi
paraparesi
recruit
inclus
criteria
clinic
examin
support
limb
hypoperfus
avail
blood
cell
count
biochem
profil
urin
analys
mri
examin
peripher
glycaemia
test
two
blood
sampl
obtain
one
affect
limb
one
healti
limbplasmat
glycaemia
measur
use
autom
glucos
analys
patient
underw
total
bodi
mri
mri
intera
philip
medic
system
provid
final
diagnosi
arteri
thrombosi
locat
document
entiti
score
eleven
patient
diagnos
peripher
thrombosi
involv
arteri
vessel
case
rel
branch
thrombu
locat
abdomin
aorta
subclavian
arteri
axillari
arteri
iliac
arteri
total
amount
abdomin
aortic
thrombosi
involv
also
intern
iliac
arteri
extern
one
intern
extern
extent
thrombosi
classifi
grade
greatest
portion
thrombu
reach
half
vessel
lumen
patient
grade
greatest
portion
thrombu
vessel
lumen
grade
thrombu
exced
lumen
substanti
decreas
pheripher
glycaemia
valu
found
sampl
aris
thrombosisaffect
limb
compar
thrombosisaffect
limb
valu
healthi
limb
measur
patient
reduct
found
account
score
patient
percentag
reduct
found
suggest
proport
decreas
relat
grade
occlus
result
studi
suggest
peripher
glycaemia
valu
affect
limb
hypoperfus
disord
arteri
thrombosi
suspect
sampl
affect
limb
healthi
one
could
use
compar
glycaemia
valu
support
earli
stage
therapi
anticip
diagnost
imag
studi
need
confirm
proport
relat
decreas
thrombu
entiti
conflict
interest
report
canin
idiopath
pulmonari
fibrosi
cipf
progress
interstiti
lung
diseas
mainli
affect
west
highland
white
terrier
whwt
pulmonari
hypertens
ph
may
develop
secondari
hypox
vasoconstrict
andor
pulmonari
parenchym
infiltr
absenc
measur
tricuspid
regurgit
tr
comorbid
condit
may
difficult
diagnos
noninvas
degre
cardiopulmonari
impair
cipf
dog
evalu
blood
ga
analysi
bga
minut
walk
test
new
echocardiograph
index
right
pulmonari
vein
pulmonari
arteri
ratio
pvpa
describ
detect
pulmonari
venou
hypertens
aim
studi
investig
pvpa
cipf
order
determin
util
detect
ph
assess
cardiopulmonari
diseas
sever
prospect
clinic
cohort
studi
includ
whwt
cipf
group
healthi
whwt
group
b
healthi
dog
breed
group
c
diamet
right
pv
pa
measur
bidimension
bd
mmode
mm
parastern
right
long
axi
view
end
wave
echocardiograph
paramet
evalu
ph
also
measur
speed
tr
acceler
time
eject
time
ratio
pulmonari
flow
et
pulmonari
arteri
aorta
ratio
paao
bga
perform
dog
group
b
c
dog
valu
given
meanaesd
bd
mm
mode
pvpa
ratio
lower
group
mm
ae
bd
ae
compar
group
b
mm
ae
bd
ae
p
group
c
mm
ae
bd
ae
p
chang
pvpa
due
increas
pa
p
decreas
pv
p
tr
found
dog
cipf
mean
pressur
gradient
ae
mmhg
et
lower
group
ae
compar
group
c
ae
p
tend
lower
compar
group
b
ae
p
paao
statist
differ
group
pvpa
correl
arteri
po
valu
b
mode
r
p
result
b
mode
r
p
pvpa
also
correl
et
speed
tr
paao
conclus
whwt
affect
cipf
pvpa
use
indic
ph
could
serv
assess
diseas
sever
conflict
interest
report
ventricular
septal
defect
vsd
fourth
common
congenit
cardiac
defect
dog
common
cat
aim
studi
evalu
longterm
outcom
vsd
patient
case
record
anim
review
reevalu
echocardiograph
follow
phone
interview
dog
pug
common
breed
follow
border
terrier
cat
domest
short
hair
common
follow
main
coon
isol
vsd
present
dog
cat
complex
defect
cd
present
case
frequent
anomali
subaort
stenosi
dog
cat
pulmon
stenosi
dog
cat
tetralog
fallot
dog
cat
cushion
defect
cat
doublechamb
right
ventricl
dcrv
dog
cat
dog
present
initi
support
causeandeffect
theori
eisenmeng
observ
dog
cat
aortic
insuffici
consid
cd
note
dog
dog
cat
isol
vsd
cat
dcrv
defect
close
spontan
nine
dog
cat
die
noncardiac
caus
age
death
mean
month
dog
cat
die
due
cardiac
caus
age
death
mean
month
cardiac
death
sudden
dog
cd
euthanasia
left
side
congest
heart
chf
failur
associ
cd
dog
cat
right
side
chf
associ
cd
cat
biventricular
failur
cat
cd
weak
eisenmeng
dog
cat
fallot
dog
cd
cat
two
cat
develop
chf
due
unrel
hcm
one
dog
isol
vsd
euthan
chf
result
indic
spontan
vsd
closur
occur
often
previous
thought
patient
isol
restrict
vsd
live
normal
life
span
without
surgic
intervent
nonrestrict
vsd
complex
defect
associ
signific
morbid
mortal
echocardiographi
earli
life
crucial
identifi
anomali
cd
well
use
prognost
longterm
outcom
identifi
patient
surgic
intervent
consid
avail
followup
echocardiographi
indic
corrobor
prognosi
detect
complic
due
vsd
detect
unassoci
acquir
cardiac
diseas
conflict
interest
report
centronuclear
myopathi
cnm
preval
congenit
inherit
disord
affect
skelet
muscl
labrador
retriev
disabl
condit
segreg
worldwid
recess
lossoffunct
founder
mutat
identifi
protein
tyrosin
phosphataselik
member
gene
ptpla
object
studi
describ
ptpla
express
pattern
heart
homozyg
wild
type
wt
heterozyg
het
homozyg
mutat
cnm
dog
assess
compar
left
myocardi
function
age
wt
het
cnm
dog
purpos
seven
wt
four
het
eleven
cnm
dog
includ
studi
ptpla
mrna
level
assess
rtpcr
rtqpcr
dog
examin
use
convent
echocardiographi
color
tissu
doppler
imag
tdi
tdideriv
strain
imag
found
express
two
wild
type
ptpla
splice
isoform
increas
postnat
wt
dog
level
halv
het
dog
drastic
reduc
cnm
dog
het
cnm
dog
slight
left
ventricular
hypertrophi
detect
use
convent
echocardiographi
tdi
strain
imag
reveal
left
ventricular
myocardi
function
significantli
alter
het
cnm
dog
compar
wt
dog
moreov
function
defect
associ
significantli
higher
valu
system
arteri
blood
pressur
although
maintain
within
normal
rang
conclus
subclin
myocardi
alter
detect
het
cnm
age
dog
french
pedigre
suggest
role
ptpla
longterm
cardiovascular
homeostasi
find
prompt
global
confirm
addit
ptpla
defici
dog
may
thu
consid
new
larges
model
human
left
ventricular
subclin
myocardi
dysfunct
conflict
interest
report
mitral
regurgit
mr
secondari
degen
mitral
valv
diseas
dmvd
common
heart
diseas
dog
dog
mr
mitral
valv
prolaps
caus
degener
mitral
valv
leaflet
chorda
tendina
extens
andor
ruptur
mitral
annulu
dilat
observ
howev
limit
data
avail
morpholog
chang
dog
mr
current
studi
confirm
anomali
mitral
complex
via
direct
observ
live
dog
mitral
regurgit
institut
last
ten
year
approxim
dog
undergon
mitral
valv
repair
surgeri
anomali
mitral
complex
observ
macroscop
directli
visual
knowledg
first
studi
evalu
anomali
mitral
valv
leaflet
chorda
tendinea
dog
undergo
mitral
valv
repair
anim
dog
underw
mitral
valv
repair
cpb
nihon
univers
februari
june
includ
studi
method
confirm
chorda
tendinea
ruptur
visual
confirm
surgeri
site
chorda
tendinea
ruptur
also
record
time
septal
chorda
mural
chorda
divid
three
divis
depend
site
respect
result
nineti
eight
dog
includ
studi
mean
age
bodi
weight
ae
year
ae
kg
respect
dog
ruptur
chorda
observ
dog
septal
leaflet
chorda
ruptur
dog
mural
leaflet
chorda
ruptur
dog
chorda
leaflet
ruptur
dog
chordal
ruptur
observ
dog
dog
ruptur
septal
chorda
chorda
often
ruptur
n
studi
ruptur
septal
chorda
tendinea
commonli
observ
first
pilot
studi
visual
evalu
anomali
mitral
valv
leaflet
chorda
tendinea
dog
undergo
mitral
valv
repair
futur
studi
compar
patholog
chang
molecular
biolog
analysi
gross
find
mitral
chorda
tendinea
dog
undergo
mitral
valv
repair
may
use
advanc
understand
diseas
conflict
interest
report
echocardiograph
aortic
valv
ao
measur
routin
obtain
cardiac
evalu
patient
cardiologist
commonli
use
diastol
ao
measur
obtain
ratiometr
weightindepend
estim
dimens
cardiac
structur
commonli
left
atrium
la
howev
consensu
exist
point
diastol
ao
measur
obtain
immedi
closur
aortic
valv
la
size
largest
ao
max
often
least
distinct
margin
pwave
ecg
ao
p
onset
ventricular
electr
systol
la
size
smallest
ao
min
examin
linear
area
dimens
ao
aod
aoa
determin
clinic
signific
differ
exist
distinct
diastol
timepoint
measur
could
interchang
examin
patient
dog
cat
present
cardiac
evalu
echocardiographi
three
replic
timepoint
linear
area
measur
ao
max
ao
p
ao
min
obtain
patient
averag
analysi
patient
aortic
valv
diseas
atrial
fibril
exclud
analysi
beattobeat
variabl
ao
measur
determin
standard
normal
limit
agreement
loa
plot
gener
pairwis
comparison
frequenc
ao
measur
largest
smallest
withinpati
measur
determin
compar
via
repeat
measur
anova
pairwis
agreement
plot
aod
aoa
demonstr
heteroscedast
normal
aod
plot
show
loa
mean
aod
measur
bia
approxim
aod
max
aod
min
aod
max
aod
p
aod
p
aod
min
normal
aoa
plot
show
loa
mean
aoa
measur
bia
approxim
aoa
max
aoa
min
aoa
max
aoa
p
aoa
p
aoa
min
aod
max
largest
measur
patient
aod
min
smallest
measur
patient
aoa
max
largest
measur
patient
aoa
min
smallest
measur
patient
rmanova
confirm
ao
max
ao
p
ao
min
p
median
withinpati
withinmeasur
variabl
aod
aoa
measur
data
suggest
ao
measur
differ
throughout
diastol
ao
max
ao
p
ao
min
dispar
greater
area
linear
estim
degre
disagr
ao
max
ao
p
small
similar
withinmeasur
variabl
thu
use
either
ao
max
ao
p
measur
result
similar
ratiometr
estim
cardiac
dimens
conflict
interest
report
felin
hypertroph
cardiomyopathi
fhcm
common
heart
diseas
cat
hcm
consid
inherit
diseas
sarcomer
fhcm
link
mutat
one
sarcomer
protein
ie
howev
pathophysiolog
mechan
behind
diseas
develop
progress
larg
unknown
studi
investig
whether
mitochondri
morpholog
chang
myocardium
accompani
mitochondri
dysfunct
enhanc
oxid
stress
format
recent
found
fhcm
myocardi
tissu
left
ventricl
lv
obtain
immedi
euthanasia
cat
diagnos
primari
hcm
echocardiographi
main
coon
british
shorthair
exot
shorthair
norwegian
forest
cat
agematch
control
cat
main
coon
norwegian
forest
cat
ultrastructur
examin
perform
use
transmiss
electron
microscopi
hcm
cat
mark
ultrastructur
chang
cardiomyocyt
observ
popul
subsarcolemm
mitochondria
ssm
absent
larg
cellular
area
cat
moder
sever
lv
hypertrophi
flatten
sarcolemma
common
find
caus
disorgan
ttubular
system
interfibrillar
mitochondria
ifm
disorgan
deplet
addit
chang
cardiomyocyt
cat
diagnos
fhcm
includ
remodel
sarcomer
disorgan
myofibril
convolut
gap
junction
accumul
intracellular
zdisc
materi
perinuclear
lipofuscin
granula
extens
extracellular
deposit
collagen
healthi
mammalian
cardiomyocyt
ttubular
system
uphold
cellular
structur
prevent
mitochondri
reticulum
format
provid
calcium
oxygen
substrat
necessari
normal
function
muscl
disorgan
sarcolemma
ttubular
system
may
caus
deplet
ssm
possibl
mechan
atrophi
disrupt
mitochondria
alter
fusionfiss
dynam
calcium
cycl
substrat
suppli
like
compromis
observ
structur
chang
propos
relat
mitochondri
dysfunct
oxid
stress
format
occur
fhcm
howev
caus
relationship
remain
unknown
conclus
morpholog
chang
mitochondria
extrasarcomer
structur
common
fhcm
regardless
breed
genotyp
phenotyp
diseas
express
moreov
mitochondri
subpopulationspecif
chang
occur
fhcm
deplet
ssm
ultrastructur
function
chang
cardiac
muscl
mitochondria
consid
import
molecular
mechan
respons
develop
progress
fhcm
may
relev
futur
treatment
target
conflict
interest
report
patent
ductu
arteriosu
pda
one
common
congenit
cardiac
defect
dog
ductal
patenc
associ
pulmonari
overcircul
left
ventricular
volum
overload
rapidli
determin
congest
heart
failur
untreat
sever
devic
close
pda
use
amplatz
canin
duct
occlud
consid
safer
devic
lowest
complic
rate
echocardiographi
repres
cornerston
pda
diagnosi
role
recent
expand
wider
field
applic
devic
size
intraop
monitor
well
tool
quantifi
cardiac
morpholog
function
speckletrack
echocardiographi
ste
use
evalu
cardiac
function
wide
varieti
diseas
human
veterinari
patient
howev
studi
evalu
use
dog
affect
pda
percutan
closur
pda
aim
studi
therefor
assess
standard
mbmode
deriv
paramet
cardiac
function
ste
deriv
longitudin
radial
circumferenti
strain
strain
rate
pda
closur
twentyf
dog
differ
breed
age
weight
prospect
recruit
complet
echocardiograph
evalu
perform
hour
pda
closur
end
diastol
systol
diamet
index
bodi
surfac
area
edviesvi
deriv
mmode
bmode
view
allometr
scale
deriv
allod
allo
spheric
index
si
pulmonari
system
flow
ratio
qpq
assess
pre
postop
ste
deriv
paramet
assess
longitudin
radial
circumferenti
strain
strain
rate
statist
signific
differ
found
standard
paramet
cardiac
function
pda
closur
p
gener
decreas
valu
hour
postop
ste
deriv
paramet
cardiac
function
show
trend
toward
decreas
back
normal
valu
statist
signific
p
circumferenti
radial
strain
strain
rate
longitudin
strain
strain
rate
reach
statist
signific
base
result
cardiac
dysfunct
identifi
use
ste
deriv
paramet
pda
closur
increas
contractil
identifi
higher
normal
ste
valu
pda
closur
decreas
back
normal
strain
strain
rate
valu
circumferenti
radial
immedi
percutan
closur
longitudin
strain
persist
higher
normal
valu
refus
hypothesi
systol
dysfunct
pda
closur
suggest
longer
revers
remodel
process
pda
closur
dr
bussadori
receiv
royalti
esaot
florenc
itali
relat
european
patent
nr
develop
xstrain
softwar
studi
fund
research
grant
cardiac
cachexia
character
progress
weight
loss
deplet
lean
bodi
mass
independ
predictor
surviv
human
patient
congest
heart
failur
chronic
degen
mitral
valv
diseas
cdmd
one
common
cardiac
diseas
dog
aim
studi
evalu
preval
effect
cardiac
cachexia
surviv
dog
cdmd
medic
record
clientown
dog
cdmd
review
mean
age
entri
ae
year
femal
male
data
obtain
record
includ
breed
sex
bodi
weight
age
diagnosi
complet
blood
count
biochem
profil
urinalysi
system
blood
pressur
thorac
radiograph
electrocardiogram
ultrasonographi
echocardiograph
examin
initi
visit
surviv
time
diagnosi
cdmd
base
echocardiograph
characterist
categor
modifi
new
york
heart
associ
nyha
function
classif
cardiac
cachexia
defin
presenc
unintent
weight
loss
within
month
diagnosi
togeth
anorexia
muscl
weak
anemia
red
cell
count
hemoglobin
gdl
hypoalbuminemia
plasma
albumin
gdl
azotemia
blood
urea
nitrogen
gdl
creatinin
gdl
dog
cardiac
disord
system
disord
would
caus
anemia
hypoalbuminemia
exclud
studi
preval
cardiac
cachexia
anemia
azotemia
respect
condit
preval
nyha
class
follow
nyha
class
preval
hypoalbuminemia
significantli
differ
among
class
oneyear
bodi
weight
chang
found
nyha
class
increas
ae
decreas
ae
decreas
ae
differ
class
signific
result
cox
proport
hazard
model
indic
surviv
time
significantli
posit
associ
nyha
function
sever
diagnosi
p
presenc
cardiac
cachexia
weight
loss
anemia
hypoalbuminemia
azotemia
p
p
p
p
p
respect
preval
cardiac
cachexia
common
advanc
cdmd
dog
paramet
cardiac
cachexia
name
weight
loss
anemia
hypoalbuminemia
azotemia
strong
prognost
factor
associ
surviv
conflict
interest
report
mitral
valv
diseas
mvd
common
cardiovascular
diseas
dog
character
myxomat
degener
caus
mitral
valv
prolaps
mvp
mitral
regurgit
mr
left
apic
systol
murmur
lasm
mvd
affect
small
breed
dog
high
preval
cavali
king
charl
spaniel
ckc
main
goal
studi
determin
preval
lasm
mvp
mr
maltes
present
breed
among
dog
mvd
taiwan
correl
measur
influenc
age
gender
reproduct
state
bodi
weight
also
investig
studi
result
compar
mvd
preval
studi
europ
northamerica
clientown
maltes
dog
male
femal
bodi
weight
kg
age
yr
sign
heart
failur
recruit
intens
grade
lasm
record
grade
mvp
mildsever
mr
sever
mildmoder
sever
evalu
echocardiographi
logist
regress
use
determin
correl
age
presenc
lasm
mvp
mr
chisquar
test
use
evalu
whether
sex
reproductivestatu
relat
preval
lasm
mvp
mr
spearman
correl
coeffici
use
assess
relationship
age
bodi
weight
lasm
intens
grade
mvp
sever
mr
preval
lasm
mvp
mr
respect
posit
correl
age
p
age
dog
lasm
mvp
mr
year
respect
lasm
intens
mvp
grade
mr
sever
posit
correl
age
p
correl
bw
reproduct
statu
femal
significantli
higher
preval
lasm
male
vs
p
maltes
dog
taiwan
high
preval
earli
develop
mvd
compar
small
breed
dog
similar
mvd
ckc
countri
sinc
recruit
asymptomat
dog
studi
may
underestim
preval
mvd
whole
maltes
popul
knowledg
first
report
document
high
preval
mvd
taiwanes
malteseth
maltes
may
new
canin
model
genet
patholog
natur
histori
studi
mvd
boehringeringelheim
sponsor
author
accommod
cost
congress
cardioren
syndrom
dog
chronic
valvular
heart
diseas
retrospect
studi
e
martinelli
p
scarpa
c
quintavalla
c
locatelli
p
brambilla
univers
parma
parma
itali
univers
milan
milan
itali
human
medicin
primari
disord
heart
often
result
secondari
dysfunct
injuri
kidney
coexist
two
problem
patient
refer
cardioren
syndrom
cr
littl
inform
cr
avail
veterinari
medicin
aim
studi
defin
preval
chronic
kidney
diseas
ckd
complic
chronic
valvular
heart
diseas
cvhd
dog
investig
relationship
class
cardiac
insuffici
acvim
class
renal
insuffici
iri
medic
record
dog
present
cardiolog
servic
depart
veterinari
scienc
public
health
univers
milan
januari
decemb
retrospect
evalu
dog
complet
physic
examin
thorac
radiograph
cvhd
diagnosi
base
echocardiograph
examin
serum
biochem
panel
includ
assess
serum
creatinin
scr
serum
urea
bun
includ
studi
dog
heart
diseas
neoplasm
system
diseas
includ
studi
one
hundr
eighteen
dog
gender
male
femal
year
age
ae
year
kg
bodyweight
ae
kg
fulfil
inclus
criteria
male
femal
neuter
repres
breed
mongrel
miniatur
poodl
york
shire
terrier
shih
tzu
pinscher
dachshund
dog
classifi
follow
acvim
acvim
acvim
acvim
c
acvim
dog
normoazotem
scr
mgdl
stage
iri
iri
iri
statist
analysi
perform
use
jmp
sa
institut
inc
p
valu
consid
signific
preval
ckd
associ
azotemia
dog
affect
cvhd
statist
signific
direct
correl
acvim
iri
class
pearson
test
p
unexpectedli
dog
receiv
drug
medic
manag
heart
failur
acvim
class
c
normoazotem
despit
definit
conclus
role
cvhd
induct
andor
progress
ckd
drawn
crosssect
studi
result
suggest
direct
correl
sever
ckd
cvhd
conflict
interest
report
grow
evid
breed
differ
concentr
sever
blood
variabl
dog
aim
studi
investig
breed
differ
plasma
concentr
compon
reninangiotensinaldosteron
system
raa
serum
cortisol
concentr
healthi
dog
healthi
privatelyown
dog
nine
breed
examin
five
center
part
european
lupaproject
absenc
cardiovascular
clinic
relev
organrel
system
diseas
ensur
thorough
clinic
investig
plasma
concentr
aldosteron
renin
activ
serum
concentr
cortisol
measur
ria
elisa
assay
overal
signific
breed
differ
found
p
variabl
bonferronicorrect
pairwis
signific
differ
breed
found
comparison
cortisol
renin
aldosteron
highest
median
concentr
found
newfoundland
valu
time
higher
breed
renin
highest
dachshund
time
higher
newfoundland
boxer
lowest
concentr
aldosteron
especi
low
belgian
shepherd
median
concentr
time
breed
cortisol
highest
finnish
lapphund
almost
time
higher
boxer
lowest
concentr
conclus
consider
interbre
variat
concentr
compon
raa
cortisol
found
healthi
dog
differ
like
influenc
genet
factor
taken
account
design
clinic
trial
test
breedspecif
refer
rang
might
necessari
conflict
interest
report
studi
assess
weight
manag
obes
dog
examin
earli
stage
weight
loss
may
properli
reflect
complet
weight
manag
regim
aim
current
studi
examin
kinet
complet
weight
manag
cycl
obes
clientown
dog
dog
refer
royal
canin
weight
manag
clinic
univers
liverpool
manag
obes
elig
inclus
dog
follow
either
complet
ie
reach
target
weight
programm
discontinu
rate
weight
loss
percentag
weight
lost
energi
assess
differ
time
point
total
dog
includ
rang
breed
age
sex
repres
rate
weight
loss
steadili
decreas
throughout
weight
loss
period
ae
wk
ae
wk
ae
wk
ae
wk
ae
wk
ae
wk
p
energi
intak
requir
maintain
weight
loss
also
progress
decreas
p
day
mean
aesd
weight
loss
ae
complianc
good
complet
complet
ongo
discontinu
thereaft
dog
complet
number
discontinu
also
increas
ae
weight
loss
complet
ongo
discontinu
ae
weight
loss
complet
ongo
stop
initi
weight
loss
good
obes
dog
thereaft
steadili
worsen
thu
studi
examin
first
month
weight
loss
fulli
repres
entir
weight
loss
process
conflict
interest
follow
conflict
interest
appli
diet
use
studi
manufactur
royal
caninwhilst
vb
employ
royal
canin
vb
ss
employ
royal
canin
ajg
readership
fund
royal
canin
obes
obesityrel
metabol
dysfunct
increas
human
well
dog
obes
dog
becom
affect
chronic
diseas
young
age
decreas
qualiti
life
shorter
lifespan
aim
studi
describ
metabol
hormon
respons
feedchalleng
test
lean
overweight
dog
twentyeight
healthi
intact
male
labrador
retriev
age
ae
year
vari
bodi
condit
score
bc
scale
includ
twelv
dog
classifi
lean
bc
ten
slightli
overweight
bc
six
overweight
bc
overnight
fast
period
blood
sampl
collect
follow
high
fat
meal
food
intak
blood
sampl
collect
hourli
four
hour
glucagon
elisa
valid
use
dog
assign
bc
support
posit
associ
serum
leptin
concentr
postprandi
triglycerid
concentr
significantli
higher
overweight
group
tendenc
higher
cholesterol
concentr
seen
overweight
group
cholesterol
affect
food
intak
glucagon
concentr
rose
food
intak
resembl
respons
seen
human
mix
meal
glucos
insulin
concentr
follow
pattern
free
fatti
acid
declin
one
hour
meal
studi
metabol
hormon
respons
high
fat
meal
similar
lean
slightli
overweight
dog
wherea
respons
overweight
dog
differ
studi
health
signific
postprandi
hypertriglyceridemia
dog
warrant
conflict
interest
studi
financi
support
swedish
veterinarian
feder
companion
anim
research
foundat
foundat
thure
f
karin
forsberg
felin
weightloss
program
often
hinder
complianc
issu
sedentari
lifestyl
purpos
studi
assess
effect
new
dietet
weight
manag
food
ndwmf
achiev
weight
loss
overweightobes
clientown
cat
object
evalu
weight
loss
paramet
cat
fed
ndwmf
describ
owner
percept
cat
qualiti
life
overweightobes
otherwis
healthi
clientown
cat
bodi
condit
score
bc
enrol
studi
n
initi
veterinari
evalu
compris
physic
examin
nutrit
assess
determin
ideal
bodi
weight
ibw
develop
weight
loss
feed
plan
daili
energi
requir
der
weight
loss
calcul
der
x
x
ibw
kg
initi
followup
evalu
monthli
month
consist
determin
bodi
weight
bw
bc
bodi
fat
index
bfi
muscl
condit
score
mc
current
feed
practic
qualiti
life
assess
owner
includ
cat
level
energi
happi
appetit
beg
behavior
flatul
stool
volum
fecal
score
statist
analysi
encompass
scatterplot
regress
analysi
summari
statist
appropri
type
analys
continu
categor
variabl
distribut
mix
model
anova
use
assess
chang
time
statist
signific
p
eighti
three
percent
cat
n
lost
weight
averag
weight
loss
sem
month
averag
weekli
weight
loss
rate
sem
signific
decreas
bc
week
bfi
week
compar
baselin
observ
mc
chang
averag
durat
weight
loss
day
sem
day
day
sem
day
visit
fourteen
percent
cat
achiev
ibw
ci
seventi
nine
percent
cat
ate
recommend
der
median
fed
major
cat
still
lost
weight
owner
perceiv
signific
increas
energi
happi
week
compar
baselin
cat
lost
weight
without
chang
appetit
beg
behavior
signific
chang
seen
score
flatul
stool
volum
fecal
score
conclus
clinic
studi
show
feed
ndwmf
clientown
overweightobes
cat
result
weight
loss
owner
report
signific
improv
cat
qualiti
life
without
neg
side
effect
porphyria
group
inborn
error
metabol
result
accumul
porphyrin
due
defici
activ
specif
enzym
heme
biosynthesi
human
clinic
classifi
either
erythroid
cutan
involv
hepat
acut
neuroviscer
attack
describ
clinic
biochem
molecular
genet
studi
porphyr
cat
new
brunswick
canada
three
separ
identifi
adult
domest
shorthair
cat
citi
saint
john
new
brunswick
found
erythrodontia
brown
discolor
teeth
fluoresc
pink
pigmenturia
mild
compens
hemolyt
disord
numer
small
dark
blue
irregularli
shape
erythrocyt
inclus
note
evid
acut
lifethreaten
neuroviscer
attack
cutan
lesion
necropsi
one
cat
reveal
massiv
deposit
porphyrin
bone
teeth
urin
edta
blood
sampl
one
cat
metabol
studi
molecular
genet
studi
perform
cat
either
edta
blood
formalin
splenic
tissu
block
urinari
daminolevulin
acid
porphobilinogen
uroporphyrin
coproporphyrin
concentr
increas
cat
studi
suggest
acut
intermitt
porphyria
aip
erythrocyt
hydroxymethylbilan
synthas
hmb
activ
erythrocyt
approxim
half
normal
suggest
domin
enzymopathi
erythrocyt
uroporphyrinogen
iiisynthas
activ
normal
sequenc
felin
hmb
gene
reveal
heterozyg
intron
base
delet
result
insert
mrna
would
predict
truncat
protein
conclus
three
domest
shorthair
cat
hmb
mutat
caus
autosom
dominantli
inherit
aip
cat
discolor
teeth
normal
mild
hemolysi
may
either
acut
intermitt
porphyria
congenit
erythroid
porphyria
interestingli
seven
diseasecaus
mutat
found
us
hmb
gene
gene
cat
biochem
molecular
character
facilit
clinic
screen
affect
cat
reach
specif
diagnosi
support
part
nih
od
ur
giger
raj
karthik
also
part
laboratori
offer
dna
test
mutat
fibrinogen
decreas
coagul
activ
form
fibrin
fdp
ddimer
repres
product
fibrinolysi
human
activ
coagul
fibrinolysi
develop
type
ascit
also
associ
sign
system
fibrinolysisthes
result
lead
suggest
ascit
fluid
inher
fibrinolyt
preliminari
studi
show
similar
result
also
dog
javma
nov
ecvim
proceed
addit
old
experiment
studi
conduct
dog
inocul
blood
solut
contain
fibrinogen
thrombin
pleural
caviti
result
activ
coagul
system
follow
fibrinolysi
therefor
object
present
studi
determin
whether
activ
coagul
fibrinolysi
ie
low
fibrinogen
elev
fdp
ddimer
occur
ascit
fluid
alredi
demonstr
also
type
pleural
effus
dog
thirtythre
dog
refer
san
marco
veterinari
clinic
pleural
effus
without
ascit
studi
fibrinogen
fdp
ddimer
concentr
measur
compar
pleural
fluid
venou
blood
via
wilcoxon
sign
rank
test
dog
pleural
effus
categor
base
pathophysiolog
fluid
format
dog
transud
due
increas
hydrostat
pressur
due
decreas
osmot
pressur
exud
due
septic
caus
haemorrhag
pleural
effus
chylou
effus
fibrinogen
concentr
pleural
effus
median
mgdl
rang
significantli
lower
p
plasma
fibrinogen
concentr
median
mgdl
rang
dog
fibrinogen
pleural
fluid
concentr
lower
plasma
concentr
fdp
concentr
pleural
effus
median
mgdl
rang
significantli
p
higher
plasma
fdp
concentr
median
mgdl
rang
case
fdp
pleural
fluid
concentr
lower
plasma
concentr
case
pleural
fluid
concentr
higher
ddimer
concentr
significantli
p
higher
pleural
effus
median
lgml
rang
plasma
median
lgml
rang
one
case
ddimer
pleural
fluid
concentr
lower
plasma
concentr
case
higher
find
support
hypothesi
activ
coagul
follow
fibrinolysi
occur
type
pleural
effus
conflict
interest
report
primari
hyperfibrinogenolysi
phf
fdp
product
increas
product
ddimer
therefor
elev
fdp
normal
ddimer
consid
indic
phf
human
dog
activ
coagul
fibrinolysi
develop
type
ascit
associ
system
phf
suggest
asciti
inher
fibrinolyt
preliminari
data
shown
activ
coagul
follow
fibrinolysi
occur
also
type
pleural
effus
pe
object
studi
determin
system
phf
occur
also
dog
pe
thirtythre
dog
refer
san
marco
veterinari
clinic
pe
without
ascit
studi
group
electron
databas
clinic
dog
inclus
control
group
healthi
dog
sick
dog
without
pe
ascit
randomli
select
individu
match
group
dog
age
sex
breed
fibrinogen
fdp
ddimer
creactiv
protein
crp
fibrinogencrp
ratio
preval
phf
ie
dog
elev
plasma
fdp
normal
ddimer
determin
differ
group
analyz
use
anova
fibrinogen
chisquar
fdp
preval
phf
kruskalw
test
crp
fibrinogencrp
ratio
ddimer
posttest
analysi
perform
tamhan
mannwhitney
test
fibrinogen
concentr
group
significantli
increas
compar
group
p
compar
group
p
fdp
concentr
group
significantli
increas
compar
group
p
compar
group
p
ddimer
concentr
group
significantli
increas
compar
group
p
compar
group
p
crp
significantli
increas
group
compar
group
p
comparison
fibrinogencrp
ratio
significantli
decreas
group
compar
group
p
comparison
preval
phf
significantli
higher
group
compar
group
p
compar
group
p
result
support
hypothesi
phf
occur
significantli
often
dog
pe
compar
healthi
dog
despit
trend
increas
phf
also
dog
pe
compar
sick
dog
differ
reach
signific
nevertheless
decreas
fibrinogencrp
ratio
group
compar
group
face
similar
ddimer
concentr
would
suggest
phf
also
preval
dog
pe
compar
sick
control
dog
conflict
interest
report
system
inflammatori
respons
syndrom
sir
refer
clinic
sign
system
inflamm
respons
non
infecti
insult
current
diagnosi
sir
base
clinic
basic
laboratori
data
sensit
screen
identifi
patient
risk
creactiv
protein
crp
major
canin
acut
phase
protein
concentr
relat
diseas
sever
underli
caus
crp
rise
respons
proinflammatori
cytokin
mainli
interleukin
il
tumor
necrosi
factor
tnf
consid
main
trigger
sir
therefor
evalu
crp
tnfa
kinet
canin
emerg
sir
patient
hypothes
crp
increas
dog
clinic
sirsdiagnosi
correl
tnfa
concentr
influenc
underli
etiolog
prognost
marker
canin
emerg
clinic
diagnos
sir
prospect
includ
serum
plasma
immedi
store
sampl
present
hour
control
visit
one
month
discharg
serum
crp
measur
caninespecif
immunoturbidimetr
crp
assay
plasma
tnfa
measur
use
bioassay
measur
biolog
activ
cytokin
concentr
diseas
categori
infect
neoplasia
n
trauma
gastricdil
volvulu
gdv
gastrointestin
gi
renal
r
miscellan
diseas
statist
analysi
perform
sa
concentr
inflammatori
cytokin
express
logarithm
univari
analysi
confirm
normal
distribut
correl
procedur
mix
procedur
linear
model
logist
procedur
perform
pvalu
sixti
seven
dog
n
r
includ
fortythre
patient
surviv
seven
die
seventeen
euthan
twenti
patient
control
visit
crp
elev
dog
present
remain
within
refer
rang
mgl
throughout
hospit
four
dog
crp
concentr
significantli
higher
ae
mgl
ae
mgl
decreas
ae
mgl
return
within
refer
rang
ae
mgl
one
dog
mgl
crp
significantli
correl
logarithm
concentr
tnfa
howev
chang
significantli
time
none
evalu
paramet
associ
diseas
categori
outcom
crp
appear
use
diagnos
sir
emerg
patient
tend
decreas
hospit
howev
crp
neither
tnfa
concentr
appear
use
predict
underli
diseas
outcom
sir
patient
conflict
interest
report
calprotectin
complex
belong
famili
primarili
releas
activ
neutrophil
macrophag
serum
calprotectin
concentr
cp
shown
increas
dog
inflammatori
diseas
inflammatori
bowel
diseas
pancreat
system
inflammatori
respons
syndrom
sepsi
canin
cp
thu
appear
biomark
inflamm
consider
daytoday
variat
fecal
canin
cp
found
healthi
dog
dog
chronic
gastrointestin
diseas
howev
biolog
variat
canin
cp
serum
report
aim
studi
determin
biolog
variat
serum
canin
cp
minimum
critic
differ
mcd
eleven
healthi
dog
use
studi
biolog
variat
serum
canin
cp
evalu
period
test
outlier
carri
level
withinrun
analyt
varianc
intra
interindividu
variat
nest
analysi
varianc
anova
model
use
calcul
analyt
cv
intraindividu
cv
interindividu
cv
g
total
variat
cv
determin
index
individu
ii
index
heterogen
ih
mcd
total
serial
specimen
collect
dog
serial
sampl
dog
serial
sampl
dog
four
withinsubject
outlier
detect
exclud
analysi
yield
total
serum
sampl
slightli
rightskew
data
outli
observ
cochran
test
outlier
among
mean
concentr
subject
reed
criterion
detect
cv
calcul
cv
cv
g
result
cv
index
individu
ii
determin
ih
yield
onesid
mcd
mgl
analyt
goal
cv
satisfi
although
serum
canin
cp
remain
within
rel
narrow
concentr
rang
healthi
dog
moder
individu
detect
moder
chang
serum
canin
cp
mgl
sequenti
measur
need
consid
clinic
relev
use
populationbas
refer
interv
may
may
appropri
serum
canin
cp
use
mcd
previous
determin
median
canin
cp
concentr
mgl
refer
sampl
group
yield
serum
canin
cp
concentr
close
upper
limit
previous
establish
refer
interv
mgl
show
refer
interv
serum
ccp
mgl
within
reason
limit
assay
use
studi
develop
gi
laboratori
texa
univers
author
also
work
gi
laboratori
texa
univers
canin
leishmaniasi
canl
multisystem
diseas
endem
mediterranean
region
past
concentr
acut
phase
protein
app
specif
creactiv
protein
crp
haptoglobin
hp
ceruloplasmin
cp
serum
amyloid
saa
albumin
alb
report
chang
dog
leishmaniasi
revert
normal
success
treatment
highlight
intrins
inflammatori
reaction
host
parasit
sinc
spectrum
clinic
laboratori
derang
broad
possibl
app
increas
specif
certain
clinicopatholog
syndrom
associ
canl
total
dog
canl
diagnos
basi
cytolog
amastigot
identif
ifat
serolog
retrospect
includ
studi
crp
saa
hp
alb
measur
interlabumu
murcia
spain
aliquot
serum
store
year
median
year
result
app
correl
laboratori
clinic
paramet
clinic
parasitolog
score
ehrlichia
leishmania
serolog
clinic
stage
accord
leishvet
use
array
linear
ordin
regress
model
well
oneway
anova
ttest
fisher
lsd
test
crp
alb
far
app
frequent
correl
clinic
laboratori
abnorm
nutrit
statu
lethargi
skin
ulcer
p
well
urinari
protein
creatinin
ratio
upc
total
serum
protein
urin
specif
graviti
p
limit
associ
hp
cp
saa
clinicopatholog
paramet
minor
linear
relationship
observ
crp
clinic
score
crp
alb
also
correl
parasitolog
score
bone
marrow
lymph
node
cytolog
p
dog
ehrlichia
titer
higher
crp
cp
lower
alb
concentr
final
crp
concentr
higher
later
compar
earlier
stage
infect
defin
leishvet
criteria
inflammatori
compon
leishmania
infect
nt
seem
exemplifi
reaction
particular
tissu
possibl
except
glomerulonephr
magnitud
increas
crp
decreas
albumin
correl
clinic
stage
bone
marrow
parasitolog
score
conflict
interest
report
consequ
abnorm
platelet
function
dog
cat
devast
use
antithrombot
therapi
prevent
thrombot
event
increasingli
common
abil
measur
platelet
function
efficaci
antithrombot
therapi
difficult
due
limit
avail
equip
inabl
delay
platelet
function
analysi
aim
studi
adapt
valid
test
procedur
protocol
previous
develop
human
use
dog
cat
residu
sampl
citrat
anticoagul
blood
use
dog
cat
present
specialist
referr
centr
variou
reason
unrel
clot
abnorm
initi
blood
stimul
use
specif
combin
either
arachidon
acidepinephrin
aaepi
design
assess
effect
antithrombot
agent
aspirin
clopidogrel
respect
minut
stimul
blood
sampl
fix
use
patent
platelet
fix
solut
develop
human
platelet
allow
delay
analysi
pselectin
establish
marker
platelet
activ
analysi
perform
flow
cytometri
order
specif
antibodi
select
recognit
canin
felin
platelet
use
platelet
identifi
antibodi
appropri
pselectin
antibodi
speci
chosen
fix
sampl
repeatedli
analys
time
point
day
follow
fixat
establish
stabil
fix
sampl
thirteen
dog
three
cat
analys
high
pselectin
express
detect
follow
stimul
aaepi
dog
cat
follow
fixat
significantli
differ
unstimul
blood
p
signific
differ
detect
pselectin
express
follow
storag
fix
sampl
timepoint
day
confirm
fix
suitabl
preserv
canin
felin
platelet
limit
number
dog
evalu
whilst
receiv
antithrombot
medic
signific
differ
activ
platelet
dog
treat
either
aspirin
p
clopidogrel
p
compar
untreat
dog
follow
stimul
aaepi
aspirin
group
adp
clopidogrel
group
result
show
fixat
delay
analysi
platelet
function
dog
cat
possibl
day
demonstr
excit
opportun
analys
platelet
function
remot
determin
efficaci
thromboprophylaxi
anim
present
clinic
onsit
platelet
analys
conflict
interest
report
sever
author
consid
thyroid
hormon
supplement
valid
initi
treatment
option
dog
aggress
relat
problem
inde
mood
behaviour
modul
properti
thyroid
hormon
may
part
mediat
interact
thyroid
hormon
neurohormon
serotonin
prolactin
present
prospect
trial
evalu
neurohormon
statu
behaviour
hypothyroid
dog
thyroid
supplement
lack
therefor
aim
studi
assess
behaviour
measur
serum
serotonin
prolactin
concentr
dog
spontan
hypothyroid
treatmenttwenti
three
clientown
dog
diagnos
spontan
primari
hypothyroid
prospect
includ
studi
diagnosi
dog
treat
levothyroxin
microgramskg
bid
behaviour
dog
screen
initi
present
week
month
initi
therapi
owner
fill
hard
copi
standard
canin
behaviour
assess
research
questionnair
cbarq
consist
score
question
evalu
seven
behaviour
categori
averag
score
question
calcul
dog
three
time
period
pair
ttest
use
comparison
serum
serotonin
prolactin
concentr
evalu
time
period
use
commerci
valid
elisa
kit
heterolog
ria
respectivelyresult
cbarq
six
week
thyroid
hormon
supplement
compar
time
zero
demonstr
signific
increas
p
excit
activ
aggress
like
becam
unmask
owe
improv
overal
activ
dog
convers
six
month
period
compar
time
zero
signific
chang
behaviour
symptom
observ
serum
serotonin
measur
dog
colorimetr
nm
time
zero
week
month
serum
serotonin
rang
rang
rang
signific
differ
note
week
month
period
compar
time
zero
p
p
serum
prolactin
concentr
measur
dog
time
zero
week
month
ngml
rang
ngml
rang
ngml
rang
differ
significantli
either
time
period
compar
time
zero
p
p
altogeth
result
studi
fail
demonstr
signific
role
thyroid
supplement
major
evalu
behaviour
symptom
well
neurohormon
statu
hypothyroid
dog
month
therapi
conflict
interest
report
iatrogen
hypothyroid
recogn
complic
radioiodin
treatment
hyperthyroid
cat
prospect
studi
preval
clinic
featur
routin
laboratori
find
result
thyroid
function
test
report
seri
hypothyroid
cat
studi
describ
featur
hypothyroid
cat
treat
radioiodin
period
octob
period
treat
hyperthyroid
cat
radioiodin
provid
preval
rate
hypothyroid
diagnos
day
median
day
treatment
dose
rang
mbq
median
mbq
median
pretreat
nmoll
hypothyroid
cat
rang
age
year
median
year
dshdlh
femal
male
p
clinic
sign
cat
includ
overweightobes
lethargydul
poor
appetit
polyuriapolydipsia
abnorm
physic
examin
includ
dermatolog
sign
dri
coat
seborrhea
mat
bradycardia
bpm
twentytwo
cat
notic
clinic
featur
hypothyroid
routin
laboratori
abnorm
includ
hypercholesterolemia
mmoll
new
worsen
azotemia
lmoll
cat
respect
median
serum
concentr
total
nmoll
refer
interv
ri
nmoll
nmoll
ri
nmoll
pmoll
ri
pmoll
low
end
ri
normal
ri
valu
maintain
cat
respect
serum
ctsh
valu
high
cat
median
ngdl
rang
ngdl
ri
ngml
thyroid
scintigraphi
show
lessthannorm
amount
residu
tissu
well
low
valu
thyroidtosalivari
ratio
uptak
pertechnet
cat
normal
scintiscan
serum
ctsh
decreas
ri
without
treatment
retest
month
later
conclus
studi
confirm
iinduc
hypothyroid
uncommon
appar
femal
sex
predilect
serum
remain
normal
cat
high
serum
ctsh
valu
thyroid
scintigraphi
aid
diagnosi
unless
cat
overt
longstand
hypothyroid
cat
subclin
diseas
rel
asymptomat
worsen
azotemia
subclin
hypothyroid
transient
cat
normal
ctsh
valu
within
month
conflict
interest
report
iatrogen
hypothyroid
recogn
complic
radioiodin
treatment
hyperthyroid
cat
clinic
use
variabl
dose
protocol
base
tumor
volum
sever
hyperthyroid
preval
overt
subclin
hypothyroid
least
period
octob
march
treat
cat
iatrogen
hypothyroid
develop
day
median
day
treatment
radioiodin
median
dose
mbq
cat
rang
age
year
median
year
dshdlh
femal
male
new
worsen
azotemia
lmoll
document
cat
respect
diagnosi
hypothyroid
base
follow
low
lownorm
serum
concentr
high
serum
tsh
concentr
ngdl
lessthannorm
amount
residu
tissu
thyroid
scintigraphi
cat
given
thyroid
hormon
replac
liquid
prepar
leventa
merck
anim
health
cat
monitor
month
interv
repeat
serum
tsh
concentr
hour
morn
dose
ten
cat
start
oncedaili
regimen
lg
suppress
high
serum
tsh
valu
refer
interv
ri
cat
persist
high
tsh
valu
switch
twicedaili
administr
lg
bid
success
lower
high
tsh
concentr
cat
remain
cat
start
twice
daili
lg
bid
normal
tsh
occur
cat
overal
treatment
success
normal
tsh
concentr
cat
oncedaili
twicedaili
dose
peak
serum
concentr
nmoll
need
cat
normal
tsh
valu
higher
serum
lower
tsh
concentr
achiev
administ
empti
stomach
rather
given
food
signific
decreas
p
serum
creatinin
occur
treatment
conclus
result
indic
twicedaili
administr
need
cat
iatrogen
hypothyroid
normal
high
serum
tsh
concentr
mani
cat
appear
absorb
rather
poorli
enhanc
give
drug
empti
stomach
azotemia
commonli
develop
cat
hypothyroid
improv
stabil
adequ
supplement
conflict
interest
report
congenit
hypothyroid
ch
report
mani
speci
hereditari
form
divid
thyroid
dysmorphogenesi
dyshormonogenesi
thyroid
hypoplasia
describ
dog
cat
molecular
basi
remain
unknown
contrast
breed
dog
goiter
ch
found
defici
thyroid
peroxidas
tpo
activ
purpos
studi
character
famili
domest
shorthair
cat
goiter
ch
diseasecaus
tpo
gene
mutat
clinic
featur
includ
dwarfism
dull
known
cretin
seen
ch
speci
also
constip
megacolon
uniqu
cat
ch
pedigre
analysi
document
autosom
recess
mode
inherit
affect
kitten
develop
goiter
low
serum
thyroxin
triiodothyronin
compar
control
high
thyroid
stimul
tsh
hormon
level
indic
thyroid
dyshormonogenesi
oral
thyroid
supplement
correct
progress
clinic
sign
prevent
constip
revers
megacolon
tpo
enzym
activ
extrem
low
hypothyroid
cat
compar
normal
cat
genom
dna
cdna
affect
carrier
normal
cat
extract
sequenc
base
upon
primer
develop
felin
genom
databas
homozyg
missens
point
mutat
tpo
result
amino
acid
chang
discov
affect
cat
mutant
allel
segreg
within
famili
goiter
ch
first
report
tpo
defici
cat
unrel
domest
shorthair
cat
goiter
ch
tpo
mutat
preval
tpo
mutat
domest
cat
popul
seem
low
ch
like
underreport
cat
support
part
nih
od
author
member
diagnost
laboratori
penngen
support
part
nih
od
glucagonlik
gastrointestin
hormon
releas
respons
food
intak
increas
insulin
secret
inhibit
glucagon
secret
slow
gastric
empti
induc
satiat
also
assum
stimul
betacel
prolifer
agonist
success
use
human
type
diabet
mellitu
usual
either
combin
insulin
antidiabet
drug
healthi
cat
twice
daili
exenatid
well
weekli
exenatid
extendedreleas
er
applic
agonist
induc
pronounc
insulin
secret
benefit
exenatid
er
regimen
weekli
inject
less
side
effect
object
studi
assess
whether
administr
exenatid
er
addit
standard
treatment
lead
improv
glycem
control
higher
remiss
rate
cat
newli
diagnos
diabet
studi
design
prospect
placebocontrol
clinic
trial
cat
randomli
assign
two
group
receiv
exenatid
er
group
bydureon
mgkg
sc
salin
solut
group
sc
group
addit
receiv
insulin
glargin
lantu
initi
dose
kg
iu
h
kg
iu
h
diet
purina
dm
exenatid
er
appli
week
case
remiss
addit
week
cessat
insulin
applic
cat
recheck
week
start
therapi
remiss
diabet
defin
absenc
clinic
sign
diabet
normal
blood
glucos
fructosamin
concentr
least
week
discontinu
insulin
inject
far
cat
complet
studi
mild
transient
side
effect
group
n
reduc
appetit
n
nausea
n
vomitu
n
tired
n
hide
dark
spot
hous
n
group
remiss
achiev
cat
good
metabol
control
nonremiss
cat
group
remiss
achiev
cat
good
metabol
control
nonremiss
cat
median
insulin
dose
given
studi
period
iu
kgday
group
iukgday
group
preliminari
result
suggest
exenatid
er
use
safe
diabet
cat
tendenc
higher
remiss
rate
better
metabol
control
lower
insulin
requir
seen
exenatid
er
ad
standard
treatment
regimen
case
need
evalu
verifi
potenti
benefici
role
exenatid
er
conflict
interest
report
felin
diabet
mellitu
share
mani
similar
human
type
diabet
mellitu
includ
clinic
physiolog
patholog
featur
diseas
domest
cat
spontan
develop
diabet
associ
insulin
resist
middl
age
later
residu
declin
insulin
secret
human
cat
share
environ
risk
factor
diabet
obes
physic
inact
moreov
amyloid
format
loss
beta
cell
found
diabet
cat
pancrea
human
subsequ
studi
molecular
mechan
fail
beta
cell
may
contribut
better
understand
pathophysiolog
cat
human
aim
present
studi
develop
method
studi
mrna
express
isletspecif
gene
healthi
diabet
cat
previou
attempt
isol
felin
islet
differ
collagenasebas
protocol
led
damag
islet
islet
coat
exocrin
acinar
cell
either
way
compromis
result
obtain
gene
express
studi
use
laser
microdissect
techniqu
abl
sampl
islet
contamin
exocrin
tissu
healthi
diabet
cat
high
rna
qualiti
confirm
gel
electrophoresi
quantit
realtim
pcr
qrtpcr
mrna
level
isletspecif
gene
insulin
iapp
chga
detect
healthi
diabet
cat
use
actin
b
gapdh
intern
refer
gene
normal
qrtpcr
data
laser
microdissect
techniqu
allow
studi
islet
without
contamin
acinar
cell
shown
studi
great
advantag
sinc
difficult
get
pure
felin
islet
collagenasebas
isol
differ
gene
express
healthi
diabet
cat
may
reveal
underli
mechan
beta
cell
dysfunct
decreas
beta
cell
mass
human
felin
type
diabet
conflict
interest
studi
financi
support
swedish
juvenil
diabet
foundat
fredrik
ingrid
thure
foundat
magnu
bergval
foundat
lar
hierta
memori
foundat
foundat
research
agria
insur
compani
felin
acromegali
increasingli
recognis
endocrinopathi
among
diabet
cat
caus
chronic
excess
growth
hormon
secret
function
somatotrophinoma
par
distali
anterior
pituitari
gland
major
human
somatotrophinoma
sporad
howev
famili
isol
pituitari
adenoma
caus
germlin
mutat
arylhydrocarbonreceptor
interact
protein
aip
felin
acromegali
phenotyp
biochem
similar
human
famili
acromegali
aip
mutat
male
predomin
somatotroph
macroadenoma
resist
octreotid
therapi
object
studi
identifi
felin
aip
gene
identifi
singl
nucleotid
polymorph
snp
within
gene
compar
snp
report
human
aip
snp
store
pituitari
tissu
acromegal
cat
use
creat
felin
aip
cdna
use
felin
specif
aip
primer
store
edta
blood
acromegal
cat
diagnosi
insulin
resist
diabet
mellitu
serum
ngml
pituitari
mass
mm
identifi
use
pituitari
comput
tomographi
necropsi
control
cat
histori
diabet
mellitu
greater
year
age
select
dna
extract
genotyp
use
pcr
agaros
gel
electrophoresi
sanger
sequenc
felin
aip
gene
identifi
encod
amino
acid
protein
homolog
human
aip
protein
blast
search
reveal
gene
contain
exon
exon
specif
primer
creat
enabl
sequenc
singl
nonconserv
snp
identifi
exon
aip
encod
amino
acid
chang
aspart
acid
glutam
acid
acromegal
patient
control
cat
two
addit
conserv
snp
also
identifi
aip
c
aip
c
exon
encod
region
aip
protein
consid
essenti
aipaip
receptor
interact
although
differ
human
aip
mutat
identifi
date
human
aip
mutat
yet
identifi
aip
ntermin
requir
stabil
aip
proteinaipreceptor
complex
essenti
regul
transloc
nucleu
bind
aryl
hydrocarbon
receptor
nuclear
transloc
lead
activ
gene
thought
act
tumor
suppressor
loss
normal
aip
activ
thought
promot
somatotrophinoma
develop
therefor
possibl
detect
aip
mutat
predispos
somatotrophinoma
tumorigenesi
two
affect
patient
studi
contain
larger
number
case
indic
conflict
interest
report
hypersomatotroph
hs
import
caus
felin
diabet
mellitu
dm
human
surgic
remov
somatotrophinoma
gener
recommend
though
hypophysectomi
program
suffer
signific
initi
morbid
mortal
given
document
steep
learn
curv
newli
establish
program
hypophysectomi
treatment
felin
hs
thu
far
describ
hand
case
treat
one
singl
experienc
hypophysectomi
team
studi
aim
evalu
learn
curv
de
novo
establish
hypophysectomi
program
analysi
periand
postop
morbid
mortal
endocrin
outcom
first
cohort
cat
hs
treat
owner
diabet
cat
confirm
hs
ngml
pituitari
mass
present
royal
veterinari
colleg
offer
hypophysectomi
cat
undergo
surgeri
oper
one
neurosurgeon
previous
cadaver
experi
procedur
adapt
transsphenoid
approach
referenc
boni
landmark
comput
tomograph
scan
reconstruct
neuronavig
softwar
somatotrophinoma
extirp
use
fine
surgic
tool
cat
receiv
intens
electrolyt
blood
pressur
monitor
periand
postop
ddavp
intraven
insulin
hydrocortison
infus
transit
subcutan
glargin
conjunctiv
ddavp
oral
hydrocortison
levothyroxin
april
cat
underw
hypophysectomi
median
rang
age
year
ngml
pituitari
height
mm
display
uncontrol
dm
due
hs
median
fructosamin
umol
none
display
overt
central
neurolog
deficit
two
cat
cat
pituitari
height
mm
requir
mechan
ventil
postop
euthan
postmortem
magnet
reson
imag
reveal
brain
herniat
cerebr
ischaemia
suspect
one
cat
suffer
cardiac
arrest
postop
time
jugular
cathet
placement
though
made
unev
recoveri
four
cat
develop
congest
heart
failur
within
day
success
treat
necessit
ongo
therapi
temporarili
diminish
tear
product
seen
cat
seven
ten
surviv
cat
went
diabet
remiss
within
median
day
other
saw
reduct
insulin
need
serum
normalis
rapidli
significantli
one
cat
median
serum
ngml
within
day
persist
neurolog
deficit
palat
wound
breakdown
encount
start
hypophysectomi
program
treat
felin
hs
associ
risk
mortal
though
surviv
case
benefit
procedur
high
incid
diabet
remiss
conflict
interest
report
pituitari
depend
hypercortisol
pdh
dog
frequent
associ
high
serum
phosphat
parathormon
concentr
pathogenesi
abnorm
remain
unknown
evalu
urinari
fraction
excret
phosphat
calcium
pdh
dog
might
help
enhanc
knowledg
regard
issu
aim
present
studi
evalu
serum
urinari
concentr
urinari
fraction
excret
phosphat
calcium
dog
pdh
medic
record
one
referr
center
retrospect
evalu
diagnosi
pdh
confirm
use
cortisol
creatinin
ratio
ldd
test
andor
acth
stimul
test
plasma
acth
concentr
ultrasonographi
adren
gland
comput
tomographi
ct
pituitari
adren
gland
dog
consist
clinic
sign
newli
diagnos
dog
treatment
pdh
evalu
two
control
group
includ
one
healthi
one
sick
control
dog
without
pdh
dog
pdh
includ
healthi
control
dog
hcd
sick
control
dog
scd
match
age
month
breed
sex
sexual
statu
data
analys
use
nonparametr
test
express
median
rang
signific
set
p
onehundredsixtyseven
dog
pdh
elig
inclus
studi
median
age
diagnosi
year
rang
median
bodi
weight
kg
rang
femal
spay
male
castrat
serum
phosphat
concentr
mgdl
significantli
p
higher
compar
hcd
mgdl
scd
mgdl
serum
calcium
concentr
mgdl
significantli
higher
compar
scd
mgdl
differ
compar
hcd
mgdl
urinari
fraction
excret
phosphat
significantli
lower
compar
hcd
scd
urinari
fraction
excret
calcium
significantli
higher
compar
hcd
scd
urinari
calcium
creatinin
ratio
significantli
higher
compar
hcd
scd
urinari
phosphat
creatinin
ratio
significantli
differ
pdh
dog
hcd
scd
conclus
pdh
dog
lower
phosphaturia
higher
calciuria
compar
control
dog
find
suggest
least
part
high
serum
phosphat
concentr
relat
renal
retent
phosphat
conflict
interest
report
four
cortisolbas
method
monitor
trilostan
treatment
canin
hyperadrenocortic
compar
result
clinic
score
scheme
base
owner
questionnair
case
canin
hyperadrenocortic
receiv
consist
dose
trilostan
one
month
recruit
first
opinion
referr
practic
dog
use
owner
ask
complet
questionnair
assess
clinic
control
dog
categoris
overcontrol
wellcontrol
moderatelycontrol
poorlycontrol
cortisol
measur
serum
sampl
taken
pretrilostan
peak
hour
posttrilostan
trough
hour
postacth
inject
dog
increas
cortisol
trilostan
administr
exclud
score
system
develop
measur
fourth
score
system
develop
use
novel
algorithm
combin
peak
trough
cortisol
peaktrough
result
score
system
categoris
dog
would
expect
overcontrol
wellcontrol
moderatelycontrol
poorlycontrol
weight
kappa
calcul
assess
agreement
categoris
accord
method
compar
categoris
use
owner
score
pearson
correl
coeffici
calcul
assess
relationship
variou
paramet
total
test
analys
compar
result
owner
questionnair
dog
correctli
categoris
use
peaktrough
peak
alon
postacth
trough
alon
respect
amongst
miscategoris
result
dog
incorrect
categori
dog
categori
use
peaktrough
peak
alon
postacth
trough
alon
respect
method
correctli
recognis
overcontrol
dog
identifi
owner
score
weight
kappa
postacth
trough
cortisol
categori
compar
owner
score
categori
respect
defin
slight
agreement
contrast
weight
kappa
peak
peaktrough
categori
respect
defin
fair
agreement
signific
correl
absolut
clinic
score
cortisol
concentr
signific
correl
cortisol
measur
novel
method
peaktrough
peak
cortisol
better
reflect
level
clinic
control
hyperadrenocortic
identifi
owner
questionnair
either
postacth
stimul
trough
cortisol
peaktrough
peak
cortisol
concentr
investig
monitor
method
trilostan
financi
support
dechra
pharmaceut
prognosi
canin
adrenocort
insuffici
gener
regard
excel
howev
pauciti
surviv
analys
literatur
aim
present
studi
evalu
surviv
dog
diagnosi
adrenocort
insuffici
base
data
cohort
swedish
clientown
dog
insur
one
insur
compani
agria
pet
insur
stockholm
sweden
time
period
dog
identifi
search
insur
claim
regist
code
adrenocort
insuffici
dog
exclud
analysi
previou
histori
hypercortisol
born
begin
studi
period
kaplanmei
surviv
analysi
perform
dog
regard
censor
regist
caus
death
adrenocort
insuffici
hypercortisol
regist
first
claim
adrenocort
insuffici
data
dog
includ
one
hundr
twentyfour
dog
regist
dead
dog
caus
death
relat
adrenocort
insuffici
estim
survivalr
ci
estim
survivalr
ci
estim
survivalr
ci
twelv
dog
still
aliv
year
conclus
longterm
surviv
dog
adrenocort
insuffici
reason
good
howev
diseasesrel
mortal
higher
expect
occur
mainli
first
year
diagnosi
conflict
interest
studi
support
grant
swedish
research
council
foundat
research
agria
insur
compani
concomit
occurr
two
endocrin
tumor
andor
hyperplasia
known
multipl
endocrin
neoplasia
men
wellknown
entiti
human
multipl
gene
mutat
identifi
two
major
form
main
affect
organ
parathyroid
pancrea
pituitari
gland
occur
clinic
variant
character
medullari
thyroid
carcinoma
mtc
pheochromocytoma
primari
hyperparathyroid
men
character
mtc
pheochromocytoma
addit
abnorm
famili
medullari
thyroid
carcinoma
dog
cat
case
report
unknown
whether
hereditari
menlik
syndrom
exist
speci
aim
studi
evalu
preval
multipl
endocrin
tumor
dog
cat
institut
identifi
possibl
breed
sex
predisposit
investig
similar
human
men
syndrom
autopsi
report
dog
cat
review
anim
least
two
endocrin
tumorshyperplasia
eth
includ
autopsi
report
dog
cat
examin
dog
eth
affect
singl
organ
multipl
eth
cat
singl
eth
multipl
eth
dog
multipl
eth
common
breed
west
highland
white
terrier
whwt
poodl
golden
retriev
mixedbre
dog
male
intact
femal
neuter
median
age
year
rang
common
combin
multipl
testicl
tumor
variou
type
common
affect
organ
adren
adren
cortic
adenomascarcinomashyperplasia
mainli
associ
pheochromocytoma
testicl
tumor
insulinoma
whwt
adren
adenoma
poodl
pheochromocytoma
associ
pituitari
adenoma
adren
hyperplasia
dog
show
tumor
combin
similar
human
syndrom
pituitari
adenoma
insulinoma
pituitari
adenoma
parathyroid
hyperplasia
cat
domest
shortlong
hair
persian
male
castrat
femal
neuter
median
age
year
rang
common
affect
organ
thyroid
gland
combin
mostli
lesion
parathyroid
adren
gland
none
cat
combin
similar
human
men
syndrom
preval
multipl
eth
dog
cat
menlik
syndrom
extrem
rare
dog
nonexist
cat
sex
predisposit
observ
possibl
breed
predisposit
need
investig
conflict
interest
report
canin
angiostrongylosi
increasingli
report
diseas
worldwild
includ
mani
european
countri
possibl
due
climat
factor
presenc
fox
act
reservoir
simpli
avail
accur
diagnost
method
although
detect
firststag
larva
use
baermann
techniqu
faecal
sampl
prefer
collect
three
consecut
day
remain
gold
standard
recent
develop
serolog
molecular
test
quantit
polymeras
chain
reaction
qpcr
avail
preval
canin
angiostrongylosi
among
healthi
cough
dog
belgium
unknown
aim
present
studi
describ
clinic
seri
recent
autochton
case
retrospect
assess
angiostrongylu
vasorum
qpcr
bronchoalveolar
lavag
fluid
balf
sampl
collect
last
year
larger
seri
dog
healthi
respiratori
condit
order
investig
past
preval
diseas
belgium
seven
dog
live
southern
eastern
belgium
recent
diagnos
angiostrongylosi
mean
age
mean
bodi
weight
kg
present
respiratori
sign
variabl
sever
dog
balf
obtain
qpcr
posit
moder
high
level
ct
larva
detect
faec
anim
remain
two
dog
balf
obtain
coproscopi
posit
dog
respond
medic
treatment
consist
cours
fenbendazol
andor
two
spoton
applic
moxidectin
interv
balf
sampl
collect
asymptomat
clientown
dog
dog
variou
respiratori
condit
includ
dog
confirm
bordetellosi
dog
eosinophil
bronchopneumopathi
ebp
dog
chronic
bronchiti
dog
bacteri
bronchopneumonia
retrospect
assess
vasorum
qpcr
assay
amongst
dog
one
balf
dog
ebp
yield
posit
qpcr
result
dog
faecal
analysi
neg
present
data
show
base
balf
qpcr
coproscopi
presenc
angiostrongylosi
healthi
cough
dog
neglig
belgium
last
month
consid
emerg
condit
must
includ
differenti
diagnosi
cough
dog
present
result
also
support
qpcr
detect
vasorum
balf
avail
adequ
reliabl
detect
techniqu
conflict
interest
report
ligneou
membran
rare
chronic
inflammatori
diseas
associ
congenit
plasminogen
defici
describ
six
unrel
dog
object
studi
report
present
clinicopatholog
post
mortem
find
three
relat
scottish
terrier
puppi
ligneou
membran
ligneou
membran
well
describ
human
inherit
autosom
recess
manner
patient
commonli
present
infant
ocular
oral
genit
lesion
common
organ
occasion
involv
congenit
obstruct
hydrocephalu
report
individu
numer
mutat
polymorph
plasminogen
gene
identifi
affect
individu
affect
scottish
terrier
two
male
one
femal
present
month
age
sever
prolif
ulcer
conjunct
gingivitisstomat
biopsi
confirm
ligneou
membran
clinic
sign
includ
increas
upper
respiratori
tract
nois
nasal
discharg
lymphadenopathi
one
male
cryptorchid
clinic
patholog
find
includ
neutrophilia
proteinuria
hypoalbuinaemia
serum
plasminogen
activ
measur
two
dog
low
one
dam
sire
affect
dog
normal
serum
plasminogen
activ
histori
clinic
sign
consist
ligneou
membran
signific
clinic
improv
evid
follow
treatment
antibiot
glucocorticoid
topic
ciclosporin
heparin
one
dog
die
cardiopulmonari
arrest
hospit
two
dog
euthan
due
progress
clinic
sign
postmortem
evalu
affect
dog
reveal
multipl
abnorm
includ
sever
prolif
fibrin
lesion
affect
trachea
larynx
epicardium
multipl
fibrou
adhes
throughout
thorac
abdomin
caviti
male
dog
intern
hydrocephalu
lack
cerebellar
vermi
first
report
ligneou
membran
relat
dog
first
report
scottish
terrier
sequenc
plasminogen
gene
affect
dog
parent
unrel
control
dog
identifi
polymorph
mutat
may
associ
ligneou
membran
dog
ongo
author
receiv
travel
scholarship
zoeti
attend
congress
health
screen
elderli
dog
often
recommend
scientif
inform
clinic
laboratori
abnorm
senior
geriatr
dog
scarc
studi
undertaken
describ
blood
pressur
measur
physic
examin
pe
abnorm
routin
laboratori
test
result
senior
geriatr
dog
appar
healthi
owner
life
expect
dog
relat
bodi
size
inclus
dog
base
humanpet
analog
chart
determin
whether
dog
senior
n
geriatr
n
verifi
health
statu
owner
ask
complet
extens
questionnair
systol
blood
pressur
sbp
measur
use
doppler
techniqu
accord
acvim
guidelin
subsequ
thorough
pe
perform
includ
bodi
muscl
condit
score
orthoped
examin
neurolog
evalu
indirect
fundoscopi
bilater
schirmer
tear
test
complet
blood
count
serum
biochemistri
urinalysi
includ
urinari
sediment
urinari
protein
creatinin
ratio
upc
bacteri
cultur
evalu
dog
sbp
exceed
mmhg
none
dog
fundoscop
lesion
secondari
hypertens
bodi
condit
score
abnorm
anim
overweight
obes
physic
examin
reveal
heart
murmur
submandibular
lymphadenopathi
moder
sever
dental
plaqu
one
sub
cutan
mass
dog
twentythre
dog
leukopen
decreas
phosphoru
increas
serum
creatinin
one
dog
decreas
total
thyroxin
concurr
increas
thyroid
stimul
hormon
crystalluria
commonli
detect
mostli
due
low
number
power
field
amorph
crystal
struvit
crystal
present
crystallur
dog
overt
borderlin
proteinuria
detect
dog
respect
four
dog
posit
urinari
cultur
sbp
significantli
differ
senior
geriatr
group
signific
effect
obes
gender
sbp
platelet
count
p
total
thyroxin
concentr
p
frequenc
orthoped
problem
p
cutan
mass
p
significantli
higher
geriatr
compar
senior
dog
hematocrit
p
bodi
temperatur
p
significantli
lower
geriatr
group
find
indic
physic
laboratori
abnorm
common
appar
healthi
senior
geriatr
dog
underlin
necess
regular
health
screen
elderli
dog
urgent
need
reliabl
mayb
age
specif
refer
interv
veterinari
medicin
cost
examin
report
studi
cover
hill
pet
nutrit
belgium
system
lupu
erythematosu
sle
chronic
autoimmun
disord
vari
clinic
manifest
diagnosi
base
clinic
sign
laboratori
find
system
rheumat
diseas
refer
slerel
diseas
immunemedi
rheumat
diseas
imrd
also
describ
common
clinic
sign
dog
stiff
pain
vari
joint
one
hallmark
sle
slerel
diseas
dog
human
high
titr
circul
antinuclear
antibodi
ana
demonstr
indirect
immunofluoresc
iif
ana
test
earlier
studi
shown
canin
iif
ana
posit
sampl
may
divid
two
main
subgroup
homogen
ana
h
speckl
ana
iif
ana
fluoresc
pattern
human
determin
specif
ana
posit
sera
frequent
employ
character
ana
reactiv
ana
specif
demonstr
man
strongli
associ
differ
system
autoimmun
diseas
also
differ
iif
ana
stain
pattern
presenc
charact
antinuclear
antibodi
canin
slerel
diseas
well
describ
aim
work
character
ana
specif
dog
slerel
diseaseimrd
sera
anaposit
dog
includ
differ
breed
analyz
elisa
line
blot
techniqu
elisa
eurolin
ana
profil
euroimmun
germani
five
preval
breed
german
shepherd
dog
nova
scotia
duck
toll
retriev
cocker
spaniel
crossbre
golden
retriev
sera
display
homogen
speckl
iif
ana
fluoresc
pattern
sever
specif
anareact
earlier
character
human
patient
identifi
major
ana
h
n
show
reactiv
nucleosom
antigen
dsdna
conduct
line
blot
sera
also
react
nucleosom
dsdna
elisa
addit
posit
elisa
total
elisa
identifi
nucleosom
dsdna
reactiv
case
reactiv
identifi
histon
pcna
rnp
ana
subgroup
smrnp
antigen
evok
frequent
reactiv
n
line
blot
elisa
case
reactiv
dsdna
pcna
ssa
ssb
identifi
sever
dog
specif
antigen
identifi
studi
progress
order
detail
character
identifi
subtyp
alreadi
known
unknown
antigen
clinic
import
canin
autoimmun
one
author
erik
lattwein
employ
euroimmun
analys
perform
chronic
kidney
diseas
ckd
high
preval
cat
routin
renal
marker
serum
creatinin
scr
urea
sensit
specif
enough
detect
earli
ckd
serum
cystatin
c
scysc
advantag
scr
detect
earli
kidney
dysfunct
human
dog
signific
higher
scysc
concentr
ckd
cat
demonstr
object
studi
determin
effect
age
gender
breed
felin
scysc
establish
refer
interv
felin
scysc
total
healthi
cat
one
year
includ
serum
cysc
determin
valid
particleenhanc
nephelometr
immunoassay
penia
serum
cr
urea
urin
specif
graviti
usg
urinari
protein
creatinin
ratio
upc
systol
blood
pressur
sbp
also
measur
test
differ
group
ftest
use
lower
upper
valu
refer
interv
obtain
quantil
scysc
observ
signific
differ
scysc
concentr
observ
young
middleag
old
cat
femal
femal
neuter
male
male
neuter
cat
purebr
domest
shortor
longhair
cat
refer
interv
felin
scysc
determin
mgl
signific
differ
scr
concentr
domest
shortor
longhair
cat
purebr
cat
sbp
significantli
influenc
gender
well
age
urea
influenc
age
gender
breed
studi
show
biolog
factor
age
gender
breed
littl
impact
felin
scysc
contrast
scr
serum
urea
make
interest
marker
therefor
studi
warrant
evalu
diagnost
valu
scysc
renal
marker
cat
studi
reciev
support
institut
promot
innov
scienc
technolog
flander
iwt
bursari
l
ghi
assess
renal
function
often
need
howev
exist
method
includ
urin
plasma
clearanc
invas
cumbersom
time
consum
pilot
studi
feasibl
transcutan
glomerular
filtrat
rate
measur
investig
transcutan
disappear
rate
express
halflif
fluoresceinisothiocyanatelabel
sinistrin
fitc
measur
three
healthi
research
dog
three
healthi
research
cat
plasma
clearanc
sinistrin
data
point
perform
speci
previous
describ
re
vet
sci
j
fel
med
surg
halflif
calcul
use
model
freeli
avail
pharmacokinet
calcul
comput
meth
prog
bio
renal
elimin
fitc
measur
transcutan
hour
data
point
use
miniatur
devic
describ
previous
purpos
rat
kidney
int
procedur
perform
awak
freeli
move
anim
use
escal
dose
fitc
mgkg
mgkg
mgkg
washout
period
least
h
anim
find
best
posit
devic
multipl
devic
place
anim
result
fitc
disappear
curv
visual
assess
determin
suitabl
locat
appropri
dose
reach
adequ
transcutan
peak
signal
kinet
analysi
speci
mgkg
adequ
kinet
calcul
suitabl
place
devic
later
thorac
wall
dog
ventral
abdomin
wall
cat
respect
transcutan
fitc
clearanc
repeat
use
optim
dose
locat
parallel
plasma
sinistrin
clearanc
plasma
sinistrin
clearanc
mlkgmin
three
dog
respect
correspond
plasma
elimin
halfliv
min
correspond
transcutan
elimin
halfliv
min
respect
plasma
sinistrin
clearanc
mlkgmin
three
cat
respect
correspond
plasma
elimin
halfliv
min
correspond
transcutan
elimin
halfliv
min
respect
conclus
transcutan
fitc
clearanc
feasibl
method
assess
gfr
awak
dog
cat
noninvas
well
toler
easi
perform
even
clinic
set
result
readili
avail
dose
mgkg
fitc
seem
adequ
kinet
assess
studi
need
establish
refer
valu
evalu
transcutan
renal
clearanc
variou
condit
conflict
interest
zhp
sg
support
ec
mariecuri
programm
nephrotool
devic
develop
support
activ
placeitng
owner
patent
cover
fitcsinistrin
technolog
measur
excret
urinari
biomark
renal
damag
occur
earli
stage
chronic
kidney
diseas
ckd
thu
facilit
earlier
diagnosi
renal
diseas
albumin
cystatin
c
renal
ultrafiltr
mostli
reabsorb
proxim
tubular
cell
therefor
increas
urinari
excret
albumin
cystatin
c
uac
ucysc
would
expect
correl
presenc
renal
tubular
damag
ckd
aim
studi
establish
biolog
valid
two
particl
enhanc
turbidimetr
assay
petia
measur
albumin
cystatin
c
previous
valid
use
felin
urin
compar
uac
ucysc
nonazotaem
cat
cat
azotaem
ckd
blood
urin
sampl
obtain
cat
three
uk
first
opinion
practic
part
geriatr
screen
programm
haematolog
serum
biochemistri
includ
total
thyroxin
concentr
urinalysi
includ
urin
protein
creatinin
ratio
upc
perform
dental
diseas
score
calculu
gingiv
bodi
condit
score
bc
record
cat
nmoll
evid
pyuria
bacteruria
signific
system
diseas
exclud
uac
ucysc
determin
nonazotaem
cat
n
cat
azotaem
ckd
n
defin
serum
creatinin
concentr
lmoll
concurr
urin
specif
graviti
comparison
nonazotaem
azotaem
ckd
group
made
use
mann
whitney
u
test
correl
assess
spearman
correl
coeffici
data
present
median
th
th
percentil
statist
signific
defin
p
uac
significantli
higher
azotaem
group
nonazotaem
group
vs
p
wherea
upc
significantli
differ
group
p
unexpectedli
ucysc
tend
lower
azotaem
cat
nonazotaem
cat
vs
p
uac
weakli
posit
correl
serum
urea
concentr
r
p
correl
serum
creatinin
concentr
ucysc
significantli
correl
serum
concentr
urea
creatinin
uac
also
weakli
neg
correl
dental
calculu
score
r
p
bc
r
p
uac
appear
sensit
test
azotaem
ckd
upc
howev
appar
low
specif
may
limit
util
uac
urinari
screen
test
ckd
increas
ucysc
determin
petia
would
appear
marker
azotaem
ckd
cat
conflict
interest
report
cystinuria
inherit
metabol
disord
caus
defect
tubular
reabsorpt
aminoacid
cystin
ornithin
lysin
arginin
cola
low
solubl
cystin
acid
urin
promot
format
cystin
crystal
urolith
urinari
tract
result
clinic
sign
stranguria
urinari
obstruct
renal
failur
affect
individu
cystinuria
occur
breed
dog
classifi
type
ia
newfoundland
landseer
labrador
iia
australian
cattl
dog
ib
miniatur
pinscher
iii
androgendepend
eg
mastiff
irish
terrier
ander
mediums
companion
dog
bred
initi
cross
wire
fox
terrier
grand
griffon
vend
een
first
recognis
intern
cystinuria
suspect
breed
case
report
literatur
date
determin
urinari
cola
concentr
adult
ander
dog
age
year
compris
intact
castrat
male
intact
spay
femal
total
intact
male
age
year
cola
valu
lmolg
creatinin
sever
develop
cystic
calculi
furthermor
intact
male
dog
increas
cola
normal
cystin
level
castrat
male
normal
cola
concentr
femal
increas
cola
cystin
concentr
form
cystin
calculi
conclud
cystinuria
cystin
calculi
occur
frequent
adult
intact
male
ander
dog
neither
seen
femal
appear
androgen
depend
type
iii
cystinuria
seen
mastifftyp
dog
irish
terrier
thu
castrat
may
resolv
increas
urinari
cola
excret
risk
cystin
calculi
format
obstruct
precis
mode
inherit
still
unclear
adult
intact
male
ander
dog
screen
urinari
cola
test
work
carri
author
previou
place
employ
univers
children
hospit
frankfurt
germani
ac
rk
em
md
ug
provid
diagnost
servic
cystinuria
inborn
error
metabol
companion
anim
ureter
urolithiasi
emerg
medic
concern
cat
report
epidemiolog
diagnosi
medic
manag
ureter
calculi
cat
particularli
europ
cat
diagnos
ureter
urolithiasi
teach
hospit
veterinari
school
alfort
includ
studi
diagnosi
confirm
radiograph
ultrasound
scan
andor
laparotomi
signal
clinic
sign
clinicopatholog
diagnost
imag
find
medic
treatment
outcom
record
epidemiolog
data
compar
refer
popul
cat
eighti
three
cat
includ
studi
occurr
ureter
urolithiasi
significantli
higher
birman
author
knowledg
first
time
higher
preval
ureter
calculi
birman
cat
report
europ
spontan
elimin
calculu
associ
small
size
mm
size
calculi
tend
bigger
cat
improv
renal
function
medic
treatment
prospect
studi
still
need
determin
best
medic
treatment
conflict
interest
report
felin
immunodefici
viru
fiv
infect
associ
kidney
diseas
mainli
characteris
increas
preval
proteinuria
fivinfect
cat
howev
studi
evalu
renal
variabl
fivposit
cat
scarc
recent
higher
systol
blood
pressur
sbp
report
small
number
fivinfect
cat
hypertens
import
caus
proteinuria
frequent
caus
renal
diseas
human
immunodefici
viru
hiv
posit
patient
therefor
main
object
describ
sbp
clinic
ill
fivposit
cat
secondli
aim
evalu
routin
renal
variabl
popul
natur
infect
clinic
ill
fivposit
cat
prospect
includ
doppler
ultrason
techniqu
use
measur
sbp
accord
acvim
guidelin
serum
creatinin
screat
urea
surea
concentr
urin
specif
graviti
usg
urinari
protein
creatinin
ratio
upc
determin
studi
includ
cat
mean
age
ae
year
mean
bodi
condit
score
ae
ninepoint
scale
sbp
rang
mmhg
mean
ae
mmhg
two
cat
hypertens
sbp
mmhg
isosthenur
urin
borderlin
proteinur
upc
one
mildli
azotem
mean
screat
ae
lmoll
refer
interv
ri
lmoll
mean
surea
concentr
ae
mmoll
ri
mmoll
thirteen
cat
show
increas
screat
level
decreas
usg
eight
proteinuria
upc
seven
increas
surea
concentr
ten
five
ten
azotem
cat
proteinur
decreas
usg
mean
upc
ae
wide
rang
borderlin
proteinuria
present
proteinuria
half
proteinur
cat
decreas
usg
mean
usg
ae
one
third
cat
decreas
usg
isosthenuria
seven
result
demonstr
proteinuria
poorli
concentr
urin
common
natur
infect
clinic
ill
fivposit
cat
confirm
previou
report
cat
human
howev
longitudin
studi
borderlin
proteinur
patient
need
elucid
clinic
relev
low
number
hypertens
patient
low
mean
sbp
studi
indic
hypertens
uncommon
unlik
caus
renal
damag
clinic
ill
fivinfect
cat
aratana
therapeut
nv
financi
support
clinic
trial
use
antivir
fiv
cat
univers
screeninng
examin
repoort
trial
part
requir
pretrial
investig
studi
present
author
also
fund
scholarship
aratana
therapeut
av
object
studi
identifi
preval
bacteri
speci
suscept
isol
doxycyclin
trimethoprimsulfamethoxazol
tm
ampicillin
amoxicillinclavulan
acid
amc
cephalothin
enrofloxacin
cat
urinari
tract
infect
uti
without
predispos
comorbid
retrospect
analysi
case
record
perform
result
inclus
cat
studi
cat
system
comorbid
cat
indwel
urinari
cathet
cat
local
comorbid
cat
comorbid
commonli
isol
bacteria
escherichia
coli
e
coli
streptococcu
speci
spp
staphylococcu
spp
enterococcu
spp
proport
gramneg
isol
significantli
higher
cat
system
comorbid
cat
indwel
urinari
cathet
p
cat
local
abnorm
p
wherea
gramposit
isol
significantli
commonli
isol
cat
indwel
urinari
cathet
local
comorbid
cat
system
comorbid
p
proport
isol
suscept
amc
enrofloxacin
tm
antimicrobi
impact
factor
higher
proport
isol
suscept
doxycyclin
ampicillin
cephalothin
respect
base
find
amc
tm
would
firstchoic
antimicrobi
agent
empir
treatment
bacteri
increas
rate
resist
exhibit
uropathogen
repres
seriou
problem
select
appropri
antibiot
aim
studi
determin
secular
trend
companion
anim
urinari
tract
infect
uti
involv
extendedspectrum
blactamas
esbl
carbapemenaseproduc
gram
neg
bacteria
name
escherichia
coli
klebsiella
pneumonia
proteu
mirabili
acinetobact
baumannii
methicillinresistantstaphylococci
mr
ampicillin
highlevelgentamicinresist
hlgr
enterococci
nine
hundr
twenti
two
uropathogen
bacteria
isol
dog
cat
januari
march
veterinari
teach
hospit
faculti
veterinari
medicin
veterinari
privat
practic
lisbon
area
isol
identifi
use
standard
commerci
system
suscept
test
perform
use
disk
diffus
broth
microdilut
method
clsi
breakpoint
appli
extendedspectrum
blactamas
esbl
product
screen
doubledisk
synergi
test
esbl
plasmidmedi
ampc
carbapemenas
meca
aac
ieaph
ia
gene
detect
pcr
gene
enzym
sequenc
among
enterobacteriacea
dhaproduc
esblproduc
cmyproduc
isol
also
multidrugresist
cefalosporinasesproduc
enterobacteriacea
detect
first
e
coli
esblproduc
e
coli
k
pneumonia
produc
ctxmgroup
enzym
ampicillinresist
enterococci
present
throughout
year
n
hlgr
appear
enterococci
confirm
detect
bifunct
enzym
confer
high
level
resist
aminoglycosid
isol
studi
show
last
decad
emerg
resist
critic
import
antimicrobi
among
uropathogen
companion
anim
concern
fact
multidrugresist
enterobacteriacea
may
compromis
effect
therapeut
option
name
third
fourth
gener
cephalosporin
fluoroquinolon
trimethoprimsulpha
combin
emerg
mrsamrsp
hlgr
among
uropathogen
also
therapeut
challeng
detect
uropathogen
antimicrobi
resist
anim
health
issu
also
matter
public
health
sinc
companion
anim
may
act
reservoir
antimicrobi
resist
bacteria
resist
gene
human
author
current
receiv
phd
grant
fund
portugues
foundat
scienc
technolog
past
author
receiv
research
support
honorari
portugues
merial
project
canin
vector
born
diseas
aim
present
studi
use
insur
data
estim
morbid
mortal
relat
kidney
diseas
swedish
dog
popul
insur
compani
data
veterinari
careinsur
lifeinsur
dog
year
studi
retrospect
incidenceand
mortal
rate
calcul
whole
group
dog
well
divid
sex
breed
breed
highest
incidenceand
mortal
rate
respect
reason
kidney
diseas
investig
divid
diagnos
ethiolog
group
total
number
veterinari
careinsur
dog
total
incid
rate
kidney
diseas
group
dog
dogyear
risk
number
dog
life
insur
group
total
kidneyrel
mortal
rate
dogyear
risk
commonli
report
ethiolog
kidney
diseas
ethiolog
determin
infecti
inflammatori
breed
highest
incid
rate
kidney
diseas
bernes
mountain
dog
miniatur
schnauzer
boxer
breed
highest
mortal
caus
kidney
diseas
bernes
mountain
dog
shetland
sheepdog
flatcoat
retriev
conclus
epidemiolog
inform
provid
studi
concern
kidney
diseas
dog
assist
clinician
establish
diagnos
assist
breeder
defin
prioriti
prevent
measur
also
provid
valuabl
inform
futur
research
senior
author
receiv
money
insur
compani
use
data
write
studi
anoth
project
jen
om
ingrid
ljungval
receiv
financi
support
research
sant
animal
agria
insur
ltd
sveland
insur
ltd
forsgren
research
foundat
author
also
undertaken
paid
consulatcni
work
boehringeringelheim
ceva
sant
animal
mast
cell
tumour
repres
common
cutan
tumour
dog
diagnosi
mast
cell
tumour
achiev
cytolog
examin
fine
needl
aspir
howev
grade
tumour
import
prognost
marker
requir
far
histolog
assess
histolog
grade
system
base
number
mitos
multinucl
cell
bizarr
nuclei
karyomegali
recent
propos
kiupel
et
al
aim
studi
assess
cytomorpholog
criteria
propos
histolog
grade
system
applic
cytolog
specimen
ninetythre
mast
cell
tumour
specimen
grade
grade
iii
accord
patnaik
histolog
specimen
fine
needl
aspir
retrospect
taken
data
set
histolog
cytolog
reevalu
accord
kiupel
grade
system
thirtysix
diagnos
histolog
high
grade
fiftyseven
consid
lowgrad
mast
cell
tumour
cytolog
examin
correspond
specimen
reveal
thirtyon
high
grade
fiftyf
lowgrad
tumour
agreement
histolog
cytolog
diagnosi
base
kiupel
grade
system
achiev
eightysix
case
accuraci
specif
sensit
five
highgrad
tumour
consid
low
grade
cytolog
cytolog
grade
mast
cell
tumour
dog
satisfactori
accuraci
sensit
specif
histolog
grade
canin
mast
cell
tumour
still
remain
gold
standard
cytolog
alreadi
give
reliabl
inform
conflict
interest
report
canin
mastocytoma
among
frequent
diagnos
neoplasm
skin
high
grade
mastocytoma
grade
iii
patnaik
classif
character
uncontrol
growth
neoplast
mast
cell
mc
poor
prognosi
recent
kittarget
tyrosin
kinas
inhibitor
masitinib
toceranib
approv
treatment
canin
mc
tumor
drug
abl
induc
respons
mastocytoma
patient
howev
mani
patient
relaps
seen
therefor
research
focus
new
drug
target
recent
transcript
factor
report
play
import
role
prolifer
surviv
human
neoplast
mc
aim
present
studi
evalu
pathway
canin
mastocytoma
address
aim
canin
mastocytoma
cell
line
well
inhibitor
direct
employ
assess
immunocytochemistri
cell
cell
found
express
cytoplasm
nuclei
intracellular
express
confirm
flow
cytometri
interestingli
cell
found
express
higher
level
compar
cell
next
treat
cell
cell
variou
concentr
inhibitor
piceatannol
pimozid
inhibitor
assess
hthymidin
uptak
compound
found
inhibit
prolifer
canin
mc
dosedepend
manner
drug
effect
found
vari
differ
cell
line
follow
rankord
potenc
ic
valu
lm
pimozid
lm
lm
piceatannol
lm
explor
mechan
druginduc
inhibit
prolifer
examin
cell
cycl
progress
apoptosi
drugexpos
cell
wherea
drug
test
induc
moder
cell
cycl
arrest
phase
drug
found
induc
substanti
apoptosi
cell
cell
evidenc
microscopi
annexinvpi
stain
togeth
data
show
drug
exert
antiprolif
apoptosisinduc
effect
canin
mastocytoma
cell
suggest
signal
pathway
may
promis
new
therapeut
target
canin
mastocytoma
clinic
relev
observ
remain
determin
conflict
interest
report
subcutan
mast
cell
tumour
sqmct
dog
rel
uncommon
compar
cutan
counterpart
veterinari
literatur
describ
tumour
specif
patholog
entiti
gener
low
probabl
aggress
progress
surgeri
consid
main
treatment
modal
medic
treatment
describ
purpos
studi
determin
progress
free
surviv
pf
chemo
cohort
dog
present
nonresect
metastas
sqmct
underw
masitinibbas
therapi
data
collect
patient
sqmct
present
particip
centr
netherland
uk
receiv
masitinibbas
therapi
treatment
protocol
employ
includ
masitinib
alon
masitinib
prednisolon
mp
masitinib
plu
vinblastin
lomustin
prednisolon
mpc
respons
therapi
measur
conform
recist
advers
event
grade
use
vcogctca
patient
group
accord
presenc
absenc
metastasi
treatment
protocol
use
previou
surgeri
remiss
statu
achiev
simpl
comparison
made
evalu
possibl
signific
twentyf
case
identifi
femal
median
age
occurr
year
diagnosi
made
histolog
prolifer
indic
defin
dog
fourteen
case
exhibit
metastasi
initi
therapi
pf
case
rang
day
medianmean
pf
day
accord
treatment
n
n
n
medianmean
pf
accord
metastasi
statu
n
n
dog
underw
previou
surgeri
n
medianmean
pf
compar
surgeri
look
remiss
statu
median
pf
patient
achiev
complet
remiss
reach
mean
pf
n
medianmean
pf
patient
partial
remiss
n
stabl
diseas
n
progress
diseas
n
case
experienc
suspect
advers
event
three
dog
two
ultim
die
seven
grade
advers
event
anaemia
n
hepatotox
n
gastrointestin
toxic
n
masitinibbas
treatment
effect
manag
sqmct
perceiv
aggress
patient
appear
benefit
prior
surgeri
metastat
statu
influenc
outcom
ad
chemotherapi
neg
influenc
pf
complet
remiss
favour
prognost
develop
author
receiv
financi
support
ab
scienc
help
cost
statist
analys
unrel
project
advanc
distinct
morpholog
subtyp
canin
nonhodgkin
lymphoma
nhl
provid
better
understand
cancer
dog
diffus
larg
bcell
lymphoma
dlbcl
frequent
form
nhl
dog
includ
distinguish
morpholog
subtyp
mainli
centroblast
polymorph
immunoblast
accord
classif
clinic
studi
report
dlbcl
clinic
outcom
treatment
surviv
time
centroblast
polymorph
subgroup
report
aim
retrospect
studi
evalu
respons
dlbcl
standard
multiag
chemotherapi
protocol
medic
record
dog
diagnosi
dlbcl
retrospect
review
inclus
criteria
avail
complet
initi
followup
inform
applic
standard
multiag
lcop
chemotherapi
protocol
previous
describ
dog
receiv
corticosteroid
initi
treatment
dog
die
reason
relat
diseas
end
induct
period
exclud
respons
chemotherapi
evalu
everi
week
induct
treatment
everi
week
statist
analysi
perform
use
kaplanmei
analysi
thirti
case
dlbcl
meet
inclus
criteria
includ
initi
popul
seven
dog
clinic
stage
iii
accord
classif
stage
iv
stage
v
nineteen
dog
substag
substag
b
dog
adequ
respons
evalu
dog
achiev
complet
remiss
median
mean
durat
first
remiss
respect
rang
median
mean
durat
surviv
time
respect
rang
one
year
surviv
rate
respect
accord
statist
analysi
neither
clinic
stage
p
substag
present
p
morpholog
subtyp
immunoblast
vs
centroblast
polymorph
p
consid
signific
prognost
factor
regard
durat
first
remiss
overal
surviv
time
complet
respons
significantli
associ
longer
surviv
time
p
conclud
dlbcl
display
good
clinic
respons
lcop
protocol
median
surviv
time
day
signific
prognost
criterion
identifi
complet
clinic
respons
treatment
prospect
control
studi
larger
popul
warrant
confirm
result
conflict
interest
report
canin
histiocyt
sarcoma
hs
aggress
round
cell
neoplasm
poor
prognosi
lomustin
doxorubicin
evalu
first
line
chemotherapi
agent
respons
rate
median
surviv
time
around
month
aim
studi
evalu
respons
epirubicin
popul
dog
hs
pretreat
lomustin
medic
record
dog
diagnosi
hs
treat
lomustin
subsequ
epirubicin
retrospect
evalu
fifteen
dog
receiv
lomustin
follow
epirubicin
measur
respons
lomustin
seven
dog
evid
diseas
cr
pr
addit
dog
achiev
stabl
diseas
overal
biolog
effect
respons
median
ttp
follow
lomustin
could
assess
dog
day
rang
fifteen
dog
receiv
epirubicin
rescu
agent
nine
follow
progress
diseas
three
stabl
diseas
lomustin
one
dog
receiv
epirubicin
complet
six
dose
lomustin
complet
remiss
two
dog
partial
remiss
chang
epirubicin
due
hepatotox
associ
lomustin
respons
rate
epirubicin
biolog
effect
respons
cr
pr
sd
pd
dog
one
dog
euthan
due
epirubicin
associ
gastrointestin
toxic
dog
stop
treatment
assess
respons
median
durat
respons
epirubicin
day
rang
dog
still
aliv
remiss
day
overal
median
surviv
time
dog
receiv
epirubicin
follow
lomustin
day
rang
singl
agent
epirubicin
valid
rescu
therapi
lomustin
canin
histiocyt
sarcoma
result
modestli
improv
overal
surviv
time
respond
patient
author
receiv
travel
scholarship
zoeti
attend
congress
incid
melanocyt
lesion
increas
among
canin
popul
canin
malign
melanoma
could
aggress
behavior
metastas
earli
cours
diseas
resist
current
therapeut
regimen
lead
need
find
marker
potenti
therapeut
target
overexpress
seem
play
key
role
melanocyt
tumour
describ
associ
high
immunoexpress
malign
behavior
order
contribut
understand
role
melanocyt
tumour
three
main
pathway
investig
angiogenesi
tumour
cell
prolifer
inflammatori
microenviron
tlymphocyt
macrophag
fifti
one
melanocyt
tumour
cutan
malign
melanoma
melanocytoma
oral
malign
melanoma
includ
sampl
submit
immunohistochem
stain
carri
streptavidinbiotinperoxidas
method
commerci
detect
system
without
melanin
blanch
detect
follow
marker
factor
viii
vegf
melanocyt
tumour
n
label
extens
intens
reveal
statist
signific
associ
angiogenesi
factor
viii
p
vegf
p
p
tlymphocyt
p
p
consid
malign
melanoma
n
case
label
extens
reveal
statist
signific
associ
angiogenesi
p
tlymphocyt
p
intens
also
posit
associ
angiogenesi
p
p
present
studi
demonstr
link
high
immunoexpress
increas
angiogenesi
tumour
tlymphocyt
macrophag
infiltr
malign
melanoma
find
reinforc
use
use
select
inhibitor
valuabl
therapeut
tool
malign
melanocyt
tumour
studi
receiv
financi
support
compani
merial
neuter
statu
risk
malign
neoplasia
well
evalu
canin
popul
exclud
neoplasia
normal
believ
sexhormon
depend
denmark
scandinavian
countri
high
proport
intact
dog
compar
popul
part
world
present
studi
hypothes
would
differ
gender
neuter
statu
popul
canin
patient
nonsexhormon
depend
malign
neoplasia
report
danish
veterinari
cancer
registri
gener
popul
august
march
canin
neoplasm
report
danish
veterinari
cancer
registri
total
number
malign
benign
compar
malign
neoplasm
total
tumor
area
distribut
known
sexhormon
depend
reproduct
organ
mammari
gland
perin
case
unknown
area
distribut
exclud
overal
distribut
malign
neoplasia
intact
male
dog
neuter
male
dog
intact
femal
dog
neuter
femal
dog
distribut
even
male
femal
dog
compar
known
standard
popul
dog
overal
statist
signific
associ
malign
neoplasia
neuter
statu
sex
gender
signific
lymphoma
mast
cell
tumor
osteosarcoma
neuter
femal
male
increas
risk
hemangiosarcoma
squamou
cell
carcinoma
malign
melanoma
find
indic
might
associ
neuter
statu
develop
malign
neoplasia
larger
prospect
studi
need
evalu
risk
nonsex
hormon
depend
cancer
neuter
dog
conflict
interest
report
serum
acut
phase
protein
app
consid
biomark
acut
phase
reaction
increasingli
use
human
veterinari
medicin
diagnosi
monitor
neoplast
diseas
cat
serum
amyloid
saa
consid
posit
major
app
haptoglobin
hp
moder
app
albumin
insulinlik
growth
neg
app
aim
present
studi
character
app
respons
cat
mammari
tumour
purpos
saa
hp
albumin
serum
concentr
determin
femal
cat
malign
mammari
tumour
cat
histori
previou
tumour
concomit
tumour
diseas
exclud
inform
cat
age
gender
breed
tumour
type
histolog
grade
tumour
size
locat
skin
ulcer
vascular
neoplast
infiltr
necrosi
metastasi
region
lymph
node
thorac
abdomin
organ
surviv
time
diagnosi
assess
blood
sampl
collect
surgeri
cat
whenev
possibl
serial
sampl
collect
control
visit
owner
gave
inform
consent
studi
popul
includ
domest
shorthair
cat
age
rang
eight
year
carcinoma
includ
solid
carcinoma
n
tubulopapillari
carcinoma
n
one
cribiform
carcinoma
one
carcinosarcoma
time
diagnosi
cat
increas
serum
concentr
hp
saa
decreas
concentr
albumin
mean
standard
deviat
valu
gdl
albumin
refer
rang
g
dl
lgdl
lgml
saa
refer
valu
lgml
gl
hp
refer
valu
gl
posit
correl
r
detect
increas
serum
concentr
saa
hp
increas
size
tumour
significantli
associ
concentr
saa
serum
hp
concentr
significantli
increas
tubulopapillari
carcinoma
decreas
solid
carcinoma
cat
serial
determin
perform
develop
thorac
metastasi
significantli
associ
decreas
serum
concentr
albumin
increas
saa
studi
suggest
felin
mammari
tumour
associ
acut
phase
respons
accord
result
obtain
saa
hp
albumin
might
import
serum
biomark
diagnosi
monitor
evolut
felin
malign
mammari
neoplasia
conflict
interest
report
histiocyt
sarcoma
hs
neoplast
prolifer
interstiti
dendrit
cell
tissu
macrophag
dog
hs
present
local
diseas
multifoc
dissemin
involv
dissemin
hs
poorli
respons
therapi
almost
alway
fatal
littl
establish
regard
aetiopatholog
histiocyt
sarcoma
dog
purpos
studi
establish
characteris
hs
cell
line
fresh
tumour
sampl
obtain
dog
dissemin
hs
order
clarifi
diseas
pathogenesi
behaviour
owner
consent
tumour
section
collect
dog
dissemin
hs
euthanas
tumour
tissu
assess
immunohistochemistri
ihc
use
antibodi
canin
support
diagnosi
histiocyt
sarcoma
primari
cell
cultur
hsc
establish
tumour
cultur
maintain
modifi
eagl
medium
fetal
bovin
serum
lglutamin
penicillin
streptomycin
standard
condit
hsc
characteris
alpha
naphthyl
acet
esteras
ana
lysozym
stain
pcr
use
detect
cell
marker
mhc
ii
ecadherin
cell
surfac
marker
compar
establish
canin
hs
cell
line
phagocyt
activ
hsc
cell
assess
use
cellular
uptak
carboxyl
fluoresc
bead
document
use
flow
cytometri
fluoresc
microscopi
tumour
tissu
strongli
posit
neg
cultur
cell
exhibit
morpholog
characterist
consist
dendrit
cell
project
pleomorph
hsc
cell
stain
posit
nonspecif
esteras
ana
lysozym
pcr
indic
cell
posit
mhc
ii
neg
ecadherin
hsc
cell
posit
mhc
ii
cell
neg
phagocyt
activ
evid
novel
hs
cell
line
hsc
establish
character
primari
tumour
tissu
collect
dog
dissemin
diseas
hsc
cell
consist
interstiti
dendrit
cell
origin
base
mhc
ii
stain
well
demonstr
phagocyt
activ
hsc
cell
also
display
express
unlik
establish
line
support
notion
hs
consist
varieti
subtyp
link
hs
growth
metastasi
suggest
may
repres
possibl
therapeut
target
studi
establish
characteris
canin
hs
cell
may
contribut
elucid
mechan
tumourigenesi
conflict
interest
report
virulentsystem
vs
fcv
induc
cutan
edema
ulcer
head
feet
occasion
jaundic
describ
usa
europ
character
first
time
vsfcv
outbreak
cat
switzerland
liechtenstein
four
outbreak
occur
three
geograph
separ
locat
schaan
liechtenstein
shelter
zurich
switzerland
lausann
switzerland
shelter
novemb
januari
pcr
fcv
felin
viru
isol
felvfiv
test
perform
saliva
blood
sampl
collect
clinic
affect
cat
furthermor
saliva
pcr
collect
addit
cat
shelter
phylogenet
analys
perform
base
capsid
gene
sequenc
fcv
vsfcv
isol
test
viru
neutral
sera
rais
common
fcv
vaccin
strain
outbreak
occur
catteri
liechtenstein
involv
five
nonvaccin
old
sibl
fever
edema
skin
tongu
ulcer
outbreak
occur
small
anim
clinic
zurich
old
cat
present
sever
paw
edema
fever
tongu
skin
ulcer
progress
hypoproteinemia
hyperbilirubinemia
outbreak
happen
catteri
lausann
five
month
apart
involv
two
litter
nonvaccin
old
kitten
cat
present
fever
nasal
discharg
edema
skin
oral
ulcer
affect
cat
test
fcvposit
neg
felv
fiv
except
one
kitten
outbreak
fivposit
cat
outbreak
recov
wherea
cat
outbreak
die
euthan
clinic
deterior
outbreak
caus
phylogenet
distinct
vsfcv
strain
shelter
queen
three
contact
cat
remain
asymptomat
although
infect
vsfcv
strain
furthermor
cat
shelter
infect
close
relat
distinct
fcv
strain
vsfcv
isol
two
outbreak
shelter
distinct
phylogenet
relat
vsfcv
isol
cat
outbreak
show
similar
viru
neutral
pattern
neutral
differ
differ
outbreak
conclus
vsfcv
outbreak
involv
multicat
environ
vsfcv
strain
similar
viru
neutral
pattern
isol
cat
outbreak
cat
infect
vsfcv
strain
develop
diseas
mortal
vari
outbreak
sera
viru
neutral
provid
merial
franc
defin
herein
presenc
sneez
nasalandor
ocular
discharg
conjunct
andor
kerat
also
oral
caviti
lesion
chronic
stomat
limp
syndrom
rare
virul
system
diseas
aim
present
studi
compar
cat
suspect
fcv
fcvsc
base
clinic
symptom
healthi
control
control
investig
potenti
risk
protect
factor
coinfect
felin
mycoplasma
feli
chlamydophila
feli
bordetella
bronchiseptica
felin
retrovirus
vaccin
gender
age
breed
hous
corticosteroid
antibiot
treatment
oropharyng
nasal
conjunctiv
swab
fcvsc
control
collect
transport
medium
process
within
hour
collect
analyz
fcv
viru
isol
test
pathogen
use
molecular
assay
sampl
collect
randomli
select
veterinari
practic
differ
area
switzerland
fcvsc
control
area
record
clinic
data
retrovir
statu
vaccin
histori
cat
questionnair
fill
privat
veterinarian
seven
test
pathogen
found
investig
popul
preval
fcvsc
vs
control
fcv
vs
vs
c
feli
vs
b
bronchiseptica
vs
feli
vs
felin
leukemia
viru
vs
felin
immunodefici
viru
vs
fcvsc
posit
fcv
significantli
often
compar
control
shed
fcv
coinfect
four
pathogen
detect
fcvsc
significantli
frequent
coinfect
compar
control
gingivostomat
oral
ulcer
urtd
highli
associ
fcv
infect
contrast
c
feli
associ
urtd
associ
nasal
ocular
discharg
feli
conjunct
ocular
discharg
risk
factor
fcv
infect
hous
group
especi
cat
intact
gender
main
coon
breed
corticosteroid
therapi
fcvposit
cat
gingivostomat
older
commonli
vaccin
fcvposit
cat
without
gingivostomat
moreov
shed
fcv
cat
urtd
vaccin
primari
immun
defin
two
vaccin
week
apart
vaccin
brand
protect
factor
fcv
infect
vaccin
associ
decreas
incid
urtd
fcvinfect
cat
analys
investig
crossneutr
pattern
prevail
fcv
isol
conflict
interest
studi
partial
fund
merial
franc
biokema
switzerland
antibodi
prepar
commonli
use
treatment
felin
upper
respiratori
tract
diseas
furtd
although
efficaci
proven
aim
studi
evalu
efficaci
commerci
serum
contain
antibodi
felin
felin
caliciviru
fcv
cat
acut
viral
furtd
prospect
random
placebocontrol
doubleblind
studi
includ
cat
acut
day
clinic
sign
andor
fcv
infect
confirm
quantit
pcr
cat
receiv
symptomat
treatment
either
hyperimmun
serum
n
week
ml
week
ml
subcutan
h
topic
eye
nostril
mouth
h
salin
n
three
day
clinic
sign
includ
furtd
score
gener
health
statu
record
daili
day
day
fcv
shed
determin
day
statist
analys
includ
oneway
analysi
varianc
mannwhitney
u
student
ttest
improv
clinic
sign
fisher
exact
test
fcv
shed
spearman
analysi
correl
clinic
sign
viru
load
clinic
sign
gener
health
statu
improv
significantli
group
howev
placebotr
cat
improv
significantli
day
cat
receiv
antibodi
alreadi
significantli
improv
furtd
score
p
gener
health
statu
p
day
signific
differ
number
cat
shed
fcv
correl
viral
load
clinic
manifest
administr
antibodi
lead
faster
improv
clinic
sign
cat
acut
viral
furtd
influenc
fcv
shed
conflict
interest
report
differ
viral
bacteri
pathogen
involv
felin
upper
respiratori
tract
diseas
furtd
although
clinic
sign
associ
certain
pathogen
clinic
sign
variabl
nonspecif
aim
studi
compar
detect
rate
felin
felin
caliciviru
fcv
chlamydophila
feli
c
feli
cat
furtd
differ
sampl
site
correl
test
result
clinic
sign
swab
nose
oropharynx
tongu
conjunctiva
taken
cat
sign
furtd
sampl
revers
transcript
polymeras
chain
reaction
rtpcr
perform
detect
fcv
polymeras
chain
reaction
pcr
detect
c
feli
fisher
exact
test
use
comparison
level
signific
p
pathogen
detect
cat
posit
fcv
c
feli
fcv
isol
significantli
often
oropharynx
fcvposit
cat
tongu
compar
conjunctiva
p
signific
differ
sampl
site
detect
c
feli
addit
prefer
sampl
site
cat
respect
clinic
sign
includ
oral
ulcer
conjunct
kerat
cat
furtd
oropharynx
recommend
prefer
sampl
site
detect
fcv
c
feli
base
upon
clinic
sign
determin
sampl
site
select
detect
pathogen
conflict
interest
report
pulmonari
haemorrhag
syndrom
lph
schuller
callanan
worral
francey
schweighaus
je
nalli
bern
univers
bern
switzerland
univers
colleg
dublin
dublin
ireland
leptospir
pulmonari
haemorrhag
syndrom
lph
sever
form
leptospirosi
increasingli
recognis
human
mani
anim
speci
past
year
patient
lph
may
develop
rapidli
progress
intraalveolar
haemorrhag
lead
high
mortal
pathogen
mechan
lph
poorli
understood
hamper
applic
effect
treatment
strategi
studi
human
experiment
infect
guinea
pig
demonstr
deposit
immunoglobulin
complement
lph
lung
tissu
absenc
signific
number
leptospir
suggest
lph
part
caus
autoimmun
aim
project
describ
histopatholog
featur
lph
dog
investig
whether
igg
igm
deposit
present
affect
canin
lung
tissu
singlestep
immunohistochemistri
ihc
dog
igg
igm
leptospir
outer
membran
vesicl
perform
lung
tissu
dog
lph
dog
pulmonari
haemorrhag
due
caus
healthi
dog
lung
acut
intraalveolar
haemorrhag
oedema
absenc
signific
inflammatori
infiltr
present
lph
lung
tissu
three
ihc
stain
pattern
observ
lph
lung
tissu
alveolar
septal
wall
stain
igg
n
n
without
intraalveolar
stain
igg
n
n
stain
intraalveolar
fluid
igg
n
n
intraalveolar
stain
appear
favour
alveolar
surfac
case
igg
n
n
healthi
control
lung
show
stain
wherea
haemorrhag
lung
show
stain
intraalveolar
fluid
iggigm
n
occasion
mild
discontinu
stain
alveolar
septa
n
leptospir
antigen
detect
tissu
result
indic
histopatholog
featur
canin
lph
similar
describ
speci
ihc
demonstr
alveolar
septal
deposit
iggigm
present
dog
natur
occur
lph
find
support
role
humor
immun
respons
develop
lph
find
indic
whether
autoimmun
primari
secondari
event
pathogenesi
lph
conflict
interest
report
leptospirosi
zoonot
bacteri
diseas
worldwid
distribut
reemerg
diseas
human
dog
acut
renal
hepat
failur
frequent
report
clinic
manifest
canin
leptospirosi
aim
studi
describ
clinic
laboratori
radiolog
featur
outcom
well
distribut
leptospira
serogroup
dog
leptospirosi
medic
record
dog
diagnos
leptospirosi
evalu
retrospect
diagnos
base
microscop
agglutin
test
mat
bloodurin
pcr
histopatholog
levad
stain
mattit
nonvaccin
vaccin
serovar
rise
titer
within
week
consid
diagnost
dog
met
inclus
criteria
dog
diagnost
mattit
present
mainli
serogroup
grippotyphosa
australi
pomona
initi
present
common
clinic
sign
lethargi
anorexia
vomitu
pain
abdomen
diarrhea
oliguria
tachypnea
delay
capillari
refil
time
pale
mucou
membran
fever
hypothermia
icter
mucou
membran
abnorm
find
cbc
includ
anemia
thrombocytopenia
leukocytosi
biochemistri
abnorm
includ
increas
creatinin
concentr
increas
liver
enzym
activ
hyperbilirubinemia
hyperphosphatemia
hyponatremia
hypoalbuminemia
urinalysi
often
reveal
glucosuria
elev
urineproteincreatinineratio
radiolog
pulmonari
chang
detect
dog
initi
cours
diseas
dog
die
euthan
due
leptospir
pulmonari
hemorrhag
syndrom
studi
nonvaccin
serogroup
common
serogroup
detect
mat
major
patient
renal
andor
hepat
diseas
detect
pulmonari
form
leptospirosi
present
dog
lung
involv
repres
sever
complic
caus
increas
mortal
depend
sever
respiratori
sign
conflict
interest
report
leptospirosi
zoonot
diseas
affect
multipl
organ
renal
hepat
involv
consid
common
aim
studi
evalu
larg
number
dog
leptospirosi
cardiac
andor
exocrin
pancreat
involv
total
dog
diagnos
leptospirosi
base
clinic
sign
either
microscop
agglutin
test
blood
urin
polymeras
chain
reaction
andor
histopatholog
time
admiss
patient
averag
two
week
canin
pancreat
lipas
immunoreact
cpli
measur
spec
cpl
ultrasensit
cardiac
troponin
ctni
creactiv
protein
crp
analyz
data
analyz
nonparametr
statist
level
signific
set
p
upon
admiss
common
clinic
sign
report
includ
lethargi
n
vomit
n
abdomin
pain
n
dyspnea
n
pale
mucou
membran
n
oliguria
n
hypothermia
n
fever
n
anemia
n
thrombocytopenia
n
leukocytosi
n
frequent
report
hematolog
find
increas
concentr
creatinin
n
phosphoru
n
alt
n
sap
n
bilirubin
n
also
frequent
record
crp
median
mgl
rang
mgl
refer
interv
ri
mgl
ctni
median
ngl
rang
ngl
ri
ngl
cpli
median
lgl
rang
lgl
ri
lgl
concentr
upper
limit
refer
interv
dog
respect
serum
cpli
concentr
suggest
cutoff
valu
diagnosi
pancreat
dog
crp
ctni
cpli
higher
upon
admiss
compar
recheck
measur
p
respect
dog
increas
serum
cpli
concentr
also
show
higher
proport
dog
increas
serum
ctni
concentr
p
statist
signific
correl
cpli
concentr
histori
abdomin
pain
andor
vomit
biochem
result
compat
multipl
organ
impair
involv
kidney
liver
heart
exocrin
pancrea
least
two
organ
affect
dog
forti
dog
recov
die
euthan
ctni
cpli
higher
nonsurvivor
differ
reach
statist
signific
howev
number
organ
affect
outcom
significantli
correl
p
data
suggest
infect
leptospira
character
system
inflamm
variabl
multipl
organ
involv
damag
often
includ
heart
also
exocrin
pancrea
studi
fund
texa
univers
primari
author
two
coauthor
work
gi
laboratori
texa
univers
canin
bartonellosi
increasingli
recogn
worldwid
may
associ
divers
clinic
manifest
recent
evid
suggest
bartonellosi
also
caus
lame
polyarthr
dog
howev
pcr
amplif
bartonella
dna
isol
bartonella
speci
canin
synovi
fluid
sf
sampl
rare
report
canin
leishmaniosi
canl
due
leishmania
infantum
multisystem
diseas
commonli
associ
polyarthr
base
hypothesi
concurr
bartonella
infect
may
contribut
factor
develop
arthriti
dog
canl
main
object
studi
investig
microbiolog
molecular
preval
bartonella
spp
dog
naturallyoccur
canl
without
cytolog
document
arthriti
previou
studi
dog
canl
retrospect
studi
bartonella
spp
infect
diagnosi
canl
base
compat
clinic
clinicopatholog
abnorm
posit
serolog
lymph
node
bone
marrow
bm
cytolog
dog
serolog
evid
vectorborn
infect
anaplasmosi
borelliosi
dirofilariosi
ehrlichiosi
dog
recent
vaccin
medic
exclud
studi
arthriti
defin
neutrophil
percentag
excess
nucleat
cell
sf
cytolog
document
dog
total
archiv
specimen
dog
includ
edtaanticoagul
blood
sampl
bm
sf
aspir
test
bartonella
spp
dna
use
bartonella
alpha
proteobacteria
growth
medium
bapgm
diagnost
platform
eight
dog
infect
one
two
bartonella
speci
includ
candidatu
bartonella
merieuxii
n
b
hensela
n
b
rochalima
n
bartonella
spp
dna
amplifi
bm
dog
blood
dog
amplifi
sf
sampl
overal
dog
dog
without
arthriti
infect
bartonella
speci
preval
bartonella
spp
dna
dog
without
arthriti
differ
v
test
independ
p
preval
giardia
dog
rang
higher
preval
puppi
howev
risk
factor
giardia
infect
around
wean
poorli
describ
aim
studi
evalu
risk
factor
giardia
infect
puppi
first
week
life
determin
impact
parasit
fece
qualiti
puppi
litter
live
breed
kennel
follow
week
age
puppi
treat
fenbendazol
panacur
msd
franc
mgkg
per
os
q
h
consecut
day
week
age
puppi
fecal
consist
evalu
use
scale
excret
enteropathogen
evalu
qpcr
canin
parvoviru
type
qrtpcr
canin
coronaviru
ccv
coproantigen
quantif
giardia
prospectgiardia
remel
mcmaster
flotat
techniqu
egg
oocyst
gener
linear
mix
model
proc
glimmix
giardia
infect
binari
outcom
use
assess
follow
effect
breed
size
age
ccv
isospora
ohioensi
infect
linear
mix
model
proc
mix
fecal
score
outcom
use
determin
follow
effect
breed
size
age
giardia
ccv
ohioensi
infect
total
fecal
sampl
collect
giardia
ohioensi
ccvwere
detect
respect
sampl
risk
giardia
infect
increas
age
odd
ratio
p
neither
breed
ccv
ohioensi
infect
influenc
risk
giardia
infect
p
p
p
p
respect
giardia
infect
impact
fece
qualiti
p
wherea
signific
influenc
p
ccv
infect
p
breed
size
p
evidenc
studi
underlin
even
adapt
deworm
program
erad
giardia
difficult
obtain
larg
dog
pack
higher
preval
giardia
puppi
week
older
could
link
immun
gap
period
giardia
associ
studi
increas
risk
diarrhea
lack
pathogen
parasit
per
se
could
hypothes
also
efficaci
treatment
prevent
clinic
sign
local
system
immun
limit
clinic
sign
financi
support
royal
canin
hepat
encephalopathi
occur
dog
complic
primari
liver
diseas
consequ
congenit
portosystem
shunt
pss
aim
studi
assess
magnet
resonac
spectroscopi
mr
use
diagnosi
twenti
dog
presumpt
diagnosi
enrol
inclus
criteria
clinic
examin
blood
cell
count
biochem
panel
least
one
plasmat
ammonia
determin
higher
lmoll
option
hystopatolog
liver
requir
magnet
reson
imag
mri
investig
clinician
even
though
mr
repres
noninvas
procedur
inform
consent
obtain
dogsown
diagnosi
confirm
pss
show
hepat
microvascular
dysplasia
hepat
cirrhosi
histolog
confirm
controlgroup
made
patient
retriev
databas
underw
mri
without
show
abnorm
brain
scan
mr
protocol
includ
fast
spinecho
sequenc
proton
densiti
radiofrequ
puls
gradientecho
mri
examin
cerebr
atrophi
evid
patient
rang
mild
sever
patient
symmetr
bilater
hyperintens
globu
pallidu
imag
evid
mr
perform
use
short
te
ms
defin
volum
interest
parietooccipit
region
side
cube
cc
volum
glutamineglutam
gln
nacetylaspart
nacetyl
aspartyl
glutam
naa
cholin
deriv
cho
myoinositol
in
analyz
compar
spectra
affect
dog
controlgroup
decreas
valu
in
cho
naa
well
high
field
mri
combin
brain
mr
provid
accur
noninvas
diagnosi
canin
accord
human
medicin
public
could
state
mr
role
diagnosi
followup
particular
mention
monitor
conflict
interest
report
diagnosi
hepatobiliari
diseas
often
requir
hepat
tissu
sampl
histolog
evalu
laparoscop
techniqu
safe
method
allow
acquisit
tissu
wedg
needl
biopsi
differ
liver
lobe
minim
invas
wayspecimen
obtain
biopsi
needl
must
interpret
caution
due
consider
variabl
tissu
involv
certain
diseas
process
hypothes
needl
biopsi
specimen
would
produc
find
diverg
produc
wedg
biopsi
specimen
goal
studi
compar
histolog
find
two
laparoscop
biopsi
method
wedg
needl
assess
sampl
technic
repres
overal
diseas
process
procedur
dog
includ
prospect
studi
studi
suspect
diffus
hepat
diseas
underw
laparoscop
hepat
biopsi
wedg
needl
biopsi
specimen
examin
basi
morpholog
criteria
comparison
made
two
type
biopsi
procedur
accord
wsava
liver
standard
group
morpholog
criteria
result
twentytwo
dog
includ
complic
report
laparoscop
procedur
median
number
portal
triad
per
needl
biopsi
specimen
rang
compar
rang
wedg
biopsi
specimen
median
length
needl
biopsi
specimen
mm
rang
mm
mm
wedg
biopsi
basi
biopsi
interpret
diagnosi
overal
similar
two
method
dog
vacuolar
hepatopathi
acut
cholang
nonspecif
acut
form
dog
chronic
hepat
cirrhosi
found
case
dog
diffus
neoplasia
miscellan
hepat
disord
fibrosi
consid
sever
dog
moder
dog
mild
dog
quantit
qualit
differ
observ
two
type
biopsi
specimen
studi
demonstr
biopsi
needl
length
least
mm
bring
satisfactori
inform
evalu
inflammatori
vacuolar
hepatopathi
fibrosi
diffus
tumor
infiltr
wedg
biopsi
allow
examin
largest
number
portal
triad
contributori
certain
form
cholang
affect
larger
canal
singl
case
imag
perihepat
count
level
capsul
fibrosi
seem
import
subcapsular
zone
contrari
observ
human
patholog
conflict
interest
report
indocyanin
green
icg
fluoresc
dye
excret
sole
liver
without
enterohepat
recircul
henc
use
decad
ideal
albeit
invas
marker
hepat
function
blood
flow
cat
dog
evalu
feasibl
minim
invas
transcutan
icg
clearanc
assess
hepat
function
instantan
transcutan
icg
clearanc
perform
healthi
research
cat
healthi
research
dog
normal
liver
function
bile
acid
stimul
test
ammonia
toler
test
use
modifi
devic
kidney
int
excit
wave
length
nm
emiss
wave
length
nm
devic
place
differ
locat
later
thorac
wall
ventrolater
abdomen
metatarsu
antebrachium
fix
light
bandag
find
suitabl
dose
reach
adequ
transcutan
peak
concentr
escal
dose
icg
mgkg
inject
intraven
wash
period
least
h
inbetween
measur
continu
hour
inject
awak
anim
move
freeli
result
icg
disappear
curv
visual
inspect
find
best
locat
minim
artifact
accept
background
nois
dose
anim
dose
mgkg
deem
ideal
thorac
abdomin
wall
gave
consist
result
halflif
icg
clearanc
calcul
use
onecompart
model
halfliv
cat
minut
respect
dog
minut
respect
conclus
transcutan
assess
icg
clearanc
feasibl
clinic
set
result
obtain
within
one
hour
assess
instantan
procedur
minim
invas
well
toler
anim
given
patient
presum
liver
problem
undergo
abdomin
ultrasound
clip
hair
necessari
devic
might
place
area
studi
necessari
obtain
refer
valu
healthi
pet
variou
condit
lead
impair
hepat
function
conflict
interest
report
gallbladd
diseas
like
gallbladd
mucocel
cholecyst
reduc
gallbladd
motil
may
lead
cholestasi
sinc
impair
gallbladd
empti
contribut
sludg
gallston
format
evalu
gallbladd
motil
requir
accur
appropri
methodolog
threedimension
ultrasonographi
shown
accur
appropri
tool
measur
gallbladd
volum
human
therefor
appli
novel
techniqu
first
time
studi
preprandi
postprandi
gallbladd
volum
healthi
mixedbre
dog
compar
result
twodimension
ultrasonographi
dog
place
dorsal
recumb
obtain
ultrasonograph
measur
gallbladd
measur
ultrasonographi
record
preprandi
state
ingest
fullfat
milk
preprandi
postprandi
gallbladd
volum
determin
ultrasonographi
significantli
higher
correspond
volum
ultrasonographi
ae
vs
ae
vs
mlkg
respect
p
ultrasonographi
dog
preprandi
gallbladd
volum
mlkg
howev
ultrasonographi
dog
preprandi
gallbladd
volum
mlkg
gallbladd
contract
index
higher
ultrasonographi
ultrasonographi
howev
reach
statist
signific
p
conclus
ultrasonographi
show
larger
gallbladd
volum
ultrasonographi
healthi
dog
seem
ultrasonographi
appropri
adjunct
devic
ultrasonographi
estim
gallbladd
volum
ultrasonographi
could
detect
whole
gallbladd
volum
research
need
determin
clinic
valu
ultrasonographi
canin
gallbladd
imag
conflict
interest
report
aim
studi
compar
highdefinit
oscillometri
hdo
doppler
ultrasonograph
measur
direct
blood
pressur
measur
consciou
dog
doppler
studi
perform
three
investig
use
differ
sphygmomanomet
differ
size
cuff
devic
measur
site
chang
randomli
among
investig
cuff
wrap
around
antebrachium
forelimb
around
midmetatarsu
hind
limb
addit
limb
site
cuff
also
place
around
base
tail
case
hdo
method
cuff
size
measur
limb
circumfer
doppler
measur
hdo
method
measur
perform
investig
cuff
provid
manufactur
use
smallest
cuff
use
hind
limb
tail
medium
cuff
use
forelimb
measur
dog
gentli
held
later
recumb
posit
measur
perform
nondepend
limb
radiotelemetri
transduc
implant
right
femor
arteri
month
year
preced
blood
pressur
measur
reason
unrel
studi
direct
blood
pressur
vari
mmhg
mmhg
doppler
hdo
measur
respect
twohundr
pair
simultan
doppler
direct
measur
dog
pair
simultan
hdo
direct
telemetr
measur
dog
obtain
least
success
consecut
measur
could
obtain
investig
site
doppler
hdo
measur
case
respect
thu
mean
measur
could
calcul
similarli
establish
everyday
clinic
practic
bia
mean
differ
precis
standard
deviat
limit
agreement
calcul
individu
pair
measur
mean
consecut
measur
use
blandaltman
spot
analysi
systol
measur
perform
tail
hdomethod
yield
smallest
bia
deviat
best
limit
agreement
studi
doppler
hdomeasur
perform
forelimb
overestim
hind
limb
measur
underestim
direct
telemetr
pressur
result
three
measur
site
hdo
perform
better
forelimb
hind
limb
dopplermeasur
howev
hdomeasur
difficult
obtain
often
result
measur
failur
compar
doppler
techniqu
cuff
size
measur
limb
circumfer
show
better
result
smaller
cuff
size
doppler
measur
conflict
interest
report
doppler
techniqu
consid
repeat
indirect
method
measur
systol
arteri
pressur
sap
dog
howev
recent
studi
emphas
effect
bodi
posit
use
limb
sap
measur
aim
studi
determin
whether
differ
exist
sap
measur
simultan
dog
use
differ
limb
two
doppler
unit
two
differ
oper
sixti
clientown
dog
admit
veterinari
hospit
differ
reason
enrol
divid
group
base
bodi
size
small
breed
dog
kg
medium
breed
kg
larg
breed
kg
dog
anxieti
statu
record
sap
measur
via
doppler
techniqu
dog
right
later
recumb
quit
environ
right
left
forelimb
sap
left
forelimb
left
hindlimb
sap
record
simultan
two
ident
doppler
unit
equip
headphon
two
oper
measur
perform
base
acvim
guidelin
five
measur
record
higher
lower
valu
discard
analysi
relationship
mean
sap
limb
bodi
weight
sex
anxieti
statu
sap
valu
evalu
mean
ae
sd
sap
significantli
higher
right
forelimb
ae
compar
left
forelimb
ae
overal
popul
differ
signific
larg
breed
dog
male
dog
sap
mmhg
sap
higher
left
forelimb
ae
compar
left
hindlimb
ae
overal
popul
differ
signific
medium
larg
breed
dog
femal
calm
anim
dog
sap
mmhg
mean
sap
left
forelimb
record
two
differ
oper
two
differ
moment
compar
differ
evid
conclus
sap
measur
differ
limb
dog
right
later
recumb
poorli
correl
measur
sap
left
forelimb
repeat
time
differ
oper
sap
trend
monitor
done
use
measur
site
anim
conflict
interest
report
amlodipin
consid
treatmenf
choic
hypertens
cat
decad
howev
unmet
need
catspecif
formul
aim
studi
assess
efficaci
chewabl
amlodipin
tablet
reduc
systol
blood
pressur
sbp
cat
diagnos
hypertens
seventyseven
clientown
cat
includ
studi
mean
age
year
studi
randomis
doubleblind
placebo
control
consist
two
phase
blind
phase
cat
receiv
mgkg
amlodipin
daili
day
respond
dose
remain
day
nonrespond
dose
increas
mgkg
thirtyf
cat
receiv
placebo
follow
protocol
arteri
blood
pressur
measur
use
high
definit
oscillometri
method
day
respond
defin
cat
show
decreas
sbp
mmhg
decreas
baselin
least
day
cat
continu
amlodipin
month
open
phase
placebo
cat
repeat
dose
escal
protocol
blind
phase
respond
rate
amlodipin
group
placebo
group
follow
dose
escal
day
appli
cat
receiv
amlodipin
placebo
respect
cat
receiv
amlodipin
ci
time
like
classifi
respond
compar
receiv
placebo
logist
regress
model
p
baselin
valu
ae
ae
mmhg
mean
sbp
decreas
ae
mmhg
amlodipin
ae
mmhg
placebo
repeat
measur
analysi
covari
model
p
day
respond
rate
influenc
factor
amlodipin
treatment
eg
baselin
blood
pressur
concomit
ace
inhibitor
therapi
renal
diseas
differ
amlodipin
placebo
group
frequenc
advers
event
report
blind
phase
likewis
chang
laboratori
valu
time
either
group
present
studi
first
larg
clinic
trial
show
amlodipin
clearli
superior
placebo
treatment
cat
hypertens
chewabl
amlodipin
formul
effect
reduc
sbp
good
palat
well
toler
use
concomitantli
ace
inhibitor
cat
renal
diseas
conflict
interest
huhtinen
j
aspegr
en
employe
sponsor
j
elliott
follow
inform
disclos
amlodipin
treatment
choic
felin
hypertens
limit
publish
data
exist
serum
concentr
achiev
hypertens
cat
aim
studi
assess
serum
amlodipin
concentr
cat
treat
new
formul
amlodipin
relat
blood
pressur
reduct
achiev
seventyseven
clientown
hypertens
cat
enrol
random
doubleblind
placebo
control
studi
consist
two
phase
phase
one
cat
group
receiv
mgkg
amlodipin
daili
day
deem
respond
see
dose
remain
day
nonrespond
dose
increas
mgkg
thirtyf
cat
group
b
receiv
placebo
follow
protocol
blood
pressur
measur
use
high
definit
oscillometri
respond
defin
cat
show
decreas
systol
blood
pressur
sbp
mmhg
decreas
baselin
follow
day
phase
group
continu
amlodipin
group
b
switch
amlodipin
dose
adjust
per
phase
group
follow
day
amlodipin
blood
collect
day
group
group
serum
amlodipin
measur
liquid
chromatographi
mass
spectrometri
sbp
measur
treatment
calcul
percentag
baselin
sbp
plot
serum
amlodipin
use
sigmoid
emax
model
winnonlin
softwar
data
express
mean
ae
se
serum
concentr
group
cat
remain
mgkg
ae
ngml
wherea
switch
mgkg
ae
ngml
data
group
b
pool
sigmoid
relationship
percentag
baselin
sbp
serum
amlodipin
found
estim
valu
lowest
percentag
baselin
blood
pressur
treatment
emax
ae
ec
valu
ae
ng
ml
slope
function
ae
serum
concentr
requir
reduc
blood
pressur
estim
ngml
present
studi
relat
blood
pressur
reduct
serum
amlodipin
felin
clinic
hypertens
limit
studi
limit
number
blood
sampl
collect
lack
inform
relat
exact
time
blood
sampl
rel
dose
cat
howev
data
could
use
defin
appropri
therapeut
serum
amlodipin
hypertens
cat
huhtinen
employe
sponsor
j
elliott
follow
inform
disclos
consult
pfizer
anim
health
zoeti
ceva
anim
health
boehring
ingelheim
vetoquinol
ltd
orion
ltd
elanco
ltd
idexx
ltd
nich
gener
ltd
triverista
ltd
virbac
ltd
advisori
board
membership
intern
renal
interest
societi
support
novarti
european
emesi
council
sponsor
pfizer
anim
health
zoeti
cardioren
board
vetoquinol
ltd
idexx
renal
advisori
board
research
grant
contract
vetoquinol
ltd
novarti
ltd
pfizer
anim
health
ltd
zoeti
royal
canin
ltd
boeringh
ingelheim
ltd
waltham
centr
pet
nutrit
ceva
anim
health
orion
ltd
l
pelligand
follow
inform
disclos
receipt
research
grant
contract
fund
orion
ltd
novarti
anim
health
transpharm
ltd
deltadot
ltd
act
consult
triverita
ltd
novarti
anim
health
commerci
assay
measur
canin
felin
pancreat
lipas
immunoreact
spec
cpl
spec
fpl
respect
idexx
laboratori
westbrook
usa
avail
year
previous
analyt
clinic
valid
recent
new
commerci
assay
measur
paramet
becom
avail
though
neither
one
assay
analyt
clinic
valid
literatur
thu
goal
studi
compar
newli
avail
assay
establish
assay
leftov
serum
sampl
diagnost
submiss
gi
laboratori
collect
base
certain
paramet
eg
result
throughout
work
rang
assay
good
qualiti
sampl
hemolyt
lipem
icter
sampl
assign
random
sampl
id
number
sampl
evalu
spec
cpl
spec
fpl
sent
dri
ice
klinik
hochberg
one
aliquot
sampl
blindli
submit
laboklin
measur
cpli
fpli
newli
releas
inhous
assay
also
gi
lab
texa
univers
repeat
analysi
spec
cpl
spec
fpl
exclud
effect
ship
signific
differ
serum
cpli
fpli
concentr
ship
gi
lab
pvalu
wilcoxon
matchedpair
sign
rank
test
respect
contrast
signific
differ
serum
cpli
fpli
concentr
newli
releas
assay
previous
establish
assay
pvalu
respect
signific
correl
newli
releas
previous
releas
assay
spearman
r
respect
correl
poor
assay
supposedli
measur
analyt
also
interpret
serum
cpli
fpli
result
previous
develop
assay
new
assay
agre
mani
sampl
final
newli
develop
assay
show
errat
result
conclus
newli
releas
assay
measur
cpli
fpli
agre
previous
establish
valid
assay
provid
differ
interpret
show
errat
result
thu
research
need
newli
releas
assay
could
recommend
clinic
use
dr
steiner
serv
director
dr
suchodolski
serv
associ
director
gastrointestin
laboratori
texa
univers
dr
steiner
also
serv
paid
consult
idexx
laboratori
westbrook
usa
gastrointestin
laboratori
idexx
laboratori
offer
cpli
fpli
test
feeforservic
basi
digest
health
main
concern
growth
morbid
mortal
wean
puppi
fecal
immunoglobulin
iga
suggest
use
noninvas
biomark
mucos
immun
purpos
studi
evalu
effect
infect
enteropathogen
fecal
iga
concentr
puppi
physiolog
factor
age
breed
size
puppi
breed
kennel
includ
studi
puppi
week
age
meanaestandard
deviat
sd
ae
week
depend
mean
adult
bodi
weight
respect
breed
puppi
divid
small
mean
adult
bodi
weight
kg
larg
kg
breed
puppi
puppi
fecal
consist
evalu
use
scale
fece
collect
evalu
presenc
fecal
enteropathogen
fecal
iga
concentr
presenc
enteropathogen
fecal
sampl
evalu
qpcr
canin
parvoviru
type
qrtpcr
canin
coronaviru
ccv
coproantigen
quantif
giardia
prospectgiardia
remel
mcmaster
flotat
techniqu
parasit
egg
oocyst
fecal
iga
concentr
measur
elisa
test
statist
analys
perform
use
sa
softwar
linear
mix
model
proc
mix
fecal
iga
concentr
outcom
use
determin
follow
effect
enteropathogen
infect
breed
size
age
fecal
score
respect
influenc
litter
breed
kennel
random
effect
also
determin
data
present
mean
ae
sd
small
breed
dog
repres
total
number
dog
includ
least
one
enteropathogen
identifi
puppi
fecal
iga
concentr
significantli
influenc
fecal
enteropathogen
p
puppi
infect
least
one
enteropathogen
significantli
lower
fecal
iga
concentr
puppi
without
enteropathogen
ae
lgg
vs
ae
lgg
breed
p
age
p
influenc
iga
concentr
small
breed
puppi
significantli
higher
fecal
iga
concentr
larg
breed
puppi
ae
lgg
vs
ae
lgg
signific
relationship
fecal
iga
concentr
fece
qualiti
evidenc
p
studi
suggest
fecal
iga
concentr
promis
marker
subclin
infect
least
one
enteropathogen
confirm
digest
physiolog
vari
breed
size
link
lower
digest
immun
higher
suscept
enteropathogen
infect
need
investig
conflict
interest
financi
support
royal
canin
canin
chronic
enteropathi
cce
includ
dietrespons
antibioticrespons
immunosuppressiverespons
enteropathi
ire
prospect
studi
design
evalu
commerci
hypoallergen
dri
diet
contain
oligopeptid
protein
sourc
manag
dog
ire
altern
immunosuppress
therapi
week
period
nineteen
dog
across
franc
quebec
enter
studi
dog
food
antibioticrespons
chronic
enteropathi
hypoproteinemia
treat
immunomodul
drug
exclud
studi
dog
includ
studi
complet
clinic
ultrasonograph
endoscop
evalu
histopatholog
evalu
intestin
biopsi
show
sign
intestin
inflamm
owner
instruct
feed
exclus
studi
diet
canin
inflammatori
bowel
diseas
activ
index
cibdai
score
fecal
score
observ
dogown
bodi
weight
evalu
baselin
week
inclus
dietari
treatment
regard
success
cibdai
score
reduc
least
protocol
review
accept
royal
canin
ethic
committe
owner
complet
inform
consent
result
present
meanaesd
rang
statist
comparison
perform
wilcoxon
test
thirteen
dog
intact
male
neuter
intact
femal
complet
trial
seven
dog
exclud
diagnos
giardia
histolog
evid
inflamm
hypoadrenocortic
mean
age
year
ae
mean
bodi
weight
kg
ae
cibdai
score
ae
inclus
ae
week
ae
week
p
p
vs
inclus
respect
fecal
score
ae
week
ae
improv
compar
inclus
score
ae
p
p
respect
low
molecular
weight
poultri
feather
hydrolyz
proteinbas
dri
extrud
diet
appear
effect
manag
idiopath
ibd
without
concurr
immunosuppress
drug
week
period
pilot
studi
preliminari
find
confirm
prospect
random
doubl
blind
studi
felin
pancreat
common
exocrin
pancreat
disord
vari
mortal
howev
avail
reliabl
method
evalu
sever
prognosi
diseas
ninetytwo
cat
diagnos
pancreat
acut
onset
compat
clinic
sign
posit
snap
fpl
tm
test
octob
septemb
enrol
studi
cat
divid
surviv
n
nonsurviv
n
group
fiftytwo
paramet
includ
signal
clinic
sign
physic
examin
clinicopatholog
examin
diagnost
imag
complic
concurr
diseas
analyz
compar
two
group
paramet
p
consid
analys
mortal
studi
hematocrit
albumin
bun
creatinin
total
bilirubin
calcium
phosphor
bodi
temperatur
systol
blood
pressur
bodi
caviti
fluid
complic
eg
system
inflammatori
respons
syndrom
sir
acut
renal
failur
arf
found
significantli
associ
diseas
sever
prognosi
select
construct
score
continu
variabl
outsid
refer
interv
separ
quartil
yield
quartilespecif
odd
ratio
or
surviv
base
integ
valu
score
system
develop
incorpor
weight
factor
assign
quartil
predict
total
score
calcul
cat
sum
weight
factor
total
score
cat
rang
sever
score
studi
achiev
area
receiv
oper
characterist
auroc
optim
cutoff
point
discrimin
outcom
sensit
specif
respect
mortal
score
wherea
score
signific
differ
p
two
group
cutoff
point
furthermor
mortal
reach
score
sever
score
system
studi
provid
reliabl
clinic
applic
method
predict
clinic
outcom
cat
pancreat
conflict
interest
report
convinc
evid
role
clostridium
c
perfringen
primari
pathogen
acut
haemorrhag
diarrhoea
syndrom
ahd
dog
recent
found
suspect
clostridi
toxin
especi
c
perfringen
enterotoxin
play
relev
role
diseas
process
howev
date
enterotoxigen
c
perfringen
strain
describ
singl
case
report
thu
aim
studi
indentifi
specif
c
perfringen
genotyp
involv
adh
small
intestin
biopsi
collect
steril
singleus
biopsi
forcep
ten
dog
ahd
immedi
cultur
dog
clostridi
strain
isol
identifi
c
perfringen
mass
spectrometri
use
malditof
ms
c
perfringen
coloni
dog
submit
specif
detect
four
major
toxin
gene
alpha
beta
epsilon
iota
enterotoxin
gene
toxin
multiplex
pcr
everi
clostridi
isol
type
c
perfringen
type
base
detect
alpha
toxin
encod
gene
isol
addit
toxin
gene
identifi
howev
none
clostridi
strain
encod
c
perfringen
enterotoxin
gene
result
studi
suggest
c
perfringen
type
import
c
perfingen
genotyp
involv
diseas
process
dog
ahd
although
c
perfringen
enterotoxinha
associ
intestin
diseas
human
dog
hors
pig
anim
speci
enterotoxin
like
respons
intestin
lesion
dog
ahd
conflict
interest
report
p
lack
treatment
respons
significantli
associ
il
il
sre
fre
p
anemia
thrombocytopenia
increas
plasma
urea
significantli
associ
il
anemia
il
sre
fre
p
thrombocytopenia
il
sre
fre
p
increas
urea
il
sre
fre
p
hypoalbuminemia
gl
hypocobalaminemia
pgml
occur
significantli
frequent
dog
sre
hypoalbuminemia
il
sre
fre
p
hypocobalaminemia
il
sre
fre
p
result
studi
show
elderli
larg
breed
dog
frequent
affect
il
sre
compar
etiolog
il
sre
associ
greater
diseas
sever
andor
neg
outcom
comparison
anemia
thrombocytopenia
increas
plasma
urea
frequent
detect
il
wherea
sever
hypoalbuminemia
hypocobalaminemia
significantli
associ
sre
conflict
interest
report
alpha
proteinas
inhibitor
pi
proteinaseresist
protein
quantifi
fecal
urin
serum
sampl
dog
recent
increas
fecal
urinari
canin
pi
ca
pi
concentr
describ
dog
gastrointestin
diseas
eg
inflammatori
bowel
diseas
ibd
also
dog
exocrin
pancreat
insuffici
dog
chronic
hepat
chronic
kidney
diseas
respect
decreas
serum
ca
pi
concentr
report
dog
ibd
proteinlos
enteropathi
ple
hypocobalaminemia
treatment
protocol
dog
ibd
andor
ple
commonli
includ
corticosteroid
effect
corticosteroid
therapi
serum
ca
pi
concentr
yet
report
aim
studi
evalu
effect
hydrocortison
serum
ca
pi
concentr
healthi
dog
twelv
healthi
beagl
dog
randomli
alloc
placebogroup
n
treatment
group
n
hydrocortisonegroup
placebogroup
receiv
empti
gelatin
capsul
po
h
wherea
hydrocortisonegroup
treat
hydrocortison
dose
mgkg
po
h
serum
sampl
obtain
baselin
day
treatment
well
day
posttreat
dog
serum
ca
pi
concentr
measur
time
point
use
inhous
radioimmunoassay
mannwhitney
u
test
use
compar
baselin
measur
group
effect
hydrocortisonetreat
serum
ca
pi
concentr
evalu
compar
ca
pi
baselin
treatment
baselin
posttreat
period
use
manova
baselin
serum
ca
pi
concentr
differ
hydrocortisoneand
placebogroup
p
serum
ca
pi
concentr
increas
significantli
p
treatment
period
hydrocortisonegroup
baselin
median
mgl
contrast
differ
observ
group
compar
serum
ca
pi
concentr
baselin
posttreat
period
p
studi
show
hydrocortisonetreat
week
affect
serum
ca
pi
concentr
healthi
dog
whether
corticosteroid
therapi
effect
fecal
urin
ca
pi
concentr
healthi
dog
remain
determin
author
work
texa
univers
whose
gi
lab
current
offer
commerci
assay
faecal
inhibitor
canin
chronic
enteropathi
ce
common
poorli
understood
syndrom
variabl
respons
therapi
prognosi
need
novel
biomark
specif
intestin
diseas
provid
object
measur
diseas
sever
progress
prognosi
serum
citrullin
use
biomark
human
intestin
diseas
specif
small
intestin
indic
global
reduc
enterocyt
mass
absorpt
function
variou
diseas
state
use
determin
quantit
intestin
integr
enterocyt
level
influenc
nutrit
inflammatori
statu
aim
studi
determin
whether
serum
citrullin
use
biomark
ce
dog
retrospect
studi
comput
record
univers
liverpool
small
anim
teach
hospit
use
identifi
dog
ce
diseas
sever
quantifi
cibdai
control
ageand
breedmatch
dog
without
gastrointestin
diseas
serum
citrullin
measur
ultrahigh
perform
liquid
chromatographi
tandem
mass
spectrometri
dog
ce
serum
citrullin
concentr
measur
present
variou
time
point
start
treatment
serum
citrullin
measur
dog
ce
control
dog
respond
dietari
manipul
foodrespons
enteropathi
fre
respond
antibacteri
antibioticrespons
diarrhoea
ard
invas
mucos
bacteria
one
respond
antibacteri
one
refractori
dog
diagnos
idiopath
ibd
basi
exclus
known
caus
failur
respond
therapeut
dietari
antibiot
trial
respond
immunosuppress
therapi
refractori
lost
followup
serum
citrullin
concentr
differ
dog
ce
median
lgml
rang
control
median
lgml
rang
p
also
differ
serum
citrullin
concentr
amongst
dog
fre
ard
ibd
control
p
serum
citrullin
differ
dog
respond
well
refractori
treatment
p
dog
without
proteinlos
enteropathi
p
dog
surviv
euthanas
ce
p
serum
citrullin
correl
cibdai
r
find
support
use
serum
citrullin
biomark
determin
diagnosi
prognosi
quantifi
sever
dog
ce
one
coauthor
marco
caldin
diagnost
laboratori
offer
citrullin
assay
chronic
enteropathi
ce
multifactori
diseas
involv
aberr
immun
respons
commens
bacteria
dietari
antigen
macrophag
import
role
human
diseas
littl
inform
avail
canin
intestin
data
date
reli
sole
macrophag
identif
use
antibodi
direct
calprotectin
recogn
macrophag
neutrophil
studi
altern
antibodi
macrophag
direct
scaveng
receptor
use
distribut
marker
compar
antigen
interest
posit
cell
accumul
intestin
human
ce
endoscop
duoden
biopsi
obtain
seven
crossbre
dog
serial
histolog
section
stain
positivelystain
cell
count
random
area
villou
crypt
region
stain
cell
localis
subject
evalu
percentag
posit
stain
cell
total
nucleat
cell
per
lm
villu
crypt
compar
antibodi
use
wilcoxon
signedrank
test
coloc
serial
section
significantli
posit
cell
crypt
versu
p
contrast
differ
express
either
marker
villi
versu
p
studi
report
first
time
exist
two
popul
macrophag
canin
intestin
result
normal
dog
use
explor
distribut
function
macrophag
dog
ce
conflict
interest
report
chronic
diarrhea
vomit
common
clinic
sign
dog
primari
eg
inflammatori
infecti
neoplast
mechan
secondari
gastrointestin
diseas
eg
exocrin
pancreat
hepat
renal
endocrin
diseas
possibl
underli
caus
aim
studi
evalu
final
diagnos
dog
chronic
diarrhea
andor
vomit
determin
preval
variou
primari
secondari
gastrointestin
diseas
dog
gastrointestin
sign
medic
record
dog
present
juli
august
chronic
diarrhea
vomit
v
diarrhea
vomit
vd
retrospect
review
dog
includ
minimum
workup
hematolog
plasma
biochemistri
profil
fecal
parasitolog
perform
final
diagnosi
record
primari
gastrointestin
diseas
record
case
includ
inflammatori
diseas
exocrin
pancreat
insuffici
hypoadrenocortic
polyendocrinopathi
dilat
cardiomyopathi
leukemia
one
dog
total
dog
present
follow
vd
v
vd
significantli
frequent
dog
primari
gastrointestin
diseas
vd
compar
dog
secondari
gastrointestin
diseas
vd
p
chi
squar
test
v
significantli
common
dog
secondari
gastrointestin
diseas
compar
dog
primari
gastrointestin
diseas
p
studi
food
respons
enteropathi
commonli
diagnos
caus
chronic
gastrointestin
sign
chronic
pancreat
frequent
caus
secondari
gastrointestin
diseas
diarrhea
significantli
associ
primari
vomit
secondari
gastrointestin
diseas
conflict
interest
report
matrix
metalloproteinas
mmp
zincdepend
endopeptidas
contribut
control
breakdown
reconstitut
extracellular
matrix
normal
patholog
condit
intestin
mucos
level
shown
increas
anim
model
human
ibd
knowledg
presens
studi
intestin
mucos
sampl
healthi
dog
well
canin
spontan
ibd
thu
main
aim
studi
identifi
presenc
mucosa
small
larg
intestin
clinic
healthi
beagl
dog
use
gelatin
zymographi
techniqu
studi
histor
intestin
tissu
sampl
four
differ
part
intestin
duodenum
jejunum
ileum
colon
use
sampl
taken
snap
frozen
liquid
nitrogen
necropsi
healthi
laboratori
beagl
dog
euthan
finish
unrel
longterm
trial
studi
canin
intestin
microbiota
base
wsava
histolog
standard
record
find
sampl
consid
insignific
activ
found
sampl
respect
among
four
differ
part
intestin
dog
ileum
highest
posit
rate
activ
respect
howev
statist
analysi
show
signific
differ
activ
separ
part
intestin
p
enzym
activ
rang
arbitrari
unit
au
au
none
intestin
sampl
show
gelatinolyt
activ
correspond
control
band
activ
studi
show
could
detect
intestin
mucosa
healthi
dog
use
zymographi
seem
use
tool
evalu
role
pathogenesi
canin
chronic
enteropathi
includ
inflammatori
bowel
diseas
conflict
interest
report
digest
perfor
call
spontan
aris
absenc
foreign
bodi
ingest
gastric
dilat
volvulu
extern
trauma
previou
digest
surgeri
dog
mani
predispos
factor
identifi
includ
antiinflammatori
administr
sever
hepat
renal
diseas
stress
shock
gastric
hyperacid
neoplasia
idiopath
inflammatori
bowel
diseas
spontan
digest
perfor
uncommonli
report
cat
object
studi
describ
clinic
characterist
spontan
digest
perfor
cat
compar
frequenc
malign
versu
nonmalign
caus
perfor
includ
studi
perfor
spontan
confirm
exploratori
surgeri
medic
record
cat
diagnos
spontan
digest
perfor
review
mean
age
cat
year
month
year
five
cat
concurr
ill
includ
viral
upper
respiratori
tract
diseas
pancreat
chronic
kidney
diseas
frequent
report
sign
includ
anorexia
vomit
lethargi
histolog
examin
perform
cat
diagnos
alimentari
lymphoma
inflammatori
lesion
six
cat
receiv
antiinflammatori
within
previou
month
half
final
diagnos
lymphoma
five
cat
lymphoma
receiv
chemotherapythre
cat
die
earli
postop
recoveri
period
cat
euthan
day
surgeri
cat
still
aliv
end
studi
absenc
pneumoperitoneum
clinic
sign
clinicopatholog
abnorm
specif
enough
allow
differenti
cat
gastrointestin
ulcer
perfor
case
diagnost
test
individu
determin
whether
perfor
occur
impend
clinician
use
multimod
diagnost
procedur
radiographi
ultrasonographi
endoscopi
abdomin
fluid
cytopatholog
avoid
delay
diagnosi
digest
perfor
histolog
examin
ulcer
essenti
lymphoma
suspect
cat
present
spontan
perfor
link
antiinflammatori
administr
spontan
perfor
cat
establish
conflict
interest
report
campylobact
speci
commonli
isol
faec
dog
cat
c
upsaliensi
cu
c
helveticu
ch
frequent
isol
two
speci
usual
consid
pathogen
dog
cat
close
relat
c
jejuni
common
caus
bacteri
gastroenter
human
develop
world
interestingli
despit
close
genet
relationship
human
cu
consid
pathogen
ch
studi
aim
describ
whole
genom
cu
ch
isol
dog
cat
silico
investig
pathogen
potenti
comparison
sever
publish
genom
c
jejuni
c
coli
genom
dna
extract
three
isol
cu
ch
recov
faec
healthi
dog
cat
sequenc
perform
use
illumina
miseq
gener
base
pair
read
read
trim
length
qualiti
contig
assembl
use
velvet
assembl
concaten
contig
gener
assembl
qualiti
rank
number
size
maximum
length
three
top
rank
assembl
annot
use
prokka
annot
tool
ribosom
mlst
nucleotid
sequenc
use
proxi
core
genom
compar
phylogeni
cu
ch
speci
campylobact
genu
visualis
neighbornet
use
splitstre
annot
draft
genom
cluster
use
orthomcl
pathogen
trait
investig
silico
use
pathogenfind
virulentpr
softwar
cu
ch
draft
genom
mb
mb
size
compris
averag
contig
averag
predict
gene
respect
cu
averag
ch
hypothet
protein
use
orthomcl
core
genom
gene
result
cu
ch
respect
neighbornet
tree
base
ribosom
mlst
nucleotid
sequenc
core
genom
confirm
close
phylogenet
relationship
ch
cu
within
campylobact
genu
pathogenfind
predict
isol
human
pathogen
probabl
pathogenfind
virulentpr
identifi
mani
pathogen
protein
cu
ch
differ
function
eg
chemotaxi
transport
motil
system
consider
fewer
c
jejuni
c
coli
studi
provid
mani
insight
pathogen
potenti
petassoci
emerg
campylobact
pathogen
knowledg
first
report
draft
genom
ch
conflict
interest
report
laboratori
marker
evalu
diagnos
andor
monitor
canin
chronic
enteropathi
includ
inflammatori
bowel
diseas
ibd
belong
famili
propos
play
central
role
innat
acquir
immun
respons
report
increas
stool
sampl
serum
andor
intestin
mucosa
human
patient
ibd
myeloperoxidas
mpo
enzym
found
mostli
granulocyt
intestin
mucos
level
mpo
shown
increas
anim
model
human
ibd
date
mpo
level
intestin
mucos
sampl
report
neither
healthi
dog
dog
suffer
ibd
start
investig
aspect
dog
object
studi
evalu
mucos
mpo
level
small
larg
intestin
use
enzymelink
immunoassay
elisa
spectrophotometr
method
respect
studi
histor
intestin
tissu
sampl
four
differ
part
intestin
duodenum
jejunum
ileum
colon
use
sampl
taken
snap
frozen
liquid
nitrogen
necropsi
healthi
laboratori
beagl
dog
euthan
finish
unrel
longterm
trial
studi
canin
intestin
microbiota
base
wsava
standard
histolog
find
sampl
consid
insignific
concentr
highest
lowest
ileum
lgl
colon
lgl
duodenum
lgl
jejunum
lgl
concentr
ileum
significantli
higher
segment
p
colon
mucos
concentr
higher
jejun
p
highest
mpo
activ
found
ileum
damin
follow
jejunum
damin
duodenum
damin
colon
damin
mpo
activ
significantli
higher
ileal
duoden
colon
mucos
sampl
p
jejun
mpo
activ
higher
colon
duoden
activ
p
studi
show
use
elisa
spectrophotometri
allow
detect
canin
intestin
mucos
mpo
respect
level
mpo
seem
differ
certain
part
intestin
mucosa
healthi
dog
assay
appear
use
evalu
role
mpo
pathogenesi
canin
chronic
enteropathi
includ
ibd
dr
heilmann
dr
suchodolski
dr
steiner
patent
pend
includ
canin
assay
use
studi
author
declar
conflict
interest
aim
present
studi
establish
incid
innoc
cardiac
murmur
fairli
larg
number
clinic
healthi
puppi
second
aim
evalu
possibl
correl
presenc
innoc
cardiac
murmur
lower
hematocrit
valu
puppi
certain
breed
routin
screen
presenc
congenit
portosystem
shunt
netherland
breeder
bring
nest
clinic
individu
measur
blood
ammonia
concentr
one
year
time
februari
januari
dog
differ
breed
examin
cairn
terrier
age
dog
vari
day
mean
day
breeder
wait
blood
result
cardiac
auscult
perform
singl
boardcertifi
cardiologist
vsz
hematocrit
measur
automat
hematolog
analyz
system
surplu
blood
sampl
cardiac
murmur
found
dog
case
soft
systol
murmur
time
music
charact
point
maxim
intens
left
hemithorax
compat
descript
innoc
cardiac
murmur
murmur
found
could
compat
congenit
cardiac
anomali
hematocrit
significantli
p
lower
group
dog
murmur
mean
standard
deviat
compar
group
without
murmur
mean
standard
deviat
multivari
analysi
show
presenc
murmur
correl
hematocrit
age
dog
physiolog
anemia
long
suspect
one
possibl
caus
innoc
cardiac
murmur
young
anim
children
howev
accord
author
knowledg
publish
report
exist
look
possibl
correl
factor
contribut
presenc
innoc
murmur
larg
unknown
larg
overlap
hematocrit
valu
dog
without
cardiac
murmur
measur
hematocrit
particular
pup
would
help
less
experienc
first
line
veterinari
practition
decid
whether
murmur
innoc
result
congenit
cardiac
anomali
limit
studi
echocardiographi
perform
rule
congenit
cardiac
anomali
caus
murmur
neither
dog
recheck
spontan
disappear
murmur
conflict
interest
report
low
intens
systol
murmur
point
maxim
intens
outflow
tract
left
side
thorax
uncommonli
heard
cardiac
auscult
appar
healthi
siberian
huski
dog
often
excel
exercis
toler
origin
murmur
athlet
dog
huski
unlik
due
heart
diseas
like
due
turbul
blood
flow
outflow
tract
caus
larg
stroke
volum
forc
cardiac
contractil
earli
systol
differenti
murmur
patholog
signific
murmur
howev
problemat
gener
practic
aim
present
studi
investig
preval
murmur
sampl
success
race
siberian
huski
dog
furthermor
studi
phonocardiograph
characterist
murmur
phonocardiogram
ecg
record
activ
race
siberian
huski
dog
normal
excel
exercis
toler
normal
stamina
confirm
success
race
phonocardiogram
easi
rapid
record
pc
laptop
connect
meditron
stethoscop
ambul
field
practic
systol
measur
durat
measur
onset
first
heart
sound
onset
second
heart
sound
murmur
durat
onset
first
heart
sound
end
murmur
durat
first
heart
sound
plu
murmur
measur
calcul
percentag
durat
systol
cardiac
murmur
grade
heard
dog
examin
phonocardiogram
dog
reveal
earli
systol
crescendodecrescendo
decrescendo
murmur
durat
maxim
systol
dog
murmur
silent
paus
end
systol
ecg
normal
dog
murmur
adult
athlet
dog
regard
definit
sign
heart
diseas
physiolog
flow
murmur
systol
common
find
activ
siberian
huski
dog
preval
examin
sampl
phonocardiographi
rapid
practic
method
differenti
diagnos
patholog
murmur
physiolog
flow
murmur
conflict
interest
report
ntprobnp
degre
overlap
clinic
normal
anim
particularli
mild
subclin
heart
diseas
prior
studi
evalu
sensit
specif
pointofcar
second
gener
elisa
util
snap
technolog
snap
felin
probnp
test
use
biolog
reagent
cardiopet
probnp
test
provid
result
minut
sought
prospect
valid
assay
popul
clinic
normal
cat
cat
recruit
base
upon
absenc
heart
murmur
gallop
andor
arrhythmia
cat
receiv
physic
examin
noninvas
blood
pressur
measur
complet
biochem
analysi
includ
urinalysi
echocardiogram
cat
consid
free
underli
cardiac
system
diseas
enrol
sixteen
adult
cat
enrol
blood
sampl
obtain
ntprobnp
concentr
hr
hr
hr
hr
hr
sampl
place
edta
tube
centrifug
within
one
hour
split
two
tube
duplic
sampl
time
point
store
sampl
collect
ship
dri
ice
overnight
run
one
batch
idexx
laboratori
measur
ntprobnp
concentr
snap
test
visual
evalu
one
blind
reader
comparison
snap
assay
vs
quantit
elisa
reveal
auc
degre
correl
assay
posit
snap
test
result
associ
ntprobnp
concentr
greater
averag
bnp
concentr
abnorm
cat
ae
determin
snap
assay
significantli
greater
normal
ae
studi
fund
idexx
univers
florida
colleg
veterinari
medicin
resid
grant
competit
acquir
echocardiograph
cineloop
left
apic
view
optim
la
analyz
atrial
longitudin
strain
st
strain
rate
sr
dog
healthi
dog
dog
mmvd
acvim
stage
stage
stage
c
endocardi
la
ste
curv
obtain
peak
atrial
longitudin
strain
pal
peak
atrial
contract
strain
pac
conduit
atrial
longitudin
strain
cal
palspac
contract
strain
index
csi
pacspal
calcul
la
sr
curv
similarli
obtain
determin
peak
posit
strain
rate
sr
left
ventricl
systol
first
neg
peak
strain
rate
sre
earli
diastol
second
neg
peak
strain
rate
sra
atrial
contract
variabl
mean
measur
use
statist
analysi
compar
variabl
acvim
stage
kruskalw
test
posthoc
pairwis
comparison
comparisonwis
normal
dog
higher
pal
cal
dog
mmvd
p
p
stage
c
dog
lower
pal
pac
cal
dog
p
p
p
csi
differ
group
p
stage
c
dog
lower
sr
p
higher
sre
p
sra
p
dog
normal
dog
lower
sre
sra
dog
mmvd
p
data
suggest
ste
might
use
assess
la
function
dog
mmvd
might
potenti
differenti
dog
sever
subclin
diseas
dog
congest
heart
failur
conflict
interest
report
sighthound
athlet
dog
claim
larger
heart
compar
similar
size
breed
left
ventricl
lv
may
enlarg
respons
cardiac
diseas
also
respons
train
call
athlet
heart
syndrom
benign
condit
distinguish
abnorm
echocardiograph
measur
normal
breedspecif
refer
valu
need
aim
studi
establish
normal
refer
rang
echocardiograph
measur
saluki
breed
studi
compris
clinic
healthi
saluki
male
femal
mean
age
month
ae
sd
month
bodyweight
bw
kg
ae
kg
case
histori
ascertain
dog
underw
physic
examin
complet
blood
count
serum
biochemistri
profil
thyroid
profil
blood
pressur
measur
ecg
standard
mmode
echocardiograph
measur
obtain
dog
systol
murmur
dog
mitral
valv
regurgit
mr
mr
color
flow
jet
arealeft
atrium
apic
view
consid
normal
linear
regress
model
use
establish
refer
rang
heart
rate
hr
vari
bpm
ae
bpm
bw
signific
predictor
lv
dimens
ie
mmode
lv
diamet
volum
diastol
lvidd
lvedv
systol
lvid
lvesv
mitral
valv
end
point
septal
separ
epss
hr
signific
predictor
fs
fraction
shorten
predict
valu
predict
interv
calcul
regress
model
mean
bw
kg
age
month
median
hr
bpm
use
normal
refer
rang
lvidd
mm
lvid
mm
lvedv
ml
lvesv
ml
fs
eject
fraction
ef
epss
mm
spheric
index
interventricular
septum
diastol
mm
systol
mm
lv
free
wall
diastol
mm
systol
mm
left
atrial
la
diamet
mm
aortic
ao
diamet
mm
laao
aortic
pulmon
flow
veloc
ms
ms
respect
studi
provid
echocardiograph
valu
normal
saluki
use
refer
valu
conflict
interest
report
mitral
valv
diseas
atrial
remodel
indic
evolut
prognosi
durat
p
wave
consid
suggest
dilat
left
atrium
human
studi
neurolog
condit
signific
impact
cardiac
electrophysiolog
alter
electr
impuls
conduct
aim
studi
examin
durat
p
wave
dog
suffer
mitral
valv
diseas
comparison
dog
diagnos
differ
neuropathi
without
cardiac
abnorm
analyz
standard
electrocardiogram
min
ecg
peripher
lead
perform
three
polymorph
group
dog
differ
age
weight
breed
group
n
healthi
dog
group
n
dog
diagnos
mitral
valv
diseas
group
n
dog
suffer
differ
neuropathi
without
associ
previous
diagnos
cardiovascular
diseas
durat
p
wave
measur
dog
five
consecut
p
wave
without
anomali
artifact
report
degre
atrial
remodel
assess
left
atrium
aorta
ratio
echocardiographi
interpret
ecg
echocardiographi
made
examin
md
result
statist
evalu
special
program
ibm
spss
vs
p
wave
record
averag
valu
ae
second
mvd
group
signific
differ
stage
heart
failur
p
correl
found
increas
dilat
left
atrium
r
statist
signific
differ
regard
p
wave
durat
compar
dog
neuropathi
group
mitral
valv
diseas
group
p
wave
record
averag
valu
ae
sec
atrial
tissu
lesion
mitral
valv
diseas
autonom
nervou
system
anomali
secondari
neurolog
condit
may
chang
conduct
electr
impuls
left
atrium
conduct
electr
impuls
level
seem
influenc
actual
dilat
impair
intraatri
interatri
conduct
pathway
caution
must
given
p
wave
analyz
dog
concurr
cardiolog
neurolog
condit
conflict
interest
report
newfoundland
dog
prospect
recruit
among
undergo
screen
congenit
acquir
heart
diseas
screen
includ
patient
histori
physic
examin
system
arteri
pressur
measur
doppler
flow
meter
transthorac
echocardiographi
mmode
echodoppl
screen
perform
consciou
dog
least
year
age
dog
without
histor
clinic
electrocardiograph
echocardiograph
sign
cardiovascular
diseas
includ
studi
unpair
twotail
student
ttest
linear
regress
perform
evalu
influenc
gender
age
bodi
weight
bw
echocardiograph
paramet
echocardiograph
measur
compar
previous
report
refer
valu
refer
limit
echocardiograph
paramet
newfoundland
dog
calcul
fortysix
healthi
adult
newfoundland
dog
gender
male
femal
year
age
mean
ae
year
kg
mean
ae
kg
fulfil
inclus
criteria
signific
weak
correl
detect
aortic
diamet
ao
age
p
r
left
atrial
aortic
ratio
laao
age
p
r
epoint
septum
separ
epss
bw
p
r
mmode
left
ventricular
intern
diamet
lvid
diastol
systol
bw
respect
p
r
p
r
ao
bw
p
r
none
echocardiograph
measur
statist
differ
male
femal
left
ventricular
intern
diamet
diastol
lvid
ao
epss
increas
bw
expect
aorta
appear
becom
wider
advanc
age
proport
studi
popul
mmode
paramet
allometr
scale
refer
rang
suggest
method
overestim
mmode
paramet
breed
find
stress
import
report
newfoundland
breed
specif
normal
rang
echocardiograph
paramet
conflict
interest
report
canin
idiopath
pulmonari
fibrosi
cipf
progress
interstiti
lung
diseas
usual
diagnos
thorac
ctscan
mainli
affect
west
highland
white
terrier
whwt
pulmonari
hypertens
ph
sever
comorbid
condit
challeng
diagnosi
may
develop
cipf
dog
ratio
right
pulmonari
vein
pulmonari
arteri
pv
pa
describ
echocardiograph
indic
ph
cipfdog
studi
intend
investig
whether
ctscan
angiographi
cardiac
find
alter
dog
cipf
compar
healthi
control
dog
correl
pvpa
measur
echocardiographi
pvpa
us
thorac
cta
imag
whwt
cipf
group
healthi
control
variou
breed
group
b
retrospect
review
one
observ
measur
obtain
transvers
postcontrast
imag
display
soft
tissu
window
pv
pa
measur
dorsal
right
atrium
perpendicular
long
axi
vessel
addit
pulmonari
trunk
pt
assess
ventral
divis
pulmonari
arteri
perpendicular
long
axi
ascend
aorta
ao
also
measur
perpendicular
long
axi
transvers
reformat
imag
obtain
view
equival
standard
chambersechocardiograph
view
right
ventricl
rv
left
ventricl
lv
measur
three
ratio
calcul
pvpa
ct
ptao
rvlv
compar
group
correl
pvpa
us
bidimension
bd
mmode
mm
statist
analys
perform
xlstat
softwar
valu
given
mean
ae
sd
statist
signific
set
p
pvpa
ct
lower
group
ae
comparison
group
b
ae
p
correl
pvpa
us
bd
r
p
mm
r
p
ptao
higher
group
ae
compar
group
b
ae
p
correl
pvpa
us
measur
bd
mode
r
p
rvlv
ratio
increas
group
ae
comparison
group
b
ae
p
correl
rvlv
pvpa
us
found
bd
r
p
mm
r
p
conclus
whwt
cipf
pvpa
ct
ptao
rvlv
ratio
measur
thorac
cta
imag
correl
pvpa
us
may
serv
assess
ph
conflict
interest
report
companion
anim
present
emerg
room
distress
need
assess
rapidli
accur
implement
lifesav
therapi
focus
cardiac
ultrasound
focu
use
adjunct
physic
examin
assess
dyspneic
anim
emerg
room
rapid
bedsid
ultrasound
evalu
perform
ec
commonli
use
human
medicin
howev
feasibl
util
focu
ec
veterinari
medicin
fulli
evalu
purpos
studi
determin
baselin
accuraci
focu
perform
ec
whether
basic
train
session
could
improv
accuraci
compar
evalu
cardiolog
specialist
fifteen
ec
includ
board
emergencycrit
care
specialist
emerg
resid
perform
focu
four
anim
normal
cat
dog
cat
dog
sever
valvular
myocardi
heart
diseas
respect
ec
semiquantit
assess
thorac
echocardiograph
paramet
includ
left
atrial
dimens
left
ventricular
systol
function
wall
thick
right
heart
dimens
presenc
absenc
pleural
pericardi
effus
structur
didact
lectur
handson
practic
session
primari
outcom
level
agreement
examin
perform
cardiologist
level
agreement
regard
ec
assess
paramet
improv
train
p
level
agreement
concern
left
atrial
diamet
improv
p
ec
confid
overal
focu
evalu
find
improv
p
summari
ec
accuraci
confid
semiquantit
assess
basic
cardiac
paramet
use
focu
improv
follow
simpl
structur
train
session
focu
might
valuabl
tool
rapidli
assess
simpl
thorac
cardiac
paramet
emerg
set
conflict
interest
report
obes
increas
health
problem
dog
success
weightloss
program
often
limit
complianc
issu
purpos
studi
determin
effect
new
dietet
weight
manag
food
ndwmf
achiev
weight
loss
overweightobes
clientown
dog
typic
household
condit
object
evalu
weight
loss
paramet
dog
fed
ndwmf
assess
owner
percept
dog
qualiti
life
overweightobes
otherwis
healthi
clientown
dog
bodi
condit
score
bc
enrol
studi
n
initi
veterinari
evalu
includ
physic
examin
nutrit
assess
determin
ideal
bodi
weight
ibw
develop
weightloss
feed
guidelin
daili
energi
requir
der
weight
loss
calcul
der
x
ibw
kg
initi
followup
evalu
monthli
month
encompass
determin
bodi
weight
bc
bodi
fat
index
bfi
muscl
condit
score
mc
feed
practic
qualiti
life
assess
owner
includ
dog
level
energi
happi
appetit
beg
behavior
flatul
stool
volum
fecal
score
statist
analysi
compris
scatterplot
regress
analysi
summari
statist
appropri
type
analys
perform
continu
categor
variabl
distribut
mix
model
anova
assess
chang
time
statist
signific
p
nineti
four
percent
dog
lost
weight
n
averag
weight
loss
sem
month
averag
weekli
weightloss
rate
sem
mean
durat
weight
loss
day
sem
day
averag
day
sem
day
recheck
thirti
nine
percent
dog
achiev
ibw
ci
fifti
five
percent
dog
ate
calori
ndwmf
recommend
der
weight
loss
median
fed
dog
ci
still
lost
weight
thirti
six
percent
dog
receiv
treat
bc
bfi
decreas
significantli
time
compar
baselin
owner
perceiv
signific
increas
energi
happi
dog
lost
weight
without
chang
appetit
beg
behavior
conclus
clinic
studi
confirm
effect
ndwmf
achiev
weight
loss
overweightobes
clientown
dog
spite
higher
recommend
calor
intak
owner
report
signific
improv
dog
qualiti
life
without
neg
side
effect
haptoglobin
moder
acut
phase
protein
cat
part
innat
immun
system
concentr
rise
within
hour
tissu
damag
aim
studi
valid
elisa
recent
develop
measur
felin
haptoglobin
compar
commonli
use
spectrophotometr
assay
concentr
haptoglobin
measur
healthi
sick
cat
use
sandwichelisa
tecomed
group
rheinbach
germani
valid
includ
detect
intraassay
interassay
variat
dilut
linear
spike
recoveri
lower
detect
limit
spectrophotometr
assay
tridelta
develop
ltd
maynooth
ireland
use
refer
method
sampl
measur
duplic
statist
analysi
perform
use
ibm
spss
statist
ibm
corpor
includ
descript
statist
spearman
correl
rs
coeffici
variat
cv
coeffici
variat
intraassay
variabl
interassay
variabl
ratio
observ
expect
dilut
parallel
serum
sampl
dilut
time
rang
ratio
observ
expect
spike
recoveri
serum
sampl
rang
lower
detect
limit
mgml
correl
assay
significantli
strong
rs
p
recent
avail
sandwichelisa
provid
high
accuraci
precis
therefor
use
measur
felin
haptoglobin
author
henni
c
wienen
work
compani
tecomed
group
develop
elisa
evalu
studi
provid
kit
help
perform
test
influenc
result
interpret
data
canin
idiopath
pulmonari
fibrosi
cipf
progress
interstiti
lung
diseas
mainli
occur
west
highland
white
terrier
whwt
breed
cipf
diagnosi
commonli
reli
thorac
highresolut
comput
tomographi
hrct
find
ultim
histopatholog
test
easili
perform
practic
identif
measur
marker
fibrosi
might
help
diagnos
andor
monitor
cours
cipf
help
vegf
angiogen
regul
involv
varieti
physiolog
patholog
process
human
ipf
serum
vegf
concentr
shown
higher
ipf
patient
compar
healthi
volunt
may
reflect
sever
lung
diseas
aim
present
studi
investig
potenti
role
vegf
peripher
blood
biomark
cipf
investig
possibl
breedrel
differ
basal
vegf
concentr
might
explain
high
predisposit
whwt
breed
cipftherefor
vegf
determin
elisa
canin
vegf
quantikin
elisa
kit
r
system
serum
whwt
cipf
confirm
hrct
andor
histopatholog
median
age
year
rang
healthi
whwt
healthi
dog
breed
includ
scottish
terrier
st
jack
russel
terrier
jrt
maltes
king
charl
spaniel
kc
labrador
retriev
lr
malinoi
belgian
shepherd
health
statu
base
clinic
examin
serum
biochemistri
haematolog
healthi
dog
thorac
hrct
perform
healthi
whwt
test
threshold
use
statist
analysi
xlstat
softwar
eight
cipf
whwt
serum
vegf
concentr
kit
detect
limit
pgml
compar
whwt
group
healthi
dog
p
concern
interbre
differ
healthi
dog
valu
obtain
kit
detect
limit
kc
jrt
lr
st
vegf
serum
level
pgml
p
result
present
studi
show
vegf
might
interest
blood
biomark
cipf
canin
vegf
quantikin
elisa
kit
appropri
measur
serum
vegf
level
healthi
canin
popul
conflict
interest
report
total
protein
tp
concentr
cell
count
pleural
abdomin
fluid
use
differenti
transud
exud
tp
measur
autom
wet
chemistri
analys
easili
use
refractomet
aim
studi
assess
refractomet
valu
tp
use
purpos
retrospect
sampl
canin
pleural
abdomin
effus
tp
concentr
measur
refractomet
well
use
pentra
abx
horiba
montpelli
includ
sampl
collect
heparin
tube
analys
within
hour
blandaltman
diagram
creat
correl
measur
calcul
spearman
nonparametr
correl
period
pleural
abdomin
effus
sampl
analys
techniqu
median
rang
tp
concentr
pleural
effus
measur
refractormet
pentra
gl
gl
respect
median
rang
tp
concentr
abdomin
effus
measur
refractomet
pentra
gl
gl
respect
tp
measur
refractomet
pentra
valu
significantli
correl
pleural
r
p
abdomin
r
p
effus
blandaltman
graph
show
bia
thorax
abdomen
refractomet
accept
rapid
effici
method
determin
total
protein
concentr
pleural
abdomin
effus
dog
differenti
transud
exud
conflict
interest
report
coagul
factor
vii
fvii
defici
report
beagl
sinc
defici
dog
show
mild
hemorrhag
tendenc
often
remain
asymptomat
incident
discov
isol
prolong
prothrombin
time
due
plasma
fvii
activ
factor
vii
defici
occur
commonli
beagl
alaskan
klee
kai
scottish
deerhound
breed
caus
singl
missens
mutat
second
epiderm
growth
factorlik
domain
fvii
drastic
reduc
secret
activ
fvii
research
beagl
also
commonli
affect
may
pharmacotoxicolog
affect
studi
specif
dna
screen
program
establish
report
discoveri
fvii
defici
welsh
springer
spaniel
wss
finland
base
upon
novel
screen
panel
known
mutat
underli
inherit
disord
differ
canin
breed
wwwmydogdnacom
among
wss
initi
test
heterozyg
homozyg
affect
fvii
mutat
confirm
sequenc
dog
order
determin
whether
mutat
caus
fvii
defici
also
breed
recruit
litterm
mother
none
wss
shown
increas
hemorrhag
tendenc
affect
bled
excess
follow
blood
collect
found
homozyg
affect
dog
litter
exhibit
markedli
prolong
prothrombin
time
normal
partial
thromboplastin
time
also
drastic
reduc
fvii
activ
normal
high
fviii
fix
activ
compar
litterm
control
heterozyg
carrier
test
show
prolong
prothrombin
time
half
normal
fvii
activ
conclus
document
presenc
fvii
defici
wss
base
upon
dna
coagul
activ
test
common
mutat
must
arisen
prior
separ
differ
fvii
defici
breed
knowledg
advantag
heterozygot
state
mild
hemorrhag
tendenc
bleed
dog
could
treat
fresh
frozen
cryopoor
plasma
human
recombin
fviia
preliminari
studi
indic
high
carrier
frequenc
wss
screen
new
platform
dna
method
ancestr
defect
help
detect
addit
hereditari
diseas
genet
predisposit
differ
breed
mutat
new
restrict
one
relat
breed
author
affili
genet
diseas
screen
test
laboratori
remark
littl
publish
haematolog
serum
biochem
phenotyp
domest
dog
inform
signal
complet
blood
cell
count
dog
normal
red
white
blood
cell
paramet
judg
exist
refer
interv
extract
veterinari
databas
similar
inform
collect
dog
normal
serum
biochem
profil
consid
paramet
glucos
inclus
criteria
normal
haematolog
profil
avail
dog
also
machin
platelet
concentr
within
refer
interv
normal
serum
biochem
profil
avail
dog
also
accompani
normal
serum
glucos
concentr
haematolog
data
pure
breed
plu
mix
breed
control
group
repres
dog
serum
biochem
data
pure
breed
plu
mix
breed
control
group
repres
individu
measur
haematolog
paramet
except
mean
corpuscular
haemoglobin
concentr
mchc
serum
biochem
analyt
except
sodium
chlorid
glucos
vari
age
concentr
white
blood
cell
wbc
neutrophil
monocyt
lymphocyt
eosinophil
platelet
red
blood
cell
paramet
vari
sex
total
protein
globulin
potassium
chlorid
creatinin
cholesterol
total
bilirubin
activ
alanin
aminotransferas
alt
creatin
kinas
ck
amylas
lipas
neuter
statu
impact
haemoglobin
concentr
mean
corpuscular
haemoglobin
mch
mchc
concentr
wbc
neutrophil
monocyt
lymphocyt
platelet
well
serum
biochem
analyt
except
albumin
sodium
calcium
urea
glucos
princip
compon
analysi
pca
haematolog
data
reveal
pure
breed
distinct
phenotyp
pca
serum
biochem
data
reveal
pure
breed
distinct
phenotyp
furthermor
haematolog
paramet
except
mchc
serum
biochem
analyt
except
urea
glucos
show
signific
differ
specif
individu
breed
mix
breed
group
twentynin
breed
distinct
haematolog
phenotyp
breed
distinct
serum
biochem
phenotyp
assess
way
tent
breedspecif
refer
interv
gener
breed
distinct
phenotyp
identifi
compar
analysi
studi
repres
first
largescal
analysi
haematolog
serum
biochem
phenotyp
dog
underlin
import
potenti
speci
elucid
genet
determin
haematolog
biochem
trait
triangul
phenotyp
breed
genet
predisposit
well
urgent
need
breedspecif
refer
interv
clinic
practic
author
receiv
fund
bbsrc
petplan
charit
trust
cruk
none
thesegr
studi
cat
age
year
older
irrespect
suspect
thyroid
statu
present
eight
veterinari
practic
portug
veterinarian
pet
owner
complet
questionnair
veterinarian
take
venou
blood
sampl
plain
tube
cat
obtain
sign
owner
consent
veterinari
questionnair
includ
histori
attitud
activ
heart
rate
thyroid
palpat
cat
age
year
diagnos
previous
hyperthyroid
exclud
blood
sampl
centrifug
serum
harvest
store
frozen
collect
laboratori
within
day
sampl
total
measur
use
chemiluminesc
method
immulit
siemen
cat
classifi
hyperthyroid
equivoc
euthyroid
base
total
concentr
nmoll
nmoll
nmoll
respect
repeat
measur
total
week
recommend
equivoc
case
individu
cat
statist
unit
descript
statist
use
summaris
data
associ
differ
clinic
sign
analys
use
chisquar
fisher
exact
test
mannwhitney
u
test
level
signific
set
thirti
cat
exclud
preval
analysi
age
year
year
n
age
state
n
four
cat
hyperthyroid
end
februari
sampl
submit
cat
met
inclus
criteria
base
thyroid
hormon
analysi
hyperthyroid
equivoc
euthyroid
cat
followup
blood
sampl
taken
hyperthyroid
appear
uncommon
portugues
cat
get
owner
return
followup
blood
sampl
appear
problemat
underreport
hyperthyroid
appear
signific
problem
portug
report
countri
thyroid
palpat
form
part
routin
physic
examin
especi
middl
age
older
cat
older
cat
portug
screen
hyperthyroid
even
absenc
detect
thyroid
nodul
author
employe
msd
anim
health
msd
anim
health
fund
studi
msd
anim
health
approv
veterinari
medicin
product
treatment
felin
hyperthyroid
product
avail
commerci
eu
market
portug
diabet
mellitu
one
commonli
encount
endocrinopathi
cat
preval
increas
past
similar
human
type
diabet
felin
diabet
associ
compar
lesion
occur
pancreat
islet
name
islet
amyloidosi
betacel
loss
studi
pathophysiolog
felin
diabet
molecular
mechan
glucos
metabol
disturb
larg
hamper
lack
method
isol
pure
pancreat
islet
aim
project
improv
previous
establish
method
isol
pancreat
islet
particular
enhanc
puriti
isol
islet
speci
cat
die
euthan
due
sever
ill
pancreat
pancreat
diseas
enrol
pancreata
perfus
postmortem
ml
collagenas
type
iv
mgml
pancreat
duct
perfus
organ
digest
waterbath
purifi
use
filtrat
method
islet
cell
viabil
puriti
determin
thiazolyl
blue
tetrazolium
bromid
mtt
assay
dithizon
stain
respect
perfus
pancrea
pancreat
duct
allow
collagenas
access
islet
use
anatom
structur
improv
islet
yield
compar
previous
establish
protocol
speci
digest
time
provid
best
islet
yield
digest
felin
pancreat
islet
remain
satisfactorili
viabl
day
cultur
system
follow
regular
media
chang
current
studi
success
optim
isol
purif
cultur
mainten
felin
islet
success
yield
viabil
islet
isol
suggest
protocol
may
provid
promis
potenti
sourc
islet
diabet
research
cat
conflict
interest
report
nesidioblastosi
describ
syndrom
acquir
hyperinsulinaemia
associ
hypoglycaemia
secondari
focal
diffus
nonneoplast
beta
cell
hyperplasia
within
pancrea
beta
cell
dysregul
thought
occur
secondari
pancreat
injuri
syndrom
report
human
increas
frequenc
previous
describ
domest
pet
six
year
old
desex
femal
british
shorthair
cat
present
acut
onset
weak
mental
dull
upon
initi
present
cat
mildli
hyperglycaem
mmoll
mmoll
follow
hour
cat
develop
central
blind
tremor
intermitt
seizur
opisthotonu
repeat
blood
sampl
reveal
mark
hypoglycaemia
mmoll
insulin
level
perform
serum
obtain
cat
hypoglycaem
inappropri
elev
pmoll
refer
rang
pmoll
intraven
bolu
glucos
result
rapid
resolut
clinic
sign
mild
transient
hyperglycaemia
mmoll
despit
frequent
feed
hypoglycaemia
mmoll
recur
intraven
glucos
continu
rate
infus
commenc
abdomin
ultrasound
unremark
although
three
cranial
mesenter
lymph
node
note
promin
mm
width
exploratori
laparotomi
reveal
firm
erythemat
left
limb
pancrea
bodi
right
limb
pancrea
appear
grossli
normal
follow
surgic
resect
left
limb
pancrea
cat
return
euglycaem
state
brief
rebound
hyperglycaemia
histopatholog
reveal
pancreat
fibrosi
mark
multifoc
micronodular
hyperplasia
exocrin
endocrin
cell
mild
lymphoplasmacyt
inflamm
ductular
ectasia
synaptophysin
immunohistochemistri
confirm
nodular
beta
cell
hyperplasia
mild
granulomat
lymphaden
hydrop
chang
within
hepatocyt
also
note
cat
recov
unev
without
intervent
gain
weight
remain
euglycaem
follow
six
month
beta
cell
hyperplasia
report
incident
histopatholog
find
euglycaem
young
beagl
first
report
case
clinic
signific
hypoglycaemia
secondari
nesidioblastosi
domest
pet
condit
rare
nesidioblastosi
increasingli
recognis
human
field
import
differenti
consid
investig
hypoglycaemia
differenti
insulinoma
without
histopatholog
evalu
age
onset
may
provid
clue
nonneoplast
diseas
cat
much
younger
previous
report
case
felin
insulinoma
year
age
diagnosi
recurr
report
human
favour
outcom
anticip
follow
partial
pancreatectomi
conflict
interest
report
hyperthyroid
common
felin
endocrinopathi
geriatr
cat
worldwid
nonetheless
data
concern
accur
preval
felin
hyperthyroid
fh
scarc
appar
exhibit
geograph
variat
import
instrument
investig
risk
factor
analysi
exposur
differ
factor
area
high
low
preval
europ
fh
consid
frequent
northern
southern
countri
aim
studi
determin
occurr
fh
region
portug
character
clinic
present
potenti
risk
factor
period
geriatr
cat
eight
year
aveiro
central
region
portug
select
cat
exclud
present
shock
moribund
treatment
drug
might
affect
total
serum
concentr
concentr
determin
chemiluminesc
immulit
siemen
diagnosi
fh
establish
serum
concentr
lgdl
refer
valu
lgdl
associ
compat
clinic
sign
inform
age
gender
breed
weight
hous
condit
indoor
vs
outdoor
use
extern
parasiticid
food
dri
vs
can
food
flavor
use
litter
box
environ
clinic
sign
laboratori
data
collect
owner
gave
inform
consent
popul
studi
includ
male
femal
mainli
domest
shorthair
cat
age
rang
eight
year
old
eight
cat
diagnos
hyperthyroid
cat
year
age
consid
n
preval
rais
hyperthyroid
popul
compris
four
male
four
femal
rang
year
old
increas
age
p
polyphagia
weight
loss
associ
increas
normal
appetit
presenc
thyroid
uni
bilater
nodul
vomit
p
hyperact
p
significantli
associ
hyperthyroid
geriatr
popul
studi
environ
also
significantli
associ
develop
fh
cat
urban
semirur
area
higher
risk
develop
diseas
cat
live
rural
environ
signific
associ
found
hyperthyroid
factor
analyz
knowledg
epidemiolog
studi
fh
perform
portug
countri
occurr
believ
low
popul
pet
cat
felin
geriatr
popul
clinic
case
diagnos
increas
conflict
interest
studi
partial
support
laborat
orio
segalab
sa
dechra
veterinari
product
canin
diabet
mellitu
cdm
propos
spontan
anim
model
human
autoimmun
diabet
compar
research
undertaken
investig
interact
genet
environment
factor
epidemiolog
studi
cdm
perform
northern
european
north
american
popul
aim
evalu
epidemiolog
clinic
featur
diabet
dog
popul
canari
island
special
focu
immunemedi
diseas
dog
attend
veterinari
teach
hospit
includ
januari
januari
previous
diagnos
new
case
consid
preval
calcul
number
cdmtotal
number
dog
attend
hospit
incid
newli
diagnos
case
divid
valu
per
year
antiinsulin
antibodi
assess
elisa
genotyp
dog
leukocyt
antigen
dla
measur
canin
antibodi
radioimmunoprecipit
assay
perform
dog
suspect
immunemedi
diabet
twentynin
dog
cdm
identifi
mean
popul
dog
per
year
mean
preval
mean
incid
case
per
year
per
age
diagnosi
year
rang
dog
neuter
femal
male
nine
breed
repres
includ
poodl
andalusian
winecellar
rathunt
dog
season
observ
diagnosi
peak
decemb
marchapril
diabet
classifi
dioestru
diabet
idiopathicimmunemedi
iatrogen
secondari
pancreat
endocrin
disord
insulintr
dog
neg
antiinsulin
antibodi
n
suspect
immunemedi
case
n
autoantibodi
reactiv
shown
two
case
n
n
previous
describ
diabetesrisk
dlatyp
identifi
although
age
preval
incid
differ
previou
studi
high
proport
entir
femal
like
explain
high
frequenc
dioestru
diabet
andalusian
winecellar
rathunt
dog
identifi
highrisk
breed
cdm
dlatyp
seen
previous
describ
least
two
associ
increas
risk
autoimmun
dog
populationbas
studi
need
differ
region
assess
heterogen
natur
diseas
conflict
interest
report
cortisoldehydroepiandrosteron
dhea
ratio
wide
use
human
medicin
marker
stress
howev
clear
whether
could
also
help
distinguish
hyperadrenocortic
hac
diseas
might
neg
impact
outcom
dexamethason
low
dose
test
therefor
aim
studi
evalu
cortisoldhearatio
addit
diagnost
marker
hac
dog
achiev
aim
refer
rang
ratio
depend
sex
evalu
healthi
dog
compar
dog
hac
healthi
dog
age
year
dog
hac
age
year
differ
breed
plasma
concentr
cortisol
immulit
system
siemen
healthcar
diagnost
dhea
beckman
coulter
measur
ratio
calcul
dog
patient
small
anim
clinic
except
five
healthi
dog
recruit
institut
pharmacolog
toxicolog
pharmaci
univers
data
cortisoldhearatio
calcul
male
dog
healthi
dog
n
dog
hac
n
neuter
male
healthi
dog
n
dog
hac
n
femal
dog
healthi
dog
n
dog
hac
n
spay
femal
healthi
dog
n
dog
hac
n
statist
analysi
perform
sigma
stat
plasma
cortisoldhearatio
healthi
male
dog
lowest
ratio
sexual
categori
mean
averag
ae
differ
significantli
sex
neuter
male
ae
p
femal
ae
p
spay
femal
ae
p
cortisoldhearatio
show
signific
differ
male
femal
dog
hac
spay
femal
hac
significantli
higher
cortisoldhearatio
ae
healthi
spay
femal
p
signific
differ
found
sexual
categori
preliminari
data
indic
cortisoldhearatio
might
promis
tool
diagnosi
hac
addit
signific
genderdepend
paramet
consid
may
gener
limit
clinic
use
studi
financi
support
brunsstiftung
conflict
interest
report
hyperthyroid
common
older
cat
aim
studi
assess
preval
felin
hyperthyroid
potenti
intrins
risk
factor
hospit
popul
southern
germani
total
thyroxin
prospect
measur
enzym
immunoassay
eia
sera
cat
older
year
present
clinic
small
anim
medicin
standard
physic
examin
perform
bodi
condit
score
bc
thyroid
palpat
score
tp
assess
associ
signal
bc
tp
analyz
student
unpair
ttest
chisquar
mannwhitney
test
level
signific
set
fifti
nine
cat
diagnos
hyperthyroid
lead
preval
ci
hyperthyroid
cat
older
nonhyperthyroid
cat
p
often
femal
p
odd
ratio
domest
short
long
hair
cat
often
affect
pedigre
p
hyperthyroid
cat
higher
tp
p
lower
weight
nonhyperthyroid
cat
p
although
bc
differ
p
cat
elev
incident
find
diseas
confirm
later
other
dead
due
unrel
diseas
patient
hyperthyroid
consid
differenti
diagnosi
confirm
cat
although
cat
addit
diagnost
mean
necessari
older
femal
domest
cat
predispos
hyperthyroid
frequent
diagnos
initi
clinic
suspect
affect
cat
elev
present
preced
clinic
sign
conflict
interest
studi
partial
fund
msd
intervet
main
endocrinopathi
affect
human
pet
felin
diabet
mellitu
accur
diagnosi
import
aspect
futur
outcom
diseas
comput
base
decis
support
system
dss
target
assist
clinician
one
step
diagnost
process
novelti
dss
emerg
possibl
assist
clinic
paraclin
diagnosi
stage
diabet
mellitu
common
combin
disord
associ
endocrinopathi
motiv
behind
develop
system
desir
maxim
reliabl
clinic
decis
design
felin
diabet
mellitu
dss
emerg
syndrom
polyuriapolydipsia
possibl
spot
accompani
patholog
fuzzi
logic
use
deal
knowledg
represent
uncertainti
fuzzi
rule
propos
repres
knowledg
emerg
anamnesi
clinician
input
clinic
paraclin
descript
confirm
diagnost
test
clinic
sign
polyuriapolydipsia
persist
hyperglycemia
polyphagia
weight
fluctuat
administr
drug
diabetogen
potenti
consid
decis
pattern
diagnosi
establish
regist
medic
record
cat
male
femal
whit
age
year
old
analyz
order
valid
dss
use
matlab
softwar
dss
implement
test
case
polyuriapolydipsia
system
provid
via
friendli
graphic
user
interfac
diagnosi
highest
probabl
set
diagnos
gener
dss
consist
diabet
mellitu
b
diabet
mellitu
induc
hypersomathotrop
hyperthyroid
hyperadrenocortic
diabetogen
medic
c
diabet
mellitu
associ
chronic
kidney
failur
heart
failur
ketoacidod
diabet
mellitu
e
pancreat
dss
appli
success
case
reveal
follow
diagnos
case
adequ
treatment
protocol
requir
accur
complet
diagnosi
advanc
comput
system
accompani
clinician
decis
make
leav
reduc
space
medic
error
superflu
expens
time
consum
test
futur
work
target
explor
possibl
combin
dss
artifici
neural
network
model
diabet
mellitu
foundat
complet
case
orient
manag
system
felin
diabet
mellitu
associ
disord
conflict
interest
report
activin
cytokin
belong
transform
growth
factor
tgf
b
superfamili
thought
activin
may
key
intermediari
mediat
fibrot
respons
activin
suggest
particip
pathogenesi
human
idiopath
pulmonari
fibrosi
ipf
studi
regard
role
activin
b
still
spare
canin
ipf
cipf
chronic
incur
interstiti
lung
diseas
occur
particularli
west
highland
white
terrier
whwt
diseas
cours
acut
exacerb
ae
poor
prognosi
occur
histopatholog
ae
cipf
featur
diffus
alveolar
damag
also
key
featur
acut
respiratori
distress
syndrom
ard
object
studi
express
activin
b
immunohistochemistri
lung
tissu
cipf
whwt
n
cipf
whwt
concurr
ae
n
dog
variou
breed
ard
n
compar
find
healthi
whwt
n
addit
western
blot
analysi
activin
b
bronchoalveolar
lavag
fluid
balf
cipf
whwt
n
healthi
whwt
n
conduct
demonstr
activin
b
activin
strongli
express
alter
alveolar
epithelium
lung
diseas
whwt
well
ard
lung
furthermor
activin
b
detect
balf
cipf
whwt
notabl
sampl
dog
ae
balf
healthi
whwt
novel
find
suggest
activin
b
particip
pathophysiolog
cipf
might
act
potenti
marker
alveolar
epitheli
damag
conflict
interest
report
dog
breed
nova
scotia
duck
toll
retriev
nsdtr
affect
sever
immunemedi
diseas
particular
steroidrespons
meningitisarter
srma
immunemedi
rheumat
diseas
imrd
imrd
system
lupu
erythematosusrel
diseas
character
chronic
stiff
pain
sever
joint
aim
studi
investig
morbid
nsdtr
test
hypothesi
nsdtr
predispos
srma
imrd
insur
data
swedish
insur
compani
agria
insur
compani
stockholm
sweden
use
studi
approxim
one
third
swedish
dog
insur
agria
insur
databas
valid
tool
epidemiolog
studi
assess
morbid
base
veterinari
care
event
diseas
diagnos
group
gener
specif
diseas
categori
individu
diagnos
like
repres
imrd
combin
morbid
defin
incid
rate
present
number
case
per
dog
year
risk
dyar
rel
risk
rr
nsdtr
compar
breed
combin
calcul
studi
includ
dog
nsdtr
common
gener
caus
veterinari
care
nsdtr
injuri
follow
gastrointestin
musculoskelet
disord
signific
increas
risk
rr
nsdtr
compar
breed
highest
rel
risk
nsdtr
system
lupu
erythematosu
rr
compar
breed
nsdtr
increas
risk
srma
rr
imrd
rr
incid
rate
case
per
dyar
srma
case
per
dyar
imrd
incid
rate
srma
imrd
nsdtr
also
compar
dog
retriev
breed
comparison
reveal
nsdtr
also
signific
increas
risk
srma
rr
imrd
rr
compar
retriev
studi
first
investig
morbid
imrd
nsdtr
import
research
breed
practic
sever
reason
incid
rate
might
underestim
exact
number
interpret
caution
howev
underestim
incid
rate
differ
dog
differ
breed
therefor
affect
risk
calcul
conclud
nsdtr
predispos
diseas
srma
imrd
increas
risk
compar
breed
retriev
brenda
n
bonnett
consult
agria
insur
compani
variou
project
agria
insur
compani
also
fund
work
lead
develop
insur
data
base
studi
base
canin
infecti
respiratori
diseas
cird
multifactori
contagi
diseas
caus
respiratori
virus
select
bacteri
pathogen
cird
shown
predispos
factor
develop
bacteri
pneumonia
bp
dog
hous
dens
popul
kennel
rehom
center
aim
studi
determin
preval
viral
coinfect
assess
effect
diseas
sever
household
dog
diagnos
bp
prospect
crosssect
observ
studi
conduct
dog
diagnos
bp
caus
opportunist
bacteria
includ
dog
chronic
day
tracheobronch
caus
bordetella
bronchiseptica
includ
control
viru
analysi
diagnosi
confirm
thorough
clinic
examin
well
cytolog
bacteri
analysi
bronchoalveolar
lavag
bal
transtrach
wash
ttw
sampl
canin
parainfluenssaviru
cpiv
canin
adenoviru
canin
herpesviru
canin
distemperviru
canin
respiratori
coronaviru
crcov
canin
pneumoviru
analys
bal
ttw
sampl
use
rtpcr
assay
cpiv
detect
crcov
respiratori
sampl
dog
bp
respiratori
virus
detect
dog
chronic
tracheobronch
signific
differ
durat
hospit
p
arteri
pao
present
p
bp
dog
without
viral
coinfect
result
indic
coinfect
respiratori
virus
common
also
household
dog
bp
addit
viral
coinfect
caus
sever
cours
bp
author
researcjh
financi
support
finnish
foundat
veterinari
r
finnish
veterinari
foundat
caus
canin
anemia
taiwan
fiveyear
retrospect
survey
eci
lin
pc
liu
chueh
bl
su
graduat
institut
veterinari
medicin
nation
taiwan
univers
taipei
taiwan
institut
veterinari
clinic
scienc
nation
taiwan
univers
taipei
taiwan
anemia
common
hematolog
disord
dog
howev
data
avail
regard
epidemiolog
caus
taiwan
investig
caus
anemia
anem
case
pcv
collect
januari
decemb
nation
taiwan
univers
veterinari
hospit
ntuvh
analyz
dog
n
present
mild
form
follow
moder
form
n
sever
form
pcv
n
among
dog
identifi
caus
dog
induc
singl
caus
wherea
dog
multipl
caus
neoplasiarel
anemia
n
infecti
pathogensrel
anemia
n
renal
diseaserel
anemia
n
postsurgeri
traumarel
anemia
n
account
singlecaus
case
respect
furthermor
present
sever
anemia
sever
anemia
primarili
result
infecti
diseaserel
anemia
follow
imha
tumorrel
anemia
infecti
diseaserel
sever
anem
dog
common
diagnos
pathogen
babesia
gibsoni
n
follow
ehrlichia
cani
n
babesia
cani
n
taken
togeth
tumor
infecti
diseas
renal
failur
frequent
caus
canin
anemia
taiwan
furthermor
b
gibsoni
appear
import
infecti
pathogen
caus
sever
anemia
may
associ
climat
geograph
area
conflict
interest
report
bordetella
bronchiseptica
bb
one
primari
caus
agent
canin
infecti
respiratori
diseas
cird
contagi
diseas
commonli
seen
young
dog
often
selflimit
although
wide
rang
respiratori
sign
found
mild
ill
sever
pneumonia
lead
death
although
mycoplasma
cyno
cyno
recent
identifi
emerg
possibl
lethal
pathogen
cird
role
cani
cyno
primari
respiratori
pathogen
still
remain
unclear
detect
bacteria
improv
quantit
polymeras
chain
reaction
qpcr
dog
cird
due
bb
frequenc
coinfect
mycoplasma
spp
particularm
cyno
possibl
role
sever
clinic
sign
unknown
aim
present
studi
investig
presenc
cani
cyno
popul
dog
infect
bb
compar
popul
healthi
dog
dog
bacteri
bronchopneumonia
bb
involv
bbp
therefor
bb
cani
cyno
detect
qpcr
bronchoalveolar
lavag
fluid
balf
sampl
dog
bb
mean
age
mean
bw
kg
dog
bbp
kg
healthi
dog
kg
bordetellosi
diagnos
base
clinic
find
togeth
demonstr
pleiomorph
coccicoccobacilli
adher
cilia
epitheli
cell
cytospin
balf
prepar
posit
qpcr
balf
clinic
sever
index
csi
assign
base
clinic
sign
cough
dyspnea
lethargi
fever
thorac
radiograph
pattern
balf
score
bbp
diagnos
base
clinic
find
balf
cytolog
cultur
cani
indiffer
detect
healthi
bbp
bb
dog
cyno
tend
frequent
detect
bb
group
healthi
bbp
dog
test
p
bb
dog
correl
could
detect
csi
presenc
cyno
test
p
conclus
present
data
suggest
cird
coinfect
bb
cyno
frequent
correl
clinic
diseas
sever
studi
requir
investig
whether
coinfect
bb
cyno
deserv
specif
therapeut
consider
conflict
interest
report
canin
idiopath
eosinophil
bronchopneumopathi
ebp
diseas
character
eosinophil
infiltr
lung
bronchial
mucosa
young
adult
aetiolog
remain
unclear
although
immunolog
hypersensit
clearli
suspect
incit
antigen
gener
unidentifi
human
cat
infect
mycoplasma
spp
discuss
potenti
trigger
inflammatori
bronchial
diseas
bordetella
bronchiseptica
bb
recogn
pathogen
agent
canin
infecti
tracheobronch
detect
bb
mycoplasma
spp
especi
mycoplasma
cyno
cyno
potenti
role
canin
inflammatori
bronchiti
investig
aim
present
studi
investig
frequenc
bb
mycoplasma
cani
cani
cyno
canin
ebp
therefor
presenc
bb
cani
cyno
retrospect
assess
quantit
polymeras
chain
reaction
qpcr
bronchoalveolar
lavag
fluid
balf
sampl
dog
ebp
mean
age
mean
bodi
weight
kg
well
dog
aspecif
chronic
bronchiti
kg
base
clinic
sign
clinic
sever
score
css
assign
ebp
dog
although
balf
cultur
cytolog
neg
bacteria
bb
frequent
detect
qpcr
ebp
dog
cb
dog
test
p
presenc
bb
ebp
dog
independ
age
significantli
associ
css
test
p
result
qpcrwere
posit
cani
cyno
ebp
dog
cb
dog
respect
differ
group
organ
relat
age
css
presenc
spp
ebp
dog
observ
conclus
cani
cyno
seem
predominantli
involv
pathogenesi
canin
ebp
howev
bb
frequent
detect
balf
ebp
dog
dog
aspecif
cb
presenc
associ
clinic
sever
whether
bb
abl
trigger
eosinophil
inflamm
easili
collect
inflam
environ
unclear
ebp
dog
could
potenti
act
bb
carrier
sourc
infect
therefor
bb
systemat
search
canin
ebp
case
treat
accordingli
conflict
interest
report
distal
renal
distal
renal
tubular
acidosi
drta
recent
report
three
dog
imha
purpos
studi
explor
hypothesi
drta
underdiagnos
concurr
disord
dog
imha
report
clinic
present
outcom
three
dog
combin
imha
drta
strongli
suspect
medic
record
dog
diagnos
imha
univers
edinburgh
hospit
small
anim
januari
may
review
identifi
case
venou
blood
ga
analysi
urinalysi
also
carri
purpos
retrospect
studi
imha
defin
presenc
anaemia
pcv
one
follow
criteria
posit
slide
agglutin
test
posit
coomb
test
moder
mark
spherocytosi
criteria
diagnosi
drta
includ
moder
mark
hyperchlorem
metabol
acidosi
normal
anion
gap
urin
ph
face
metabol
acidosi
hypokalaemia
mmoll
fiftyseven
record
evalu
case
exclud
due
insuffici
clinic
inform
includ
inabl
determin
urinari
ph
due
sever
pigmenturia
four
case
case
suffici
clinic
data
assess
likelihood
drta
one
case
fulfil
criteria
two
case
fulfil
one
criteria
drta
strongli
suspect
base
clinic
progress
persist
urin
ph
face
sever
metabol
acidosi
three
case
concurr
imha
drta
suspect
two
surviv
discharg
one
still
aliv
time
write
month
discharg
euthanas
month
discharg
follow
develop
multipl
joint
effus
skin
lesion
suggest
sle
venou
blood
ga
analysi
assess
urin
ph
consid
case
imha
exclud
possibl
concurr
drta
particularli
persist
hypokalaemia
detect
prospect
evalu
larger
cohort
imha
case
requir
determin
actual
incid
concurr
drta
conflict
interest
report
persist
renal
proteinuria
consid
earli
marker
chronic
kidney
diseas
ckd
list
among
initi
factor
progress
factor
accord
kdoqi
guidelin
nevertheless
data
avail
preval
proteinuria
cat
affect
ckd
assum
nephropathi
mainli
character
tubulointerstiti
damag
aim
studi
determin
preval
proteinuria
cat
affect
ckd
valuat
relat
urin
protein
creatinin
ratio
upc
iri
substag
proteinuria
toward
purebr
sex
age
haematolog
biochemistri
urinalysi
wilcoxon
test
linear
regress
chisquar
test
use
statist
analysi
data
cat
consid
nonren
proteinuria
exclus
criterion
proteinur
cat
upc
ckd
cat
could
substag
bordelin
proteinur
cat
proteinuria
tend
increas
age
p
worsen
nephropathi
p
proteinuria
relat
anaem
state
ckd
cat
upc
significantli
increas
rbc
count
hb
ht
mch
decreas
p
p
respect
proteinuria
tend
increas
wbc
count
p
neutrophil
increas
p
tend
decreas
lymphocyt
increas
p
furthermor
upc
significantli
increas
presenc
inflammatori
serum
protein
electrophoret
pattern
upc
tend
increas
phosphoru
alp
increas
p
p
respect
role
phosphoru
ckd
well
known
increas
alp
question
hypothes
higher
alp
level
ckd
could
relat
balp
increas
due
bone
remodel
secondari
renal
hyperparathyroid
consid
urin
paramet
upc
increas
urinari
specif
graviti
ph
decreas
probabl
relat
worsen
ckd
develop
metabol
acidosi
glicosuria
present
regardless
caus
furthermor
proteinuria
increas
presenc
rbc
urinari
sediment
sampl
cast
observ
particularli
rbc
cast
consid
alway
patholog
indic
glomerular
damag
present
upc
valu
assess
proteinur
cat
data
analysi
suggest
need
deepen
analyt
variabl
upc
opportun
reconsid
interv
substag
proteinuria
cat
conflict
interest
report
aim
retrospect
studi
evalu
relat
urin
cultur
result
urinalysi
paramet
b
result
antimicrobi
suscept
test
urin
sampl
collect
cystocentesi
dog
cat
whose
diagnost
workup
includ
differenti
diagnosi
uti
sampl
underw
complet
urinalysi
upc
ratio
assess
urin
cultur
infect
vs
steril
result
relat
urin
physic
chemic
paramet
observ
urinari
sediment
analysi
statist
analysi
perform
use
jmp
sa
institut
inc
p
valu
consid
signific
urin
cultur
result
posit
dog
cat
presenc
uti
significantli
relat
urin
physic
properti
color
turbid
usg
leukocyturia
infect
tend
frequent
urin
sampl
character
light
yellow
color
cloudi
sublimpid
aspect
low
usg
nevertheless
urin
limpid
infect
sampl
normal
usg
found
dog
uti
cat
although
leukocyturia
tend
becom
higher
infect
sampl
dog
cat
p
infect
sediment
wbc
count
normal
haematuria
detect
dipstick
significantli
relat
uti
dog
cat
nevertheless
rbc
count
sediment
relat
infect
speci
rbc
count
normal
infect
felin
sampl
canin
sampl
signific
relat
presenc
absenc
uti
albuminuria
bilirubinuria
glycosuria
detect
upc
tend
becom
significantli
higher
dog
although
chisquar
test
show
signific
relat
infect
detect
bacteria
urinari
sediment
pseudobacteriuria
found
sampl
furthermor
bacteria
nt
observ
infect
sampl
usg
e
coli
isol
major
sampl
compar
speci
staphylococcu
proteu
streptococcu
urinalysi
pitfal
high
antibiot
resist
verifi
toward
wide
use
molecul
penicillin
cephalosporin
quinolon
strongli
indic
import
perform
antimicrobi
suscept
test
avoid
risk
failur
associ
use
abus
empir
therapi
uti
conflict
interest
report
azotemia
dog
chronic
heart
failur
may
reflect
impair
renal
function
inadequ
renal
perfus
also
due
organ
renal
injuri
impair
renal
function
observ
dog
heart
failur
alter
renal
hemodynam
due
decreas
cardiac
output
result
renal
hypoperfus
result
elev
blood
urea
nitrogen
creatinin
defin
azotemia
azotemia
prognost
factor
dog
mitral
regurgit
therefor
preserv
andor
restor
renal
function
thought
improv
prognosi
medic
treatment
heart
failur
howev
includ
angiotensin
convert
enzym
inhibitor
loop
diuret
shown
increas
risk
develop
azotemia
hypothes
mitral
valv
repair
surgeri
amelior
renal
function
improv
system
hemodynam
chang
renal
function
dog
mitral
regurgit
assess
evalu
timedepend
chang
glomelular
filtrat
rate
inulin
clearanc
cardiac
surgeri
eighteen
dog
sever
mitral
regurgit
azotemia
plasma
urea
nitrogen
level
mgdl
plasma
creatinin
level
mgdl
includ
studi
glomerular
filtrat
rate
dog
evalu
determin
inulin
clearanc
month
surgeri
serum
atrial
natriuret
peptid
level
plasma
ntpro
brain
natriuret
peptid
level
plasma
urea
nitrogen
concentr
plasma
creatinin
concentr
measur
time
point
well
initi
stage
heart
failur
base
intern
small
anim
cardiac
health
council
isachc
left
atrialaorta
ratio
echocardiographi
vertebr
heart
size
thorac
radiograph
also
measur
glomerular
filtrat
rate
significantli
increas
month
surgeri
mlminm
mlminkg
compar
surgeri
mlminm
mlminkg
p
isachc
stage
heart
failur
improv
month
surgeri
compar
surgeri
addit
serum
atrial
natriuret
peptid
level
plasma
ntpro
brain
natriuret
peptid
level
plasma
urea
nitrogen
concentr
laao
vh
significantli
decreas
surgeri
p
use
diuret
decreas
mitral
valv
repair
surgeri
consequ
decreas
plasma
urea
nitrogen
creatinin
level
observ
therefor
suggest
main
caus
azotemia
dog
mitral
regurgit
may
due
inadequ
renal
blood
flow
exacerb
use
diuret
conflict
interest
report
glomerular
filtrat
rate
gfr
gener
consid
gold
standard
measur
kidney
function
gfr
calcul
measur
serum
iohexol
clearanc
use
concentr
hour
follow
bolu
inject
valid
serum
sampl
spike
low
mg
ml
medium
mgml
high
mgml
iohexol
concentr
analys
along
standard
calibr
curv
concentr
rang
mgml
use
deltadot
labelfre
high
perform
capillari
electrophoresi
hpce
system
data
analys
use
deltadot
gener
separ
transform
gst
clinic
spike
serum
sampl
also
sent
analysi
mass
spectrometri
ms
refer
laboratori
sampl
comparison
concentr
obtain
hpce
ms
compar
bland
altman
plot
gfr
clinic
sampl
calcul
measur
iohexol
concentr
use
method
report
bexfield
valid
method
produc
lower
limit
detect
mgml
lower
limit
quantif
mgml
upper
limit
quantif
mgml
standard
curv
excel
linear
r
maximum
inaccuraci
less
true
valu
except
lloq
within
averag
within
day
variabl
less
level
day
variabl
less
except
lloq
less
agreement
result
obtain
measur
hpce
ms
good
bia
lower
upper
limit
agreement
respect
method
specif
confirm
absenc
matrix
effect
six
serum
specimen
obtain
clinic
dog
clinic
sampl
analys
gfr
report
day
turnaround
time
conclus
hpce
provid
accur
precis
method
measur
iohexol
canin
serum
conflict
interest
l
pelligand
follow
inform
disclos
receipt
research
grant
contract
fund
orion
ltd
novarti
anim
health
transpharm
ltd
deltadot
ltd
act
consult
triverita
ltd
novarti
anim
health
william
employe
rvc
work
collabor
deltadot
ltd
j
elliott
follow
inform
disclos
consult
pfizer
anim
health
zoeti
ceva
anim
health
boehring
ingelheim
vetoquinol
ltd
orion
ltd
elanco
ltd
idexx
ltd
nich
gener
ltd
triverista
ltd
virbac
ltd
advisori
board
membership
intern
renal
interest
societi
support
novarti
european
emesi
council
sponsor
pfizer
anim
health
zoeti
cardioren
board
vetoquinol
ltd
idexx
renal
advisori
board
research
grant
contract
vetoquinol
ltd
novarti
ltd
pfizer
anim
health
ltd
zoeti
royal
canin
ltd
boeringh
ingelheim
ltd
waltham
centr
pet
nutrit
ceva
anim
health
orion
ltd
cystic
pancreat
neoplasia
cat
cm
borschenski
k
steiger
staudach
schlitter
esposito
h
aupperl
laboklin
gmbh
co
kg
bad
kissingen
germani
tu
unchen
institut
patholog
unchen
germani
veterinari
clinic
dr
staudach
aachen
germani
pancreat
neoplasm
cat
mostli
exhibit
solid
growth
pattern
diagnos
carcinoma
contrast
report
cystic
pancreat
lesion
exist
benign
cystic
pancreat
lesion
describ
literatur
accord
histolog
pattern
term
cyst
acinar
cystadenoma
pseudocyst
man
cystic
pancreat
neoplasm
classifi
accord
localis
intraextraduct
growth
pattern
differenti
mucin
tubulo
papillari
serou
acinar
aim
studi
characteris
felin
pancreat
neoplasm
detail
base
human
classif
system
special
view
cystic
lesion
pancreat
mass
sent
laboklin
domest
cat
year
investig
routin
macroscop
histolog
method
h
e
stain
neoplasm
show
cystic
n
solid
n
pattern
cystic
pancreat
tumor
cm
diamet
classifi
benign
variant
five
malign
variant
three
case
base
human
classif
system
classifi
tubulopapillari
n
acinar
n
mix
n
adenoma
mix
carcinoma
n
respect
solid
pancreat
nodul
diagnos
carcinoma
tubular
n
acinar
n
differenti
pattern
summari
gross
structur
solid
versu
cystic
seem
prognost
relev
contrast
solid
tumor
cystic
pancreat
lesion
cat
behav
benign
higher
percentag
case
result
better
prognosi
therefor
surgic
excis
cystic
mass
recommend
respect
human
classif
system
three
differ
subtyp
cystic
pancreat
neoplasm
detect
cat
describ
veterinari
medicin
tubulopapillari
acinar
mix
best
knowledg
first
report
cystic
adenocarcinoma
felin
pancrea
correspond
clinic
histolog
investig
need
better
diagnost
ultrasound
mri
prognost
characteris
cystic
lesion
felin
pancrea
conflict
interest
report
immunohistochem
detect
express
canin
mast
cell
tumour
recent
describ
team
prada
et
al
howev
prognost
valu
need
establish
aim
present
work
studi
prognost
valu
express
investig
relationship
sever
clinic
patholog
variabl
includ
overal
surviv
os
time
includ
dog
mast
cell
tumour
grade
grade
ii
grade
iii
immunohistochem
express
carri
streptavidinbiotin
method
immunoreact
evalu
consid
number
posit
cell
extens
intens
score
follow
clinic
patholog
featur
consid
anim
age
sex
tumour
anatom
locat
tumour
size
skin
ulcer
histolog
grade
histolog
safeti
margin
number
mitosi
express
correl
clinic
patholog
data
overal
surviv
intens
statist
significantli
associ
skin
ulcer
p
histolog
grade
p
absenc
histolog
safeti
margin
p
high
mitot
number
p
overal
surviv
p
extens
immunohistochem
score
present
statist
relationship
variabl
consid
neither
overal
surviv
result
suggest
import
role
dog
mast
cell
tumour
progress
could
constitut
promis
therapeut
target
neoplasia
howev
studi
also
demonstr
mct
intens
prognost
valu
number
posit
cell
extens
immunohistochem
score
consequ
intens
elect
evalu
posit
mct
immunohistochem
studi
merial
provid
financi
support
immunohistochem
analayi
research
centr
also
receiv
financi
suppoprt
cecav
ceca
citab
dog
radiat
subcutan
sarcoma
includ
medic
record
review
patient
characterist
treatment
protocol
adjuv
therapi
outcom
analys
followup
inform
obtain
medic
record
phone
convers
veterinarian
pet
owner
thirtytwo
dog
includ
studi
mean
age
year
mean
bodyweight
kg
male
dog
slightli
overrepres
cur
intent
radiotherapi
appli
dog
palli
intent
dog
mean
total
dose
gray
respect
dog
microscop
diseas
radiat
five
dog
receiv
liposom
doxorubicin
concomitantli
radiotherapi
two
receiv
adjuv
doxorubicin
one
intralesion
cisplatin
overal
median
surviv
time
day
cur
day
palli
treatment
overal
median
surviv
time
dog
macroscop
diseas
day
patient
microscop
diseas
reach
radiotherapi
gener
accept
new
treatment
modal
pet
owner
refer
veterinarian
compar
literatur
best
outcom
achiev
dog
radiat
microscop
diseas
conflict
interest
conflict
interest
report
oncept
indic
treatment
stage
ii
iii
oral
melanoma
local
control
surviv
time
significantli
increas
follow
vaccin
similar
improv
surviv
time
also
report
digit
melanoma
medic
record
dog
diagnos
melanoma
march
decemb
retrospect
evalu
inclus
criteria
histopatholog
diagnosi
melanoma
surgic
excis
tumour
vaccin
use
oncept
vaccin
dog
met
inclus
criteria
nific
renal
involv
dog
cvl
result
indic
